#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Social-Cognitive Brain Function and Connectivity During Visual Perspective-Taking in Autism and Schizophrenia
#Text=Background
#Text=Autism spectrum disorder (ASD) and schizophrenia are neurodevelopmental conditions that are characterized by significant social impairment.
1-1	0-16	Social-Cognitive	_
1-2	17-22	Brain	_
1-3	23-31	Function	_
1-4	32-35	and	_
1-5	36-48	Connectivity	_
1-6	49-55	During	_
1-7	56-62	Visual	_
1-8	63-81	Perspective-Taking	_
1-9	82-84	in	_
1-10	85-91	Autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-11	92-95	and	_
1-12	96-109	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	110-120	Background	_
1-14	121-127	Autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[1]
1-15	128-136	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[1]
1-16	137-145	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[1]
1-17	146-147	(	_
1-18	147-150	ASD	_
1-19	150-151	)	_
1-20	152-155	and	_
1-21	156-169	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-22	170-173	are	_
1-23	174-192	neurodevelopmental	_
1-24	193-203	conditions	_
1-25	204-208	that	_
1-26	209-212	are	_
1-27	213-226	characterized	_
1-28	227-229	by	_
1-29	230-241	significant	_
1-30	242-248	social	_
1-31	249-259	impairment	_
1-32	259-260	.	_

#Text=Emerging genomic and neurobiological evidence has increasingly pointed to shared pathophysiologic mechanisms in the two disorders.
2-1	261-269	Emerging	_
2-2	270-277	genomic	_
2-3	278-281	and	_
2-4	282-297	neurobiological	_
2-5	298-306	evidence	_
2-6	307-310	has	_
2-7	311-323	increasingly	_
2-8	324-331	pointed	_
2-9	332-334	to	_
2-10	335-341	shared	_
2-11	342-358	pathophysiologic	_
2-12	359-369	mechanisms	_
2-13	370-372	in	_
2-14	373-376	the	_
2-15	377-380	two	_
2-16	381-390	disorders	_
2-17	390-391	.	_

#Text=Overlap in social impairment may reflect similar underlying neural dysfunction in social-cognitive brain networks, yet few studies have directly compared brain function and communication between those with ASD and schizophrenia.
3-1	392-399	Overlap	_
3-2	400-402	in	_
3-3	403-409	social	_
3-4	410-420	impairment	_
3-5	421-424	may	_
3-6	425-432	reflect	_
3-7	433-440	similar	_
3-8	441-451	underlying	_
3-9	452-458	neural	_
3-10	459-470	dysfunction	_
3-11	471-473	in	_
3-12	474-490	social-cognitive	_
3-13	491-496	brain	_
3-14	497-505	networks	_
3-15	505-506	,	_
3-16	507-510	yet	_
3-17	511-514	few	_
3-18	515-522	studies	_
3-19	523-527	have	_
3-20	528-536	directly	_
3-21	537-545	compared	_
3-22	546-551	brain	_
3-23	552-560	function	_
3-24	561-564	and	_
3-25	565-578	communication	_
3-26	579-586	between	_
3-27	587-592	those	_
3-28	593-597	with	_
3-29	598-601	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
3-30	602-605	and	_
3-31	606-619	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-32	619-620	.	_

#Text=Methods
#Text=Outpatients with schizophrenia (n = 36), ASD (n = 33), and healthy volunteers (n = 37) completed a visual perspective-taking task during functional neuroimaging at 3T to assess similarities and differences in fronto-temporal brain function and connectivity during social-cognitive processing.
4-1	621-628	Methods	_
4-2	629-640	Outpatients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
4-3	641-645	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
4-4	646-659	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
4-5	660-661	(	_
4-6	661-662	n	_
4-7	663-664	=	_
4-8	665-667	36	_
4-9	667-668	)	_
4-10	668-669	,	_
4-11	670-673	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-12	674-675	(	_
4-13	675-676	n	_
4-14	677-678	=	_
4-15	679-681	33	_
4-16	681-682	)	_
4-17	682-683	,	_
4-18	684-687	and	_
4-19	688-695	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
4-20	696-706	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
4-21	707-708	(	_
4-22	708-709	n	_
4-23	710-711	=	_
4-24	712-714	37	_
4-25	714-715	)	_
4-26	716-725	completed	_
4-27	726-727	a	_
4-28	728-734	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
4-29	735-753	perspective-taking	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
4-30	754-758	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
4-31	759-765	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
4-32	766-776	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[5]
4-33	777-789	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[5]
4-34	790-792	at	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[5]
4-35	793-795	3T	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[5]
4-36	796-798	to	_
4-37	799-805	assess	_
4-38	806-818	similarities	_
4-39	819-822	and	_
4-40	823-834	differences	_
4-41	835-837	in	_
4-42	838-853	fronto-temporal	_
4-43	854-859	brain	_
4-44	860-868	function	_
4-45	869-872	and	_
4-46	873-885	connectivity	_
4-47	886-892	during	_
4-48	893-909	social-cognitive	_
4-49	910-920	processing	_
4-50	920-921	.	_

#Text=Analyses employed general linear models to examine differences in amplitude of BOLD-signal response between disorder groups, and computed functional connectivity coefficients to investigate differences in the connectivity profiles of networks implicated in social cognition.
5-1	922-930	Analyses	_
5-2	931-939	employed	_
5-3	940-947	general	_
5-4	948-954	linear	_
5-5	955-961	models	_
5-6	962-964	to	_
5-7	965-972	examine	_
5-8	973-984	differences	_
5-9	985-987	in	_
5-10	988-997	amplitude	_
5-11	998-1000	of	_
5-12	1001-1012	BOLD-signal	_
5-13	1013-1021	response	_
5-14	1022-1029	between	_
5-15	1030-1038	disorder	_
5-16	1039-1045	groups	_
5-17	1045-1046	,	_
5-18	1047-1050	and	_
5-19	1051-1059	computed	_
5-20	1060-1070	functional	_
5-21	1071-1083	connectivity	_
5-22	1084-1096	coefficients	_
5-23	1097-1099	to	_
5-24	1100-1111	investigate	_
5-25	1112-1123	differences	_
5-26	1124-1126	in	_
5-27	1127-1130	the	_
5-28	1131-1143	connectivity	_
5-29	1144-1152	profiles	_
5-30	1153-1155	of	_
5-31	1156-1164	networks	_
5-32	1165-1175	implicated	_
5-33	1176-1178	in	_
5-34	1179-1185	social	_
5-35	1186-1195	cognition	_
5-36	1195-1196	.	_

#Text=Results
#Text=Despite similar behavioral impairments, participants with ASD and schizophrenia evidenced distinct neural abnormalities during perspective-taking.
6-1	1197-1204	Results	_
6-2	1205-1212	Despite	_
6-3	1213-1220	similar	_
6-4	1221-1231	behavioral	_
6-5	1232-1243	impairments	_
6-6	1243-1244	,	_
6-7	1245-1257	participants	_
6-8	1258-1262	with	_
6-9	1263-1266	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
6-10	1267-1270	and	_
6-11	1271-1284	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-12	1285-1294	evidenced	_
6-13	1295-1303	distinct	_
6-14	1304-1310	neural	_
6-15	1311-1324	abnormalities	_
6-16	1325-1331	during	_
6-17	1332-1350	perspective-taking	_
6-18	1350-1351	.	_

#Text=Functional activation results indicated reduced temporo-parietal junction and medial prefrontal activity in ASD compared to schizophrenia (all Puncor < .002).
7-1	1352-1362	Functional	_
7-2	1363-1373	activation	_
7-3	1374-1381	results	_
7-4	1382-1391	indicated	_
7-5	1392-1399	reduced	_
7-6	1400-1416	temporo-parietal	_
7-7	1417-1425	junction	_
7-8	1426-1429	and	_
7-9	1430-1436	medial	_
7-10	1437-1447	prefrontal	_
7-11	1448-1456	activity	_
7-12	1457-1459	in	_
7-13	1460-1463	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
7-14	1464-1472	compared	_
7-15	1473-1475	to	_
7-16	1476-1489	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-17	1490-1491	(	_
7-18	1491-1494	all	_
7-19	1495-1501	Puncor	_
7-20	1502-1503	<	_
7-21	1504-1508	.002	_
7-22	1508-1509	)	_
7-23	1509-1510	.	_

#Text=Functional connectivity analyses further revealed significantly greater local orbitofrontal connectivity in ASD than schizophrenia (all PFDR < .028) during perspective-taking.
8-1	1511-1521	Functional	_
8-2	1522-1534	connectivity	_
8-3	1535-1543	analyses	_
8-4	1544-1551	further	_
8-5	1552-1560	revealed	_
8-6	1561-1574	significantly	_
8-7	1575-1582	greater	_
8-8	1583-1588	local	_
8-9	1589-1602	orbitofrontal	_
8-10	1603-1615	connectivity	_
8-11	1616-1618	in	_
8-12	1619-1622	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
8-13	1623-1627	than	_
8-14	1628-1641	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-15	1642-1643	(	_
8-16	1643-1646	all	_
8-17	1647-1651	PFDR	_
8-18	1652-1653	<	_
8-19	1654-1658	.028	_
8-20	1658-1659	)	_
8-21	1660-1666	during	_
8-22	1667-1685	perspective-taking	_
8-23	1685-1686	.	_

#Text=Differences in brain activation and connectivity were unrelated to antipsychotic medication dose.
9-1	1687-1698	Differences	_
9-2	1699-1701	in	_
9-3	1702-1707	brain	_
9-4	1708-1718	activation	_
9-5	1719-1722	and	_
9-6	1723-1735	connectivity	_
9-7	1736-1740	were	_
9-8	1741-1750	unrelated	_
9-9	1751-1753	to	_
9-10	1754-1767	antipsychotic	_
9-11	1768-1778	medication	_
9-12	1779-1783	dose	_
9-13	1783-1784	.	_

#Text=Conclusions
#Text=Autism and schizophrenia are characterized by similar social-cognitive impairments that may stem from different underlying abnormalities in the functional organization and communication of the social brain.
#Text=1.
10-1	1785-1796	Conclusions	_
10-2	1797-1803	Autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
10-3	1804-1807	and	_
10-4	1808-1821	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-5	1822-1825	are	_
10-6	1826-1839	characterized	_
10-7	1840-1842	by	_
10-8	1843-1850	similar	_
10-9	1851-1867	social-cognitive	_
10-10	1868-1879	impairments	_
10-11	1880-1884	that	_
10-12	1885-1888	may	_
10-13	1889-1893	stem	_
10-14	1894-1898	from	_
10-15	1899-1908	different	_
10-16	1909-1919	underlying	_
10-17	1920-1933	abnormalities	_
10-18	1934-1936	in	_
10-19	1937-1940	the	_
10-20	1941-1951	functional	_
10-21	1952-1964	organization	_
10-22	1965-1968	and	_
10-23	1969-1982	communication	_
10-24	1983-1985	of	_
10-25	1986-1989	the	_
10-26	1990-1996	social	_
10-27	1997-2002	brain	_
10-28	2002-2003	.	_
10-29	2004-2005	1	_
10-30	2005-2006	.	_

#Text=Introduction
#Text=Autism spectrum disorder (ASD) and schizophrenia are neurodevelopmental conditions that share similarities in some of their cognitive and behavioral manifestations.
11-1	2007-2019	Introduction	_
11-2	2020-2026	Autism	_
11-3	2027-2035	spectrum	_
11-4	2036-2044	disorder	_
11-5	2045-2046	(	_
11-6	2046-2049	ASD	_
11-7	2049-2050	)	_
11-8	2051-2054	and	_
11-9	2055-2068	schizophrenia	_
11-10	2069-2072	are	_
11-11	2073-2091	neurodevelopmental	_
11-12	2092-2102	conditions	_
11-13	2103-2107	that	_
11-14	2108-2113	share	_
11-15	2114-2126	similarities	_
11-16	2127-2129	in	_
11-17	2130-2134	some	_
11-18	2135-2137	of	_
11-19	2138-2143	their	_
11-20	2144-2153	cognitive	_
11-21	2154-2157	and	_
11-22	2158-2168	behavioral	_
11-23	2169-2183	manifestations	_
11-24	2183-2184	.	_

#Text=Although the two disorders emerge at different developmental periods, both are characterized by significant impairments in social behavior and understanding.
12-1	2185-2193	Although	_
12-2	2194-2197	the	_
12-3	2198-2201	two	_
12-4	2202-2211	disorders	_
12-5	2212-2218	emerge	_
12-6	2219-2221	at	_
12-7	2222-2231	different	_
12-8	2232-2245	developmental	_
12-9	2246-2253	periods	_
12-10	2253-2254	,	_
12-11	2255-2259	both	_
12-12	2260-2263	are	_
12-13	2264-2277	characterized	_
12-14	2278-2280	by	_
12-15	2281-2292	significant	_
12-16	2293-2304	impairments	_
12-17	2305-2307	in	_
12-18	2308-2314	social	_
12-19	2315-2323	behavior	_
12-20	2324-2327	and	_
12-21	2328-2341	understanding	_
12-22	2341-2342	.	_

#Text=Individuals with these conditions often spend the majority of their adult lives socially isolated, have few to no significant friendships, and a poor quality of life.
13-1	2343-2354	Individuals	_
13-2	2355-2359	with	_
13-3	2360-2365	these	_
13-4	2366-2376	conditions	_
13-5	2377-2382	often	_
13-6	2383-2388	spend	_
13-7	2389-2392	the	_
13-8	2393-2401	majority	_
13-9	2402-2404	of	_
13-10	2405-2410	their	_
13-11	2411-2416	adult	_
13-12	2417-2422	lives	_
13-13	2423-2431	socially	_
13-14	2432-2440	isolated	_
13-15	2440-2441	,	_
13-16	2442-2446	have	_
13-17	2447-2450	few	_
13-18	2451-2453	to	_
13-19	2454-2456	no	_
13-20	2457-2468	significant	_
13-21	2469-2480	friendships	_
13-22	2480-2481	,	_
13-23	2482-2485	and	_
13-24	2486-2487	a	_
13-25	2488-2492	poor	_
13-26	2493-2500	quality	_
13-27	2501-2503	of	_
13-28	2504-2508	life	_
13-29	2508-2509	.	_

#Text=Brain-based impairments in social cognition, e.g., those abilities that support the processing and interpretation of socio-emotional information in oneself and others, have been shown to contribute to some of the interpersonal challenges that characterize ASD and schizophrenia.
14-1	2510-2521	Brain-based	_
14-2	2522-2533	impairments	_
14-3	2534-2536	in	_
14-4	2537-2543	social	_
14-5	2544-2553	cognition	_
14-6	2553-2554	,	_
14-7	2555-2558	e.g	_
14-8	2558-2559	.	_
14-9	2559-2560	,	_
14-10	2561-2566	those	_
14-11	2567-2576	abilities	_
14-12	2577-2581	that	_
14-13	2582-2589	support	_
14-14	2590-2593	the	_
14-15	2594-2604	processing	_
14-16	2605-2608	and	_
14-17	2609-2623	interpretation	_
14-18	2624-2626	of	_
14-19	2627-2642	socio-emotional	_
14-20	2643-2654	information	_
14-21	2655-2657	in	_
14-22	2658-2665	oneself	_
14-23	2666-2669	and	_
14-24	2670-2676	others	_
14-25	2676-2677	,	_
14-26	2678-2682	have	_
14-27	2683-2687	been	_
14-28	2688-2693	shown	_
14-29	2694-2696	to	_
14-30	2697-2707	contribute	_
14-31	2708-2710	to	_
14-32	2711-2715	some	_
14-33	2716-2718	of	_
14-34	2719-2722	the	_
14-35	2723-2736	interpersonal	_
14-36	2737-2747	challenges	_
14-37	2748-2752	that	_
14-38	2753-2765	characterize	_
14-39	2766-2769	ASD	_
14-40	2770-2773	and	_
14-41	2774-2787	schizophrenia	_
14-42	2787-2788	.	_

#Text=Further, direct comparisons of social cognition deficits across the two disorders have yielded analogous profiles and impairments of similar magnitude in many, but not all cases, increasingly suggesting the possibility of common underlying mechanisms contributing to social disability in ASD and schizophrenia.
15-1	2789-2796	Further	_
15-2	2796-2797	,	_
15-3	2798-2804	direct	_
15-4	2805-2816	comparisons	_
15-5	2817-2819	of	_
15-6	2820-2826	social	_
15-7	2827-2836	cognition	_
15-8	2837-2845	deficits	_
15-9	2846-2852	across	_
15-10	2853-2856	the	_
15-11	2857-2860	two	_
15-12	2861-2870	disorders	_
15-13	2871-2875	have	_
15-14	2876-2883	yielded	_
15-15	2884-2893	analogous	_
15-16	2894-2902	profiles	_
15-17	2903-2906	and	_
15-18	2907-2918	impairments	_
15-19	2919-2921	of	_
15-20	2922-2929	similar	_
15-21	2930-2939	magnitude	_
15-22	2940-2942	in	_
15-23	2943-2947	many	_
15-24	2947-2948	,	_
15-25	2949-2952	but	_
15-26	2953-2956	not	_
15-27	2957-2960	all	_
15-28	2961-2966	cases	_
15-29	2966-2967	,	_
15-30	2968-2980	increasingly	_
15-31	2981-2991	suggesting	_
15-32	2992-2995	the	_
15-33	2996-3007	possibility	_
15-34	3008-3010	of	_
15-35	3011-3017	common	_
15-36	3018-3028	underlying	_
15-37	3029-3039	mechanisms	_
15-38	3040-3052	contributing	_
15-39	3053-3055	to	_
15-40	3056-3062	social	_
15-41	3063-3073	disability	_
15-42	3074-3076	in	_
15-43	3077-3080	ASD	_
15-44	3081-3084	and	_
15-45	3085-3098	schizophrenia	_
15-46	3098-3099	.	_

#Text=Emerging biological evidence has supported the notion of shared genetic and neural mechanisms across autism and schizophrenia spectra.
16-1	3100-3108	Emerging	_
16-2	3109-3119	biological	_
16-3	3120-3128	evidence	_
16-4	3129-3132	has	_
16-5	3133-3142	supported	_
16-6	3143-3146	the	_
16-7	3147-3153	notion	_
16-8	3154-3156	of	_
16-9	3157-3163	shared	_
16-10	3164-3171	genetic	_
16-11	3172-3175	and	_
16-12	3176-3182	neural	_
16-13	3183-3193	mechanisms	_
16-14	3194-3200	across	_
16-15	3201-3207	autism	_
16-16	3208-3211	and	_
16-17	3212-3225	schizophrenia	_
16-18	3226-3233	spectra	_
16-19	3233-3234	.	_

#Text=With respect to studies of brain functions supporting social cognition, a recent meta-analysis of the separate social neuroscience literatures in ASD and schizophrenia indicated that both conditions were characterized by medial-temporal and ventrolateral prefrontal hypoactivity during social-cognitive processing. found similarly reduced brain activity in the amygdala, fusiform gyrus and ventrolateral prefrontal cortex in 12 adults with ASD and 12 adults with paranoid schizophrenia during a trustworthiness task. also found comparable reductions in superior temporal sulcus and ventromedial prefrontal cortex activity during a mentalizing task relative to healthy volunteers among 23 individuals with ASD and 18 patients with paranoid schizophrenia.
17-1	3235-3239	With	_
17-2	3240-3247	respect	_
17-3	3248-3250	to	_
17-4	3251-3258	studies	_
17-5	3259-3261	of	_
17-6	3262-3267	brain	_
17-7	3268-3277	functions	_
17-8	3278-3288	supporting	_
17-9	3289-3295	social	_
17-10	3296-3305	cognition	_
17-11	3305-3306	,	_
17-12	3307-3308	a	_
17-13	3309-3315	recent	_
17-14	3316-3329	meta-analysis	_
17-15	3330-3332	of	_
17-16	3333-3336	the	_
17-17	3337-3345	separate	_
17-18	3346-3352	social	_
17-19	3353-3365	neuroscience	_
17-20	3366-3377	literatures	_
17-21	3378-3380	in	_
17-22	3381-3384	ASD	_
17-23	3385-3388	and	_
17-24	3389-3402	schizophrenia	_
17-25	3403-3412	indicated	_
17-26	3413-3417	that	_
17-27	3418-3422	both	_
17-28	3423-3433	conditions	_
17-29	3434-3438	were	_
17-30	3439-3452	characterized	_
17-31	3453-3455	by	_
17-32	3456-3471	medial-temporal	_
17-33	3472-3475	and	_
17-34	3476-3489	ventrolateral	_
17-35	3490-3500	prefrontal	_
17-36	3501-3513	hypoactivity	_
17-37	3514-3520	during	_
17-38	3521-3537	social-cognitive	_
17-39	3538-3548	processing	_
17-40	3548-3549	.	_
17-41	3550-3555	found	_
17-42	3556-3565	similarly	_
17-43	3566-3573	reduced	_
17-44	3574-3579	brain	_
17-45	3580-3588	activity	_
17-46	3589-3591	in	_
17-47	3592-3595	the	_
17-48	3596-3604	amygdala	_
17-49	3604-3605	,	_
17-50	3606-3614	fusiform	_
17-51	3615-3620	gyrus	_
17-52	3621-3624	and	_
17-53	3625-3638	ventrolateral	_
17-54	3639-3649	prefrontal	_
17-55	3650-3656	cortex	_
17-56	3657-3659	in	_
17-57	3660-3662	12	_
17-58	3663-3669	adults	_
17-59	3670-3674	with	_
17-60	3675-3678	ASD	_
17-61	3679-3682	and	_
17-62	3683-3685	12	_
17-63	3686-3692	adults	_
17-64	3693-3697	with	_
17-65	3698-3706	paranoid	_
17-66	3707-3720	schizophrenia	_
17-67	3721-3727	during	_
17-68	3728-3729	a	_
17-69	3730-3745	trustworthiness	_
17-70	3746-3750	task	_
17-71	3750-3751	.	_
17-72	3752-3756	also	_
17-73	3757-3762	found	_
17-74	3763-3773	comparable	_
17-75	3774-3784	reductions	_
17-76	3785-3787	in	_
17-77	3788-3796	superior	_
17-78	3797-3805	temporal	_
17-79	3806-3812	sulcus	_
17-80	3813-3816	and	_
17-81	3817-3829	ventromedial	_
17-82	3830-3840	prefrontal	_
17-83	3841-3847	cortex	_
17-84	3848-3856	activity	_
17-85	3857-3863	during	_
17-86	3864-3865	a	_
17-87	3866-3877	mentalizing	_
17-88	3878-3882	task	_
17-89	3883-3891	relative	_
17-90	3892-3894	to	_
17-91	3895-3902	healthy	_
17-92	3903-3913	volunteers	_
17-93	3914-3919	among	_
17-94	3920-3922	23	_
17-95	3923-3934	individuals	_
17-96	3935-3939	with	_
17-97	3940-3943	ASD	_
17-98	3944-3947	and	_
17-99	3948-3950	18	_
17-100	3951-3959	patients	_
17-101	3960-3964	with	_
17-102	3965-3973	paranoid	_
17-103	3974-3987	schizophrenia	_
17-104	3987-3988	.	_

#Text=Furthermore, they extended this work to examine functional connectivity, and found that both autism and schizophrenia were characterized by reduced fronto-temporal (superior temporal sulcus to ventromedial prefrontal cortex) connectivity.
18-1	3989-4000	Furthermore	_
18-2	4000-4001	,	_
18-3	4002-4006	they	_
18-4	4007-4015	extended	_
18-5	4016-4020	this	_
18-6	4021-4025	work	_
18-7	4026-4028	to	_
18-8	4029-4036	examine	_
18-9	4037-4047	functional	_
18-10	4048-4060	connectivity	_
18-11	4060-4061	,	_
18-12	4062-4065	and	_
18-13	4066-4071	found	_
18-14	4072-4076	that	_
18-15	4077-4081	both	_
18-16	4082-4088	autism	_
18-17	4089-4092	and	_
18-18	4093-4106	schizophrenia	_
18-19	4107-4111	were	_
18-20	4112-4125	characterized	_
18-21	4126-4128	by	_
18-22	4129-4136	reduced	_
18-23	4137-4152	fronto-temporal	_
18-24	4153-4154	(	_
18-25	4154-4162	superior	_
18-26	4163-4171	temporal	_
18-27	4172-4178	sulcus	_
18-28	4179-4181	to	_
18-29	4182-4194	ventromedial	_
18-30	4195-4205	prefrontal	_
18-31	4206-4212	cortex	_
18-32	4212-4213	)	_
18-33	4214-4226	connectivity	_
18-34	4226-4227	.	_

#Text=This growing literature suggests that the behavioral overlap in social-cognitive deficits present in ASD and schizophrenia may be due to shared neural mechanisms reflecting reduced coordination and activation of fronto-temporal systems.
19-1	4228-4232	This	_
19-2	4233-4240	growing	_
19-3	4241-4251	literature	_
19-4	4252-4260	suggests	_
19-5	4261-4265	that	_
19-6	4266-4269	the	_
19-7	4270-4280	behavioral	_
19-8	4281-4288	overlap	_
19-9	4289-4291	in	_
19-10	4292-4308	social-cognitive	_
19-11	4309-4317	deficits	_
19-12	4318-4325	present	_
19-13	4326-4328	in	_
19-14	4329-4332	ASD	_
19-15	4333-4336	and	_
19-16	4337-4350	schizophrenia	_
19-17	4351-4354	may	_
19-18	4355-4357	be	_
19-19	4358-4361	due	_
19-20	4362-4364	to	_
19-21	4365-4371	shared	_
19-22	4372-4378	neural	_
19-23	4379-4389	mechanisms	_
19-24	4390-4400	reflecting	_
19-25	4401-4408	reduced	_
19-26	4409-4421	coordination	_
19-27	4422-4425	and	_
19-28	4426-4436	activation	_
19-29	4437-4439	of	_
19-30	4440-4455	fronto-temporal	_
19-31	4456-4463	systems	_
19-32	4463-4464	.	_

#Text=However, few studies have directly compared social-cognitive brain function in the two disorders, particularly in adequately powered samples.
20-1	4465-4472	However	_
20-2	4472-4473	,	_
20-3	4474-4477	few	_
20-4	4478-4485	studies	_
20-5	4486-4490	have	_
20-6	4491-4499	directly	_
20-7	4500-4508	compared	_
20-8	4509-4525	social-cognitive	_
20-9	4526-4531	brain	_
20-10	4532-4540	function	_
20-11	4541-4543	in	_
20-12	4544-4547	the	_
20-13	4548-4551	two	_
20-14	4552-4561	disorders	_
20-15	4561-4562	,	_
20-16	4563-4575	particularly	_
20-17	4576-4578	in	_
20-18	4579-4589	adequately	_
20-19	4590-4597	powered	_
20-20	4598-4605	samples	_
20-21	4605-4606	.	_

#Text=This study sought to examine fronto-temporal brain function and connectivity during a visual perspective-taking task among individuals with ASD, schizophrenia, and healthy volunteers.
21-1	4607-4611	This	_
21-2	4612-4617	study	_
21-3	4618-4624	sought	_
21-4	4625-4627	to	_
21-5	4628-4635	examine	_
21-6	4636-4651	fronto-temporal	_
21-7	4652-4657	brain	_
21-8	4658-4666	function	_
21-9	4667-4670	and	_
21-10	4671-4683	connectivity	_
21-11	4684-4690	during	_
21-12	4691-4692	a	_
21-13	4693-4699	visual	_
21-14	4700-4718	perspective-taking	_
21-15	4719-4723	task	_
21-16	4724-4729	among	_
21-17	4730-4741	individuals	_
21-18	4742-4746	with	_
21-19	4747-4750	ASD	_
21-20	4750-4751	,	_
21-21	4752-4765	schizophrenia	_
21-22	4765-4766	,	_
21-23	4767-4770	and	_
21-24	4771-4778	healthy	_
21-25	4779-4789	volunteers	_
21-26	4789-4790	.	_

#Text=It was hypothesized that relative to healthy individuals, participants with ASD and schizophrenia would evidence similar reductions in fronto-temporal activity in social-cognitive brain networks during perspective-taking.
22-1	4791-4793	It	_
22-2	4794-4797	was	_
22-3	4798-4810	hypothesized	_
22-4	4811-4815	that	_
22-5	4816-4824	relative	_
22-6	4825-4827	to	_
22-7	4828-4835	healthy	_
22-8	4836-4847	individuals	_
22-9	4847-4848	,	_
22-10	4849-4861	participants	_
22-11	4862-4866	with	_
22-12	4867-4870	ASD	_
22-13	4871-4874	and	_
22-14	4875-4888	schizophrenia	_
22-15	4889-4894	would	_
22-16	4895-4903	evidence	_
22-17	4904-4911	similar	_
22-18	4912-4922	reductions	_
22-19	4923-4925	in	_
22-20	4926-4941	fronto-temporal	_
22-21	4942-4950	activity	_
22-22	4951-4953	in	_
22-23	4954-4970	social-cognitive	_
22-24	4971-4976	brain	_
22-25	4977-4985	networks	_
22-26	4986-4992	during	_
22-27	4993-5011	perspective-taking	_
22-28	5011-5012	.	_

#Text=Further, it was hypothesized that both patient groups would demonstrate reduced functional connectivity between prefrontal and temporal networks previously shown to support perspective-taking in healthy individuals.
#Text=2.
23-1	5013-5020	Further	_
23-2	5020-5021	,	_
23-3	5022-5024	it	_
23-4	5025-5028	was	_
23-5	5029-5041	hypothesized	_
23-6	5042-5046	that	_
23-7	5047-5051	both	_
23-8	5052-5059	patient	_
23-9	5060-5066	groups	_
23-10	5067-5072	would	_
23-11	5073-5084	demonstrate	_
23-12	5085-5092	reduced	_
23-13	5093-5103	functional	_
23-14	5104-5116	connectivity	_
23-15	5117-5124	between	_
23-16	5125-5135	prefrontal	_
23-17	5136-5139	and	_
23-18	5140-5148	temporal	_
23-19	5149-5157	networks	_
23-20	5158-5168	previously	_
23-21	5169-5174	shown	_
23-22	5175-5177	to	_
23-23	5178-5185	support	_
23-24	5186-5204	perspective-taking	_
23-25	5205-5207	in	_
23-26	5208-5215	healthy	_
23-27	5216-5227	individuals	_
23-28	5227-5228	.	_
23-29	5229-5230	2	_
23-30	5230-5231	.	_

#Text=Method
#Text=2.1.
24-1	5232-5238	Method	http://www.case.edu/ProvCaRe/provcare#StudyMethod
24-2	5239-5242	2.1	_
24-3	5242-5243	.	_

#Text=Participants
#Text=Participants consisted of 36 individuals with schizophrenia or schizoaffective disorder, 33 individuals with ASD, and 37 healthy volunteers.
25-1	5244-5256	Participants	_
25-2	5257-5269	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-3	5270-5279	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-4	5280-5282	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-5	5283-5285	36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-6	5286-5297	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
25-7	5298-5302	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
25-8	5303-5316	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
25-9	5317-5319	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
25-10	5320-5335	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[8]
25-11	5336-5344	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[8]
25-12	5344-5345	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-13	5346-5348	33	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-14	5349-5360	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[9]
25-15	5361-5365	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[9]
25-16	5366-5369	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[9]
25-17	5369-5370	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-18	5371-5374	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-19	5375-5377	37	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
25-20	5378-5385	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
25-21	5386-5396	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
25-22	5396-5397	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=Participants were recruited for brain imaging studies at the University of Pittsburgh and generally included if they were age 18 years or older, had an IQ ≥ 80, and were free from any MRI contraindications.
26-1	5398-5410	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-2	5411-5415	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-3	5416-5425	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-4	5426-5429	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-5	5430-5435	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-6	5436-5443	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-7	5444-5451	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-8	5452-5454	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-9	5455-5458	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-10	5459-5469	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-11	5470-5472	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-12	5473-5483	Pittsburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-13	5484-5487	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-14	5488-5497	generally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-15	5498-5506	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-16	5507-5509	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-17	5510-5514	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-18	5515-5519	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-19	5520-5523	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-20	5524-5526	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-21	5527-5532	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-22	5533-5535	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-23	5536-5541	older	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-24	5541-5542	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-25	5543-5546	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-26	5547-5549	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-27	5550-5552	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-28	5553-5554	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-29	5555-5557	80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-30	5557-5558	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-31	5559-5562	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-32	5563-5567	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-33	5568-5572	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-34	5573-5577	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-35	5578-5581	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-36	5582-5585	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[12]
26-37	5586-5603	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
26-38	5603-5604	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=Individuals with schizophrenia (n = 31) or schizoaffective disorder (n = 5) were required to be receiving antipsychotic medication and have their diagnosis verified by the Structured Clinical Interview for DSM-IV (SCID).
27-1	5605-5616	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-2	5617-5621	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-3	5622-5635	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-4	5636-5637	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-5	5637-5638	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-6	5639-5640	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-7	5641-5643	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-8	5643-5644	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-9	5645-5647	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
27-10	5648-5663	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[15]
27-11	5664-5672	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[15]
27-12	5673-5674	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-13	5674-5675	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-14	5676-5677	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-15	5678-5679	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-16	5679-5680	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-17	5681-5685	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-18	5686-5694	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-19	5695-5697	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-20	5698-5700	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-21	5701-5710	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-22	5711-5724	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-23	5725-5735	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-24	5736-5739	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-25	5740-5744	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-26	5745-5750	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-27	5751-5760	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-28	5761-5769	verified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-29	5770-5772	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-30	5773-5776	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
27-31	5777-5787	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-32	5788-5796	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-33	5797-5806	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-34	5807-5810	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-35	5811-5817	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-36	5818-5819	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-37	5819-5823	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-38	5823-5824	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[16]
27-39	5824-5825	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=Individuals with ASD were required to meet criteria for autism (n = 17) or autism spectrum disorder (n = 15) based on the Autism Diagnostic Observation Schedule (ADOS).
28-1	5826-5837	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[18]
28-2	5838-5842	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[18]
28-3	5843-5846	ASD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[18]
28-4	5847-5851	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-5	5852-5860	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-6	5861-5863	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-7	5864-5868	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-8	5869-5877	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-9	5878-5881	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-10	5882-5888	autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[19]
28-11	5889-5890	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-12	5890-5891	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-13	5892-5893	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-14	5894-5896	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-15	5896-5897	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-16	5898-5900	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-17	5901-5907	autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[20]
28-18	5908-5916	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[20]
28-19	5917-5925	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder[20]
28-20	5926-5927	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-21	5927-5928	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-22	5929-5930	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-23	5931-5933	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-24	5933-5934	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-25	5935-5940	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-26	5941-5943	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-27	5944-5947	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
28-28	5948-5954	Autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-29	5955-5965	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-30	5966-5977	Observation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-31	5978-5986	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-32	5987-5988	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-33	5988-5992	ADOS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-34	5992-5993	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[21]
28-35	5993-5994	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]

#Text=Healthy individuals were included if they were free from a current psychiatric diagnosis as evaluated using the SCID.
29-1	5995-6002	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]
29-2	6003-6014	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]
29-3	6015-6019	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-4	6020-6028	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-5	6029-6031	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-6	6032-6036	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-7	6037-6041	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-8	6042-6046	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-9	6047-6051	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-10	6052-6053	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-11	6054-6061	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-12	6062-6073	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-13	6074-6083	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-14	6084-6086	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-15	6087-6096	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-16	6097-6102	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-17	6103-6106	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
29-18	6107-6111	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
29-19	6111-6112	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]

#Text=Table 1 provides an overview of demographic and clinical characteristics for the sample.
30-1	6113-6118	Table	_
30-2	6119-6120	1	_
30-3	6121-6129	provides	_
30-4	6130-6132	an	_
30-5	6133-6141	overview	_
30-6	6142-6144	of	_
30-7	6145-6156	demographic	_
30-8	6157-6160	and	_
30-9	6161-6169	clinical	_
30-10	6170-6185	characteristics	_
30-11	6186-6189	for	_
30-12	6190-6193	the	_
30-13	6194-6200	sample	_
30-14	6200-6201	.	_

#Text=Participants were mostly young adults and predominantly male.
31-1	6202-6214	Participants	_
31-2	6215-6219	were	_
31-3	6220-6226	mostly	_
31-4	6227-6232	young	_
31-5	6233-6239	adults	_
31-6	6240-6243	and	_
31-7	6244-6257	predominantly	_
31-8	6258-6262	male	_
31-9	6262-6263	.	_

#Text=No significant differences were observed between study groups with regard to age, race, or IQ.
32-1	6264-6266	No	_
32-2	6267-6278	significant	_
32-3	6279-6290	differences	_
32-4	6291-6295	were	_
32-5	6296-6304	observed	_
32-6	6305-6312	between	_
32-7	6313-6318	study	_
32-8	6319-6325	groups	_
32-9	6326-6330	with	_
32-10	6331-6337	regard	_
32-11	6338-6340	to	_
32-12	6341-6344	age	_
32-13	6344-6345	,	_
32-14	6346-6350	race	_
32-15	6350-6351	,	_
32-16	6352-6354	or	_
32-17	6355-6357	IQ	_
32-18	6357-6358	.	_

#Text=However, fewer individuals with ASD were female, and healthy volunteers had attended more years of education than both patient groups (all p < .001), with no difference between patients (p = .679).
33-1	6359-6366	However	_
33-2	6366-6367	,	_
33-3	6368-6373	fewer	_
33-4	6374-6385	individuals	_
33-5	6386-6390	with	_
33-6	6391-6394	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
33-7	6395-6399	were	_
33-8	6400-6406	female	_
33-9	6406-6407	,	_
33-10	6408-6411	and	_
33-11	6412-6419	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]
33-12	6420-6430	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]
33-13	6431-6434	had	_
33-14	6435-6443	attended	_
33-15	6444-6448	more	_
33-16	6449-6454	years	_
33-17	6455-6457	of	_
33-18	6458-6467	education	_
33-19	6468-6472	than	_
33-20	6473-6477	both	_
33-21	6478-6485	patient	_
33-22	6486-6492	groups	_
33-23	6493-6494	(	_
33-24	6494-6497	all	_
33-25	6498-6499	p	_
33-26	6500-6501	<	_
33-27	6502-6506	.001	_
33-28	6506-6507	)	_
33-29	6507-6508	,	_
33-30	6509-6513	with	_
33-31	6514-6516	no	_
33-32	6517-6527	difference	_
33-33	6528-6535	between	_
33-34	6536-6544	patients	_
33-35	6545-6546	(	_
33-36	6546-6547	p	_
33-37	6548-6549	=	_
33-38	6550-6554	.679	_
33-39	6554-6555	)	_
33-40	6555-6556	.	_

#Text=All individuals with schizophrenia were receiving antipsychotic medication, by design, and 3 individuals with ASD were receiving antipsychotic treatment as part of their routine care.
34-1	6557-6560	All	_
34-2	6561-6572	individuals	_
34-3	6573-6577	with	_
34-4	6578-6591	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
34-5	6592-6596	were	_
34-6	6597-6606	receiving	_
34-7	6607-6620	antipsychotic	_
34-8	6621-6631	medication	_
34-9	6631-6632	,	_
34-10	6633-6635	by	_
34-11	6636-6642	design	_
34-12	6642-6643	,	_
34-13	6644-6647	and	_
34-14	6648-6649	3	_
34-15	6650-6661	individuals	_
34-16	6662-6666	with	_
34-17	6667-6670	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
34-18	6671-6675	were	_
34-19	6676-6685	receiving	_
34-20	6686-6699	antipsychotic	_
34-21	6700-6709	treatment	_
34-22	6710-6712	as	_
34-23	6713-6717	part	_
34-24	6718-6720	of	_
34-25	6721-6726	their	_
34-26	6727-6734	routine	_
34-27	6735-6739	care	_
34-28	6739-6740	.	_

#Text=Psychiatric symptomatology was low for all groups, significantly lower for healthy individuals than patients (all p < .001), and not significantly different between ASD and schizophrenia (p = .580).
#Text=2.2.
35-1	6741-6752	Psychiatric	_
35-2	6753-6767	symptomatology	_
35-3	6768-6771	was	_
35-4	6772-6775	low	_
35-5	6776-6779	for	_
35-6	6780-6783	all	_
35-7	6784-6790	groups	_
35-8	6790-6791	,	_
35-9	6792-6805	significantly	_
35-10	6806-6811	lower	_
35-11	6812-6815	for	_
35-12	6816-6823	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
35-13	6824-6835	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
35-14	6836-6840	than	_
35-15	6841-6849	patients	_
35-16	6850-6851	(	_
35-17	6851-6854	all	_
35-18	6855-6856	p	_
35-19	6857-6858	<	_
35-20	6859-6863	.001	_
35-21	6863-6864	)	_
35-22	6864-6865	,	_
35-23	6866-6869	and	_
35-24	6870-6873	not	_
35-25	6874-6887	significantly	_
35-26	6888-6897	different	_
35-27	6898-6905	between	_
35-28	6906-6909	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
35-29	6910-6913	and	_
35-30	6914-6927	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
35-31	6928-6929	(	_
35-32	6929-6930	p	_
35-33	6931-6932	=	_
35-34	6933-6937	.580	_
35-35	6937-6938	)	_
35-36	6938-6939	.	_
35-37	6940-6943	2.2	_
35-38	6943-6944	.	_

#Text=Visual Perspective-Taking Task
#Text=Brain functions supporting visual perspective-taking ability were assessed using a novel paradigm based on a looking-time task developed by Epley and colleagues and previously described elsewhere.
36-1	6945-6951	Visual	_
36-2	6952-6970	Perspective-Taking	_
36-3	6971-6975	Task	_
36-4	6976-6981	Brain	_
36-5	6982-6991	functions	_
36-6	6992-7002	supporting	_
36-7	7003-7009	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-8	7010-7028	perspective-taking	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-9	7029-7036	ability	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-10	7037-7041	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-11	7042-7050	assessed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-12	7051-7056	using	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-13	7057-7058	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-14	7059-7064	novel	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-15	7065-7073	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-16	7074-7079	based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-17	7080-7082	on	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-18	7083-7084	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-19	7085-7097	looking-time	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-20	7098-7102	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]
36-21	7103-7112	developed	_
36-22	7113-7115	by	_
36-23	7116-7121	Epley	_
36-24	7122-7125	and	_
36-25	7126-7136	colleagues	_
36-26	7137-7140	and	_
36-27	7141-7151	previously	_
36-28	7152-7161	described	_
36-29	7162-7171	elsewhere	_
36-30	7171-7172	.	_

#Text=The task requires participants to identify items in a 5 × 5 virtual grid array (see Figure 1) from the perspective of a confederate (the research assistant).
37-1	7173-7176	The	_
37-2	7177-7181	task	_
37-3	7182-7190	requires	_
37-4	7191-7203	participants	_
37-5	7204-7206	to	_
37-6	7207-7215	identify	_
37-7	7216-7221	items	_
37-8	7222-7224	in	_
37-9	7225-7226	a	_
37-10	7227-7228	5	_
37-11	7229-7230	×	_
37-12	7231-7232	5	_
37-13	7233-7240	virtual	_
37-14	7241-7245	grid	_
37-15	7246-7251	array	_
37-16	7252-7253	(	_
37-17	7253-7256	see	_
37-18	7257-7263	Figure	_
37-19	7264-7265	1	_
37-20	7265-7266	)	_
37-21	7267-7271	from	_
37-22	7272-7275	the	_
37-23	7276-7287	perspective	_
37-24	7288-7290	of	_
37-25	7291-7292	a	_
37-26	7293-7304	confederate	_
37-27	7305-7306	(	_
37-28	7306-7309	the	_
37-29	7310-7318	research	_
37-30	7319-7328	assistant	_
37-31	7328-7329	)	_
37-32	7329-7330	.	_

#Text=The virtual grid array contains two sides with four occludes, such that items visible from the participant’s perspective are not always in view from the perspective of the assistant.
38-1	7331-7334	The	_
38-2	7335-7342	virtual	_
38-3	7343-7347	grid	_
38-4	7348-7353	array	_
38-5	7354-7362	contains	_
38-6	7363-7366	two	_
38-7	7367-7372	sides	_
38-8	7373-7377	with	_
38-9	7378-7382	four	_
38-10	7383-7391	occludes	_
38-11	7391-7392	,	_
38-12	7393-7397	such	_
38-13	7398-7402	that	_
38-14	7403-7408	items	_
38-15	7409-7416	visible	_
38-16	7417-7421	from	_
38-17	7422-7425	the	_
38-18	7426-7437	participant	_
38-19	7437-7438	’	_
38-20	7438-7439	s	_
38-21	7440-7451	perspective	_
38-22	7452-7455	are	_
38-23	7456-7459	not	_
38-24	7460-7466	always	_
38-25	7467-7469	in	_
38-26	7470-7474	view	_
38-27	7475-7479	from	_
38-28	7480-7483	the	_
38-29	7484-7495	perspective	_
38-30	7496-7498	of	_
38-31	7499-7502	the	_
38-32	7503-7512	assistant	_
38-33	7512-7513	.	_

#Text=Participants were instructed that the research assistant was going to play the game with them from the MRI control room and that because the assistant would only be able to see the back of the array, the participant had to be sure to only select objects that the assistant could see from her perspective.
39-1	7514-7526	Participants	_
39-2	7527-7531	were	_
39-3	7532-7542	instructed	_
39-4	7543-7547	that	_
39-5	7548-7551	the	_
39-6	7552-7560	research	_
39-7	7561-7570	assistant	_
39-8	7571-7574	was	_
39-9	7575-7580	going	_
39-10	7581-7583	to	_
39-11	7584-7588	play	_
39-12	7589-7592	the	_
39-13	7593-7597	game	_
39-14	7598-7602	with	_
39-15	7603-7607	them	_
39-16	7608-7612	from	_
39-17	7613-7616	the	_
39-18	7617-7620	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-19	7621-7628	control	_
39-20	7629-7633	room	_
39-21	7634-7637	and	_
39-22	7638-7642	that	_
39-23	7643-7650	because	_
39-24	7651-7654	the	_
39-25	7655-7664	assistant	_
39-26	7665-7670	would	_
39-27	7671-7675	only	_
39-28	7676-7678	be	_
39-29	7679-7683	able	_
39-30	7684-7686	to	_
39-31	7687-7690	see	_
39-32	7691-7694	the	_
39-33	7695-7699	back	_
39-34	7700-7702	of	_
39-35	7703-7706	the	_
39-36	7707-7712	array	_
39-37	7712-7713	,	_
39-38	7714-7717	the	_
39-39	7718-7729	participant	_
39-40	7730-7733	had	_
39-41	7734-7736	to	_
39-42	7737-7739	be	_
39-43	7740-7744	sure	_
39-44	7745-7747	to	_
39-45	7748-7752	only	_
39-46	7753-7759	select	_
39-47	7760-7767	objects	_
39-48	7768-7772	that	_
39-49	7773-7776	the	_
39-50	7777-7786	assistant	_
39-51	7787-7792	could	_
39-52	7793-7796	see	_
39-53	7797-7801	from	_
39-54	7802-7805	her	_
39-55	7806-7817	perspective	_
39-56	7817-7818	.	_

#Text=The target object and 8 distractor objects, randomly interspersed, then appeared in the array for each trial.
40-1	7819-7822	The	_
40-2	7823-7829	target	_
40-3	7830-7836	object	_
40-4	7837-7840	and	_
40-5	7841-7842	8	_
40-6	7843-7853	distractor	_
40-7	7854-7861	objects	_
40-8	7861-7862	,	_
40-9	7863-7871	randomly	_
40-10	7872-7884	interspersed	_
40-11	7884-7885	,	_
40-12	7886-7890	then	_
40-13	7891-7899	appeared	_
40-14	7900-7902	in	_
40-15	7903-7906	the	_
40-16	7907-7912	array	_
40-17	7913-7916	for	_
40-18	7917-7921	each	_
40-19	7922-7927	trial	_
40-20	7927-7928	.	_

#Text=Trials were 8000 ms in length and consisted of a 2500 ms instruction image (e.g., “hand me the bottle”), a 3500 ms task image displaying the grid array and selection options, and a 2000 ms fixed inter-trial interval during which a blank fixation screen was presented.
41-1	7929-7935	Trials	_
41-2	7936-7940	were	_
41-3	7941-7945	8000	_
41-4	7946-7948	ms	_
41-5	7949-7951	in	_
41-6	7952-7958	length	_
41-7	7959-7962	and	_
41-8	7963-7972	consisted	_
41-9	7973-7975	of	_
41-10	7976-7977	a	_
41-11	7978-7982	2500	_
41-12	7983-7985	ms	_
41-13	7986-7997	instruction	_
41-14	7998-8003	image	_
41-15	8004-8005	(	_
41-16	8005-8008	e.g	_
41-17	8008-8009	.	_
41-18	8009-8010	,	_
41-19	8011-8012	“	_
41-20	8012-8016	hand	_
41-21	8017-8019	me	_
41-22	8020-8023	the	_
41-23	8024-8030	bottle	_
41-24	8030-8031	”	_
41-25	8031-8032	)	_
41-26	8032-8033	,	_
41-27	8034-8035	a	_
41-28	8036-8040	3500	_
41-29	8041-8043	ms	_
41-30	8044-8048	task	_
41-31	8049-8054	image	_
41-32	8055-8065	displaying	_
41-33	8066-8069	the	_
41-34	8070-8074	grid	_
41-35	8075-8080	array	_
41-36	8081-8084	and	_
41-37	8085-8094	selection	_
41-38	8095-8102	options	_
41-39	8102-8103	,	_
41-40	8104-8107	and	_
41-41	8108-8109	a	_
41-42	8110-8114	2000	_
41-43	8115-8117	ms	_
41-44	8118-8123	fixed	_
41-45	8124-8135	inter-trial	_
41-46	8136-8144	interval	_
41-47	8145-8151	during	_
41-48	8152-8157	which	_
41-49	8158-8159	a	_
41-50	8160-8165	blank	_
41-51	8166-8174	fixation	_
41-52	8175-8181	screen	_
41-53	8182-8185	was	_
41-54	8186-8195	presented	_
41-55	8195-8196	.	_

#Text=A total of 63 trials were administered in blocks of 7 trials each, which consisted of either randomly interspersed control (k = 27) or perspective-taking trials (k = 36).
42-1	8197-8198	A	_
42-2	8199-8204	total	_
42-3	8205-8207	of	_
42-4	8208-8210	63	_
42-5	8211-8217	trials	_
42-6	8218-8222	were	_
42-7	8223-8235	administered	_
42-8	8236-8238	in	_
42-9	8239-8245	blocks	_
42-10	8246-8248	of	_
42-11	8249-8250	7	_
42-12	8251-8257	trials	_
42-13	8258-8262	each	_
42-14	8262-8263	,	_
42-15	8264-8269	which	_
42-16	8270-8279	consisted	_
42-17	8280-8282	of	_
42-18	8283-8289	either	_
42-19	8290-8298	randomly	_
42-20	8299-8311	interspersed	_
42-21	8312-8319	control	_
42-22	8320-8321	(	_
42-23	8321-8322	k	_
42-24	8323-8324	=	_
42-25	8325-8327	27	_
42-26	8327-8328	)	_
42-27	8329-8331	or	_
42-28	8332-8350	perspective-taking	_
42-29	8351-8357	trials	_
42-30	8358-8359	(	_
42-31	8359-8360	k	_
42-32	8361-8362	=	_
42-33	8363-8365	36	_
42-34	8365-8366	)	_
42-35	8366-8367	.	_

#Text=Although the task was administered in blocks, it was modeled using an event-related design because of the random interspersion of control and perspective-taking trials within a single block.
43-1	8368-8376	Although	_
43-2	8377-8380	the	_
43-3	8381-8385	task	_
43-4	8386-8389	was	_
43-5	8390-8402	administered	_
43-6	8403-8405	in	_
43-7	8406-8412	blocks	_
43-8	8412-8413	,	_
43-9	8414-8416	it	_
43-10	8417-8420	was	_
43-11	8421-8428	modeled	_
43-12	8429-8434	using	_
43-13	8435-8437	an	_
43-14	8438-8451	event-related	_
43-15	8452-8458	design	_
43-16	8459-8466	because	_
43-17	8467-8469	of	_
43-18	8470-8473	the	_
43-19	8474-8480	random	_
43-20	8481-8494	interspersion	_
43-21	8495-8497	of	_
43-22	8498-8505	control	_
43-23	8506-8509	and	_
43-24	8510-8528	perspective-taking	_
43-25	8529-8535	trials	_
43-26	8536-8542	within	_
43-27	8543-8544	a	_
43-28	8545-8551	single	_
43-29	8552-8557	block	_
43-30	8557-8558	.	_

#Text=All conditions asked the participant to complete the same task: select an item in the grid array from the visual perspective of the assistant.
44-1	8559-8562	All	_
44-2	8563-8573	conditions	_
44-3	8574-8579	asked	_
44-4	8580-8583	the	_
44-5	8584-8595	participant	_
44-6	8596-8598	to	_
44-7	8599-8607	complete	_
44-8	8608-8611	the	_
44-9	8612-8616	same	_
44-10	8617-8621	task	_
44-11	8621-8622	:	_
44-12	8623-8629	select	_
44-13	8630-8632	an	_
44-14	8633-8637	item	_
44-15	8638-8640	in	_
44-16	8641-8644	the	_
44-17	8645-8649	grid	_
44-18	8650-8655	array	_
44-19	8656-8660	from	_
44-20	8661-8664	the	_
44-21	8665-8671	visual	_
44-22	8672-8683	perspective	_
44-23	8684-8686	of	_
44-24	8687-8690	the	_
44-25	8691-8700	assistant	_
44-26	8700-8701	.	_

#Text=During control trials, this item was unambiguous and not occluded from the view of the assistant.
45-1	8702-8708	During	_
45-2	8709-8716	control	_
45-3	8717-8723	trials	_
45-4	8723-8724	,	_
45-5	8725-8729	this	_
45-6	8730-8734	item	_
45-7	8735-8738	was	_
45-8	8739-8750	unambiguous	_
45-9	8751-8754	and	_
45-10	8755-8758	not	_
45-11	8759-8767	occluded	_
45-12	8768-8772	from	_
45-13	8773-8776	the	_
45-14	8777-8781	view	_
45-15	8782-8784	of	_
45-16	8785-8788	the	_
45-17	8789-8798	assistant	_
45-18	8798-8799	.	_

#Text=For perspective-taking trials, either two similar items were presented in the grid array and one was occluded (simple trials) or three similar items of varying sizes, with one occluded, were presented and the participant was tasked with selecting the largest or smallest item based on what the assistant could see (complex trials).
46-1	8800-8803	For	_
46-2	8804-8822	perspective-taking	_
46-3	8823-8829	trials	_
46-4	8829-8830	,	_
46-5	8831-8837	either	_
46-6	8838-8841	two	_
46-7	8842-8849	similar	_
46-8	8850-8855	items	_
46-9	8856-8860	were	_
46-10	8861-8870	presented	_
46-11	8871-8873	in	_
46-12	8874-8877	the	_
46-13	8878-8882	grid	_
46-14	8883-8888	array	_
46-15	8889-8892	and	_
46-16	8893-8896	one	_
46-17	8897-8900	was	_
46-18	8901-8909	occluded	_
46-19	8910-8911	(	_
46-20	8911-8917	simple	_
46-21	8918-8924	trials	_
46-22	8924-8925	)	_
46-23	8926-8928	or	_
46-24	8929-8934	three	_
46-25	8935-8942	similar	_
46-26	8943-8948	items	_
46-27	8949-8951	of	_
46-28	8952-8959	varying	_
46-29	8960-8965	sizes	_
46-30	8965-8966	,	_
46-31	8967-8971	with	_
46-32	8972-8975	one	_
46-33	8976-8984	occluded	_
46-34	8984-8985	,	_
46-35	8986-8990	were	_
46-36	8991-9000	presented	_
46-37	9001-9004	and	_
46-38	9005-9008	the	_
46-39	9009-9020	participant	_
46-40	9021-9024	was	_
46-41	9025-9031	tasked	_
46-42	9032-9036	with	_
46-43	9037-9046	selecting	_
46-44	9047-9050	the	_
46-45	9051-9058	largest	_
46-46	9059-9061	or	_
46-47	9062-9070	smallest	_
46-48	9071-9075	item	_
46-49	9076-9081	based	_
46-50	9082-9084	on	_
46-51	9085-9089	what	_
46-52	9090-9093	the	_
46-53	9094-9103	assistant	_
46-54	9104-9109	could	_
46-55	9110-9113	see	_
46-56	9114-9115	(	_
46-57	9115-9122	complex	_
46-58	9123-9129	trials	_
46-59	9129-9130	)	_
46-60	9130-9131	.	_

#Text=For the purposes of this research, simple and complex perspective-taking trials were aggregated, as we have not previously observed an empirical distinction between these two types of perspective-taking trials.
#Text=2.3.
47-1	9132-9135	For	_
47-2	9136-9139	the	_
47-3	9140-9148	purposes	_
47-4	9149-9151	of	_
47-5	9152-9156	this	_
47-6	9157-9165	research	_
47-7	9165-9166	,	_
47-8	9167-9173	simple	_
47-9	9174-9177	and	_
47-10	9178-9185	complex	_
47-11	9186-9204	perspective-taking	_
47-12	9205-9211	trials	_
47-13	9212-9216	were	_
47-14	9217-9227	aggregated	_
47-15	9227-9228	,	_
47-16	9229-9231	as	_
47-17	9232-9234	we	_
47-18	9235-9239	have	_
47-19	9240-9243	not	_
47-20	9244-9254	previously	_
47-21	9255-9263	observed	_
47-22	9264-9266	an	_
47-23	9267-9276	empirical	_
47-24	9277-9288	distinction	_
47-25	9289-9296	between	_
47-26	9297-9302	these	_
47-27	9303-9306	two	_
47-28	9307-9312	types	_
47-29	9313-9315	of	_
47-30	9316-9334	perspective-taking	_
47-31	9335-9341	trials	_
47-32	9341-9342	.	_
47-33	9343-9346	2.3	_
47-34	9346-9347	.	_

#Text=Image Acquisition and Processing
#Text=Magnetic resonance imaging data were collected on a 3T Siemens Verio whole-body scanner with a 12-channel head coil at the Scientific Imaging and Brain Research Center, Carnegie Mellon University.
48-1	9348-9353	Image	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]
48-2	9354-9365	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]
48-3	9366-9369	and	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]
48-4	9370-9380	Processing	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]
48-5	9381-9389	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[29]
48-6	9390-9399	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[29]
48-7	9400-9407	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[29]
48-8	9408-9412	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[29]
48-9	9413-9417	were	_
48-10	9418-9427	collected	_
48-11	9428-9430	on	_
48-12	9431-9432	a	_
48-13	9433-9435	3T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
48-14	9436-9443	Siemens	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
48-15	9444-9449	Verio	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
48-16	9450-9460	whole-body	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
48-17	9461-9468	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
48-18	9469-9473	with	_
48-19	9474-9475	a	_
48-20	9476-9478	12	_
48-21	9478-9479	-	_
48-22	9479-9486	channel	_
48-23	9487-9491	head	_
48-24	9492-9496	coil	_
48-25	9497-9499	at	_
48-26	9500-9503	the	_
48-27	9504-9514	Scientific	_
48-28	9515-9522	Imaging	_
48-29	9523-9526	and	_
48-30	9527-9532	Brain	_
48-31	9533-9541	Research	_
48-32	9542-9548	Center	_
48-33	9548-9549	,	_
48-34	9550-9558	Carnegie	_
48-35	9559-9565	Mellon	_
48-36	9566-9576	University	_
48-37	9576-9577	.	_

#Text=Functional MR data were acquired using an echo T2*-weighted sequence with real-time motion correction (voxel size of 3.2 mm, TR = 2000 ms, TE = 30 ms, flip angle = 79°, 64 × 64 matrix, 36 slices).
49-1	9578-9588	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]
49-2	9589-9591	MR	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]
49-3	9592-9596	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]
49-4	9597-9601	were	_
49-5	9602-9610	acquired	_
49-6	9611-9616	using	_
49-7	9617-9619	an	_
49-8	9620-9624	echo	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[32]
49-9	9625-9627	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[32]
49-10	9627-9628	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[32]
49-11	9628-9629	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[32]
49-12	9629-9637	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[32]
49-13	9638-9646	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[32]
49-14	9647-9651	with	_
49-15	9652-9661	real-time	_
49-16	9662-9668	motion	_
49-17	9669-9679	correction	_
49-18	9680-9681	(	_
49-19	9681-9686	voxel	_
49-20	9687-9691	size	_
49-21	9692-9694	of	_
49-22	9695-9698	3.2	_
49-23	9699-9701	mm	_
49-24	9701-9702	,	_
49-25	9703-9705	TR	_
49-26	9706-9707	=	_
49-27	9708-9712	2000	_
49-28	9713-9715	ms	_
49-29	9715-9716	,	_
49-30	9717-9719	TE	_
49-31	9720-9721	=	_
49-32	9722-9724	30	_
49-33	9725-9727	ms	_
49-34	9727-9728	,	_
49-35	9729-9733	flip	_
49-36	9734-9739	angle	_
49-37	9740-9741	=	_
49-38	9742-9744	79	_
49-39	9744-9745	°	_
49-40	9745-9746	,	_
49-41	9747-9749	64	_
49-42	9750-9751	×	_
49-43	9752-9754	64	_
49-44	9755-9761	matrix	_
49-45	9761-9762	,	_
49-46	9763-9765	36	_
49-47	9766-9772	slices	_
49-48	9772-9773	)	_
49-49	9773-9774	.	_

#Text=High resolution anatomical data were collected using a standard 3D MPRAGE sequence for the purposes of individual subject normalization.
50-1	9775-9779	High	_
50-2	9780-9790	resolution	_
50-3	9791-9801	anatomical	_
50-4	9802-9806	data	_
50-5	9807-9811	were	_
50-6	9812-9821	collected	_
50-7	9822-9827	using	_
50-8	9828-9829	a	_
50-9	9830-9838	standard	_
50-10	9839-9841	3D	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[33]
50-11	9842-9848	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[33]
50-12	9849-9857	sequence	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[33]
50-13	9858-9861	for	_
50-14	9862-9865	the	_
50-15	9866-9874	purposes	_
50-16	9875-9877	of	_
50-17	9878-9888	individual	_
50-18	9889-9896	subject	_
50-19	9897-9910	normalization	_
50-20	9910-9911	.	_

#Text=All images were visually inspected for quality assurance, assessed for significant motion or signal artifacts, and preprocessed in Statistical Parametric Mapping (SPM) software, version 12 (Wellcome Department of Cognitive Neurology, Institute of Neurology, London, UK).
51-1	9912-9915	All	_
51-2	9916-9922	images	_
51-3	9923-9927	were	_
51-4	9928-9936	visually	_
51-5	9937-9946	inspected	_
51-6	9947-9950	for	_
51-7	9951-9958	quality	_
51-8	9959-9968	assurance	_
51-9	9968-9969	,	_
51-10	9970-9978	assessed	_
51-11	9979-9982	for	_
51-12	9983-9994	significant	_
51-13	9995-10001	motion	_
51-14	10002-10004	or	_
51-15	10005-10011	signal	_
51-16	10012-10021	artifacts	_
51-17	10021-10022	,	_
51-18	10023-10026	and	_
51-19	10027-10039	preprocessed	_
51-20	10040-10042	in	_
51-21	10043-10054	Statistical	_
51-22	10055-10065	Parametric	_
51-23	10066-10073	Mapping	_
51-24	10074-10075	(	_
51-25	10075-10078	SPM	_
51-26	10078-10079	)	_
51-27	10080-10088	software	_
51-28	10088-10089	,	_
51-29	10090-10097	version	_
51-30	10098-10100	12	_
51-31	10101-10102	(	_
51-32	10102-10110	Wellcome	_
51-33	10111-10121	Department	_
51-34	10122-10124	of	_
51-35	10125-10134	Cognitive	_
51-36	10135-10144	Neurology	_
51-37	10144-10145	,	_
51-38	10146-10155	Institute	_
51-39	10156-10158	of	_
51-40	10159-10168	Neurology	_
51-41	10168-10169	,	_
51-42	10170-10176	London	_
51-43	10176-10177	,	_
51-44	10178-10180	UK	_
51-45	10180-10181	)	_
51-46	10181-10182	.	_

#Text=Preprocessing consisted of a standard indirect normalization pipeline, where functional MR data were aligned, normalized based on high-resolution anatomical data, and smoothed using an 8mm Gaussian kernel.
52-1	10183-10196	Preprocessing	_
52-2	10197-10206	consisted	_
52-3	10207-10209	of	_
52-4	10210-10211	a	_
52-5	10212-10220	standard	_
52-6	10221-10229	indirect	_
52-7	10230-10243	normalization	_
52-8	10244-10252	pipeline	_
52-9	10252-10253	,	_
52-10	10254-10259	where	_
52-11	10260-10270	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[34]
52-12	10271-10273	MR	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[34]
52-13	10274-10278	data	_
52-14	10279-10283	were	_
52-15	10284-10291	aligned	_
52-16	10291-10292	,	_
52-17	10293-10303	normalized	_
52-18	10304-10309	based	_
52-19	10310-10312	on	_
52-20	10313-10328	high-resolution	_
52-21	10329-10339	anatomical	_
52-22	10340-10344	data	_
52-23	10344-10345	,	_
52-24	10346-10349	and	_
52-25	10350-10358	smoothed	_
52-26	10359-10364	using	_
52-27	10365-10367	an	_
52-28	10368-10371	8mm	_
52-29	10372-10380	Gaussian	_
52-30	10381-10387	kernel	_
52-31	10387-10388	.	_

#Text=Motion and signal outliers were infrequent (M = 1.57%, SD = 3.69%) and did not differ significantly between groups, F(2, 103) = 1.63, p = .201.
53-1	10389-10395	Motion	_
53-2	10396-10399	and	_
53-3	10400-10406	signal	_
53-4	10407-10415	outliers	_
53-5	10416-10420	were	_
53-6	10421-10431	infrequent	_
53-7	10432-10433	(	_
53-8	10433-10434	M	_
53-9	10435-10436	=	_
53-10	10437-10442	1.57%	_
53-11	10442-10443	,	_
53-12	10444-10446	SD	_
53-13	10447-10448	=	_
53-14	10449-10454	3.69%	_
53-15	10454-10455	)	_
53-16	10456-10459	and	_
53-17	10460-10463	did	_
53-18	10464-10467	not	_
53-19	10468-10474	differ	_
53-20	10475-10488	significantly	_
53-21	10489-10496	between	_
53-22	10497-10503	groups	_
53-23	10503-10504	,	_
53-24	10505-10506	F	_
53-25	10506-10507	(	_
53-26	10507-10508	2	_
53-27	10508-10509	,	_
53-28	10510-10513	103	_
53-29	10513-10514	)	_
53-30	10515-10516	=	_
53-31	10517-10521	1.63	_
53-32	10521-10522	,	_
53-33	10523-10524	p	_
53-34	10525-10526	=	_
53-35	10527-10531	.201	_
53-36	10531-10532	.	_

#Text=Average normalized movement was also minimal (M = .19mm, SD = .14mm).
54-1	10533-10540	Average	_
54-2	10541-10551	normalized	_
54-3	10552-10560	movement	_
54-4	10561-10564	was	_
54-5	10565-10569	also	_
54-6	10570-10577	minimal	_
54-7	10578-10579	(	_
54-8	10579-10580	M	_
54-9	10581-10582	=	_
54-10	10583-10588	.19mm	_
54-11	10588-10589	,	_
54-12	10590-10592	SD	_
54-13	10593-10594	=	_
54-14	10595-10600	.14mm	_
54-15	10600-10601	)	_
54-16	10601-10602	.	_

#Text=However, healthy individuals did display less in-scanner motion than participants with ASD and schizophrenia, F(2, 103) = 6.18, p = .003, who did not differ significantly from each other, t(67) = −.61, p = .544.
55-1	10603-10610	However	_
55-2	10610-10611	,	_
55-3	10612-10619	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[35]
55-4	10620-10631	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[35]
55-5	10632-10635	did	_
55-6	10636-10643	display	_
55-7	10644-10648	less	_
55-8	10649-10659	in-scanner	_
55-9	10660-10666	motion	_
55-10	10667-10671	than	_
55-11	10672-10684	participants	_
55-12	10685-10689	with	_
55-13	10690-10693	ASD	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
55-14	10694-10697	and	_
55-15	10698-10711	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
55-16	10711-10712	,	_
55-17	10713-10714	F	_
55-18	10714-10715	(	_
55-19	10715-10716	2	_
55-20	10716-10717	,	_
55-21	10718-10721	103	_
55-22	10721-10722	)	_
55-23	10723-10724	=	_
55-24	10725-10729	6.18	_
55-25	10729-10730	,	_
55-26	10731-10732	p	_
55-27	10733-10734	=	_
55-28	10735-10739	.003	_
55-29	10739-10740	,	_
55-30	10741-10744	who	_
55-31	10745-10748	did	_
55-32	10749-10752	not	_
55-33	10753-10759	differ	_
55-34	10760-10773	significantly	_
55-35	10774-10778	from	_
55-36	10779-10783	each	_
55-37	10784-10789	other	_
55-38	10789-10790	,	_
55-39	10791-10792	t	_
55-40	10792-10793	(	_
55-41	10793-10795	67	_
55-42	10795-10796	)	_
55-43	10797-10798	=	_
55-44	10799-10800	−	_
55-45	10800-10803	.61	_
55-46	10803-10804	,	_
55-47	10805-10806	p	_
55-48	10807-10808	=	_
55-49	10809-10813	.544	_
55-50	10813-10814	.	_

#Text=To address the impact of motion on functional connectivity estimates, which are particularly sensitive to head displacement, an aCompCor approach was taken to connectivity estimation, which has been shown to adequately remove motion and other physiological artifacts.
56-1	10815-10817	To	_
56-2	10818-10825	address	_
56-3	10826-10829	the	_
56-4	10830-10836	impact	_
56-5	10837-10839	of	_
56-6	10840-10846	motion	_
56-7	10847-10849	on	_
56-8	10850-10860	functional	_
56-9	10861-10873	connectivity	_
56-10	10874-10883	estimates	_
56-11	10883-10884	,	_
56-12	10885-10890	which	_
56-13	10891-10894	are	_
56-14	10895-10907	particularly	_
56-15	10908-10917	sensitive	_
56-16	10918-10920	to	_
56-17	10921-10925	head	_
56-18	10926-10938	displacement	_
56-19	10938-10939	,	_
56-20	10940-10942	an	_
56-21	10943-10951	aCompCor	_
56-22	10952-10960	approach	_
56-23	10961-10964	was	_
56-24	10965-10970	taken	_
56-25	10971-10973	to	_
56-26	10974-10986	connectivity	_
56-27	10987-10997	estimation	_
56-28	10997-10998	,	_
56-29	10999-11004	which	_
56-30	11005-11008	has	_
56-31	11009-11013	been	_
56-32	11014-11019	shown	_
56-33	11020-11022	to	_
56-34	11023-11033	adequately	_
56-35	11034-11040	remove	_
56-36	11041-11047	motion	_
56-37	11048-11051	and	_
56-38	11052-11057	other	_
56-39	11058-11071	physiological	_
56-40	11072-11081	artifacts	_
56-41	11081-11082	.	_

#Text=Movement parameters obtained during realignment were also included as nuisance variables in all first-level models.
57-1	11083-11091	Movement	_
57-2	11092-11102	parameters	_
57-3	11103-11111	obtained	_
57-4	11112-11118	during	_
57-5	11119-11130	realignment	_
57-6	11131-11135	were	_
57-7	11136-11140	also	_
57-8	11141-11149	included	_
57-9	11150-11152	as	_
57-10	11153-11161	nuisance	_
57-11	11162-11171	variables	_
57-12	11172-11174	in	_
57-13	11175-11178	all	_
57-14	11179-11190	first-level	_
57-15	11191-11197	models	_
57-16	11197-11198	.	_

#Text=Finally, second-level between-group functional activation and connectivity analyses also included average normalized movement as a confounding covariate.
#Text=2.4.
58-1	11199-11206	Finally	_
58-2	11206-11207	,	_
58-3	11208-11220	second-level	_
58-4	11221-11234	between-group	_
58-5	11235-11245	functional	_
58-6	11246-11256	activation	_
58-7	11257-11260	and	_
58-8	11261-11273	connectivity	_
58-9	11274-11282	analyses	_
58-10	11283-11287	also	_
58-11	11288-11296	included	_
58-12	11297-11304	average	_
58-13	11305-11315	normalized	_
58-14	11316-11324	movement	_
58-15	11325-11327	as	_
58-16	11328-11329	a	_
58-17	11330-11341	confounding	_
58-18	11342-11351	covariate	_
58-19	11351-11352	.	_
58-20	11353-11356	2.4	_
58-21	11356-11357	.	_

#Text=Procedures
#Text=Participants were recruited from the University of Pittsburgh Center for Excellence in Autism Research, Western Psychiatric Institute and Clinic schizophrenia outpatient programs, and the local community.
59-1	11358-11368	Procedures	http://www.case.edu/ProvCaRe/provcare#StudyMethod
59-2	11369-11381	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-3	11382-11386	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-4	11387-11396	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-5	11397-11401	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-6	11402-11405	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-7	11406-11416	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-8	11417-11419	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-9	11420-11430	Pittsburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-10	11431-11437	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-11	11438-11441	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-12	11442-11452	Excellence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-13	11453-11455	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-14	11456-11462	Autism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-15	11463-11471	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-16	11471-11472	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-17	11473-11480	Western	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-18	11481-11492	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-19	11493-11502	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-20	11503-11506	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-21	11507-11513	Clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-22	11514-11527	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-23	11528-11538	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-24	11539-11547	programs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-25	11547-11548	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-26	11549-11552	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-27	11553-11556	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-28	11557-11562	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-29	11563-11572	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]
59-30	11572-11573	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[36]

#Text=Upon recruitment, participants were screened using the SCID or ADOS, and standardized IQ assessments by a trained clinical interviewer and neuropsychological tester.
60-1	11574-11578	Upon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-2	11579-11590	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-3	11590-11591	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-4	11592-11604	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-5	11605-11609	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-6	11610-11618	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-7	11619-11624	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-8	11625-11628	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-9	11629-11633	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[38]
60-10	11634-11636	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-11	11637-11641	ADOS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[39]
60-12	11641-11642	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-13	11643-11646	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-14	11647-11659	standardized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-15	11660-11662	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-16	11663-11674	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-17	11675-11677	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-18	11678-11679	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-19	11680-11687	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-20	11688-11696	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-21	11697-11708	interviewer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-22	11709-11712	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-23	11713-11731	neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-24	11732-11738	tester	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
60-25	11738-11739	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]

#Text=Eligible participants then completed a series of cognitive and clinical batteries, along with neuroimaging data collection on a separate day.
61-1	11740-11748	Eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-2	11749-11761	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-3	11762-11766	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-4	11767-11776	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-5	11777-11778	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-6	11779-11785	series	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-7	11786-11788	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-8	11789-11798	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-9	11799-11802	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-10	11803-11811	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-11	11812-11821	batteries	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-12	11821-11822	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-13	11823-11828	along	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-14	11829-11833	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-15	11834-11846	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[41]
61-16	11847-11851	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[41]
61-17	11852-11862	collection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[41]
61-18	11863-11865	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-19	11866-11867	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-20	11868-11876	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-21	11877-11880	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
61-22	11880-11881	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]

#Text=The study was reviewed and approved by the University of Pittsburgh Institutional Review Board, and all participants provided written informed consent prior to study participation.
#Text=2.5.
62-1	11882-11885	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-2	11886-11891	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-3	11892-11895	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-4	11896-11904	reviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-5	11905-11908	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-6	11909-11917	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-7	11918-11920	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-8	11921-11924	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-9	11925-11935	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-10	11936-11938	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-11	11939-11949	Pittsburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-12	11950-11963	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-13	11964-11970	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-14	11971-11976	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-15	11976-11977	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-16	11978-11981	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-17	11982-11985	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-18	11986-11998	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-19	11999-12007	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-20	12008-12015	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-21	12016-12024	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-22	12025-12032	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-23	12033-12038	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-24	12039-12041	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-25	12042-12047	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-26	12048-12061	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-27	12061-12062	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[42]
62-28	12063-12066	2.5	_
62-29	12066-12067	.	_

#Text=Data Analysis
#Text=Behavioral performance on the visual perspective-taking task was examined using a series of linear mixed-effects models predicting accuracy and response latency from task condition, group status, and their interaction.
63-1	12068-12072	Data	_
63-2	12073-12081	Analysis	_
63-3	12082-12092	Behavioral	_
63-4	12093-12104	performance	_
63-5	12105-12107	on	_
63-6	12108-12111	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[43]
63-7	12112-12118	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[43]
63-8	12119-12137	perspective-taking	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[43]
63-9	12138-12142	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[43]
63-10	12143-12146	was	_
63-11	12147-12155	examined	_
63-12	12156-12161	using	_
63-13	12162-12163	a	_
63-14	12164-12170	series	_
63-15	12171-12173	of	_
63-16	12174-12180	linear	_
63-17	12181-12194	mixed-effects	_
63-18	12195-12201	models	_
63-19	12202-12212	predicting	_
63-20	12213-12221	accuracy	_
63-21	12222-12225	and	_
63-22	12226-12234	response	_
63-23	12235-12242	latency	_
63-24	12243-12247	from	_
63-25	12248-12252	task	_
63-26	12253-12262	condition	_
63-27	12262-12263	,	_
63-28	12264-12269	group	_
63-29	12270-12276	status	_
63-30	12276-12277	,	_
63-31	12278-12281	and	_
63-32	12282-12287	their	_
63-33	12288-12299	interaction	_
63-34	12299-12300	.	_

#Text=Functional neuroimaging data were first analyzed to investigate group differences in task-related brain activity using a series of general linear models implemented in SPM12.
64-1	12301-12311	Functional	_
64-2	12312-12324	neuroimaging	_
64-3	12325-12329	data	_
64-4	12330-12334	were	_
64-5	12335-12340	first	_
64-6	12341-12349	analyzed	_
64-7	12350-12352	to	_
64-8	12353-12364	investigate	_
64-9	12365-12370	group	_
64-10	12371-12382	differences	_
64-11	12383-12385	in	_
64-12	12386-12398	task-related	_
64-13	12399-12404	brain	_
64-14	12405-12413	activity	_
64-15	12414-12419	using	_
64-16	12420-12421	a	_
64-17	12422-12428	series	_
64-18	12429-12431	of	_
64-19	12432-12439	general	_
64-20	12440-12446	linear	_
64-21	12447-12453	models	_
64-22	12454-12465	implemented	_
64-23	12466-12468	in	_
64-24	12469-12474	SPM12	_
64-25	12474-12475	.	_

#Text=First-level models predicted blood-oxygen-level-dependent (BOLD) response from task condition (perspective-taking vs. control), adjusting for motion and timeseries outliers using the Artifact Detection Tools.
65-1	12476-12487	First-level	_
65-2	12488-12494	models	_
65-3	12495-12504	predicted	_
65-4	12505-12533	blood-oxygen-level-dependent	_
65-5	12534-12535	(	_
65-6	12535-12539	BOLD	_
65-7	12539-12540	)	_
65-8	12541-12549	response	_
65-9	12550-12554	from	_
65-10	12555-12559	task	_
65-11	12560-12569	condition	_
65-12	12570-12571	(	_
65-13	12571-12589	perspective-taking	_
65-14	12590-12592	vs	_
65-15	12592-12593	.	_
65-16	12594-12601	control	_
65-17	12601-12602	)	_
65-18	12602-12603	,	_
65-19	12604-12613	adjusting	_
65-20	12614-12617	for	_
65-21	12618-12624	motion	_
65-22	12625-12628	and	_
65-23	12629-12639	timeseries	_
65-24	12640-12648	outliers	_
65-25	12649-12654	using	_
65-26	12655-12658	the	_
65-27	12659-12667	Artifact	_
65-28	12668-12677	Detection	_
65-29	12678-12683	Tools	_
65-30	12683-12684	.	_

#Text=Second-level models predicted perspective-taking BOLD contrasts [perspective-taking - control] from group status, and contrasted the three study groups using a pairwise approach.
66-1	12685-12697	Second-level	_
66-2	12698-12704	models	_
66-3	12705-12714	predicted	_
66-4	12715-12733	perspective-taking	_
66-5	12734-12738	BOLD	_
66-6	12739-12748	contrasts	_
66-7	12749-12750	[	_
66-8	12750-12768	perspective-taking	_
66-9	12769-12770	-	_
66-10	12771-12778	control	_
66-11	12778-12779	]	_
66-12	12780-12784	from	_
66-13	12785-12790	group	_
66-14	12791-12797	status	_
66-15	12797-12798	,	_
66-16	12799-12802	and	_
66-17	12803-12813	contrasted	_
66-18	12814-12817	the	_
66-19	12818-12823	three	_
66-20	12824-12829	study	_
66-21	12830-12836	groups	_
66-22	12837-12842	using	_
66-23	12843-12844	a	_
66-24	12845-12853	pairwise	_
66-25	12854-12862	approach	_
66-26	12862-12863	.	_

#Text=Type I error was maintained at .05 using a combined voxel-extent threshold of 82 and uncorrected α threshold of .005 based on 10,000 Monte Carlo simulations using the August 25, 2016 complied version of 3dClustSim that implements several changes to maintain better control over false positives.
67-1	12864-12868	Type	_
67-2	12869-12870	I	_
67-3	12871-12876	error	_
67-4	12877-12880	was	_
67-5	12881-12891	maintained	_
67-6	12892-12894	at	_
67-7	12895-12898	.05	_
67-8	12899-12904	using	_
67-9	12905-12906	a	_
67-10	12907-12915	combined	_
67-11	12916-12928	voxel-extent	_
67-12	12929-12938	threshold	_
67-13	12939-12941	of	_
67-14	12942-12944	82	_
67-15	12945-12948	and	_
67-16	12949-12960	uncorrected	_
67-17	12961-12962	α	_
67-18	12963-12972	threshold	_
67-19	12973-12975	of	_
67-20	12976-12980	.005	_
67-21	12981-12986	based	_
67-22	12987-12989	on	_
67-23	12990-12996	10,000	_
67-24	12997-13002	Monte	_
67-25	13003-13008	Carlo	_
67-26	13009-13020	simulations	_
67-27	13021-13026	using	_
67-28	13027-13030	the	_
67-29	13031-13037	August	_
67-30	13038-13040	25	_
67-31	13040-13041	,	_
67-32	13042-13046	2016	_
67-33	13047-13055	complied	_
67-34	13056-13063	version	_
67-35	13064-13066	of	_
67-36	13067-13077	3dClustSim	_
67-37	13078-13082	that	_
67-38	13083-13093	implements	_
67-39	13094-13101	several	_
67-40	13102-13109	changes	_
67-41	13110-13112	to	_
67-42	13113-13121	maintain	_
67-43	13122-13128	better	_
67-44	13129-13136	control	_
67-45	13137-13141	over	_
67-46	13142-13147	false	_
67-47	13148-13157	positives	_
67-48	13157-13158	.	_

#Text=Subsequently, seed-based connectivity models were implemented in the Functional Connectivity Toolbox for SPM12 to examine between-group differences in brain connectivity.
68-1	13159-13171	Subsequently	_
68-2	13171-13172	,	_
68-3	13173-13183	seed-based	_
68-4	13184-13196	connectivity	_
68-5	13197-13203	models	_
68-6	13204-13208	were	_
68-7	13209-13220	implemented	_
68-8	13221-13223	in	_
68-9	13224-13227	the	_
68-10	13228-13238	Functional	_
68-11	13239-13251	Connectivity	_
68-12	13252-13259	Toolbox	_
68-13	13260-13263	for	_
68-14	13264-13269	SPM12	_
68-15	13270-13272	to	_
68-16	13273-13280	examine	_
68-17	13281-13294	between-group	_
68-18	13295-13306	differences	_
68-19	13307-13309	in	_
68-20	13310-13315	brain	_
68-21	13316-13328	connectivity	_
68-22	13328-13329	.	_

#Text=These models predicted differential regional connectivity values during perspective-taking - control conditions from group status, and employed a false discovery approach of pFDR = .05 at the seed level to maintain Type I error at acceptable levels.
69-1	13330-13335	These	_
69-2	13336-13342	models	_
69-3	13343-13352	predicted	_
69-4	13353-13365	differential	_
69-5	13366-13374	regional	_
69-6	13375-13387	connectivity	_
69-7	13388-13394	values	_
69-8	13395-13401	during	_
69-9	13402-13420	perspective-taking	_
69-10	13421-13422	-	_
69-11	13423-13430	control	_
69-12	13431-13441	conditions	_
69-13	13442-13446	from	_
69-14	13447-13452	group	_
69-15	13453-13459	status	_
69-16	13459-13460	,	_
69-17	13461-13464	and	_
69-18	13465-13473	employed	_
69-19	13474-13475	a	_
69-20	13476-13481	false	_
69-21	13482-13491	discovery	_
69-22	13492-13500	approach	_
69-23	13501-13503	of	_
69-24	13504-13508	pFDR	_
69-25	13509-13510	=	_
69-26	13511-13514	.05	_
69-27	13515-13517	at	_
69-28	13518-13521	the	_
69-29	13522-13526	seed	_
69-30	13527-13532	level	_
69-31	13533-13535	to	_
69-32	13536-13544	maintain	_
69-33	13545-13549	Type	_
69-34	13550-13551	I	_
69-35	13552-13557	error	_
69-36	13558-13560	at	_
69-37	13561-13571	acceptable	_
69-38	13572-13578	levels	_
69-39	13578-13579	.	_

#Text=A whole-brain analysis was considered, but given the growing number of studies indicating specific regional involvement in social-cognitive processing, particularly theory of mind and perspective-taking, a region of interest approach was used.
70-1	13580-13581	A	_
70-2	13582-13593	whole-brain	_
70-3	13594-13602	analysis	_
70-4	13603-13606	was	_
70-5	13607-13617	considered	_
70-6	13617-13618	,	_
70-7	13619-13622	but	_
70-8	13623-13628	given	_
70-9	13629-13632	the	_
70-10	13633-13640	growing	_
70-11	13641-13647	number	_
70-12	13648-13650	of	_
70-13	13651-13658	studies	_
70-14	13659-13669	indicating	_
70-15	13670-13678	specific	_
70-16	13679-13687	regional	_
70-17	13688-13699	involvement	_
70-18	13700-13702	in	_
70-19	13703-13719	social-cognitive	_
70-20	13720-13730	processing	_
70-21	13730-13731	,	_
70-22	13732-13744	particularly	_
70-23	13745-13751	theory	_
70-24	13752-13754	of	_
70-25	13755-13759	mind	_
70-26	13760-13763	and	_
70-27	13764-13782	perspective-taking	_
70-28	13782-13783	,	_
70-29	13784-13785	a	_
70-30	13786-13792	region	_
70-31	13793-13795	of	_
70-32	13796-13804	interest	_
70-33	13805-13813	approach	_
70-34	13814-13817	was	_
70-35	13818-13822	used	_
70-36	13822-13823	.	_

#Text=Regions of interest were specified a priori, were identical for activation and connectivity analyses, and included the dorsolateral prefrontal cortex, medial prefrontal cortex, orbitofrontal cortex (subdivided into superior, middle, inferior, and medial [x centered] components), ventromedial prefrontal cortex, anterior cingulate cortex, and temporo-parietal junction based on previous literature.
71-1	13824-13831	Regions	_
71-2	13832-13834	of	_
71-3	13835-13843	interest	_
71-4	13844-13848	were	_
71-5	13849-13858	specified	_
71-6	13859-13860	a	_
71-7	13861-13867	priori	_
71-8	13867-13868	,	_
71-9	13869-13873	were	_
71-10	13874-13883	identical	_
71-11	13884-13887	for	_
71-12	13888-13898	activation	_
71-13	13899-13902	and	_
71-14	13903-13915	connectivity	_
71-15	13916-13924	analyses	_
71-16	13924-13925	,	_
71-17	13926-13929	and	_
71-18	13930-13938	included	_
71-19	13939-13942	the	_
71-20	13943-13955	dorsolateral	_
71-21	13956-13966	prefrontal	_
71-22	13967-13973	cortex	_
71-23	13973-13974	,	_
71-24	13975-13981	medial	_
71-25	13982-13992	prefrontal	_
71-26	13993-13999	cortex	_
71-27	13999-14000	,	_
71-28	14001-14014	orbitofrontal	_
71-29	14015-14021	cortex	_
71-30	14022-14023	(	_
71-31	14023-14033	subdivided	_
71-32	14034-14038	into	_
71-33	14039-14047	superior	_
71-34	14047-14048	,	_
71-35	14049-14055	middle	_
71-36	14055-14056	,	_
71-37	14057-14065	inferior	_
71-38	14065-14066	,	_
71-39	14067-14070	and	_
71-40	14071-14077	medial	_
71-41	14078-14079	[	_
71-42	14079-14080	x	_
71-43	14081-14089	centered	_
71-44	14089-14090	]	_
71-45	14091-14101	components	_
71-46	14101-14102	)	_
71-47	14102-14103	,	_
71-48	14104-14116	ventromedial	_
71-49	14117-14127	prefrontal	_
71-50	14128-14134	cortex	_
71-51	14134-14135	,	_
71-52	14136-14144	anterior	_
71-53	14145-14154	cingulate	_
71-54	14155-14161	cortex	_
71-55	14161-14162	,	_
71-56	14163-14166	and	_
71-57	14167-14183	temporo-parietal	_
71-58	14184-14192	junction	_
71-59	14193-14198	based	_
71-60	14199-14201	on	_
71-61	14202-14210	previous	_
71-62	14211-14221	literature	_
71-63	14221-14222	.	_

#Text=Regional definitions were obtained using the automated anatomical labeling atlas by and temporo-parietal junction empirical masks from.
72-1	14223-14231	Regional	_
72-2	14232-14243	definitions	_
72-3	14244-14248	were	_
72-4	14249-14257	obtained	_
72-5	14258-14263	using	_
72-6	14264-14267	the	_
72-7	14268-14277	automated	_
72-8	14278-14288	anatomical	_
72-9	14289-14297	labeling	_
72-10	14298-14303	atlas	_
72-11	14304-14306	by	_
72-12	14307-14310	and	_
72-13	14311-14327	temporo-parietal	_
72-14	14328-14336	junction	_
72-15	14337-14346	empirical	_
72-16	14347-14352	masks	_
72-17	14353-14357	from	_
72-18	14357-14358	.	_

#Text=A combined region of interest mask was used for all analyses, rather than analyzing each region independently, and analyzed voxels were restricted to those included in this mask.
73-1	14359-14360	A	_
73-2	14361-14369	combined	_
73-3	14370-14376	region	_
73-4	14377-14379	of	_
73-5	14380-14388	interest	_
73-6	14389-14393	mask	_
73-7	14394-14397	was	_
73-8	14398-14402	used	_
73-9	14403-14406	for	_
73-10	14407-14410	all	_
73-11	14411-14419	analyses	_
73-12	14419-14420	,	_
73-13	14421-14427	rather	_
73-14	14428-14432	than	_
73-15	14433-14442	analyzing	_
73-16	14443-14447	each	_
73-17	14448-14454	region	_
73-18	14455-14468	independently	_
73-19	14468-14469	,	_
73-20	14470-14473	and	_
73-21	14474-14482	analyzed	_
73-22	14483-14489	voxels	_
73-23	14490-14494	were	_
73-24	14495-14505	restricted	_
73-25	14506-14508	to	_
73-26	14509-14514	those	_
73-27	14515-14523	included	_
73-28	14524-14526	in	_
73-29	14527-14531	this	_
73-30	14532-14536	mask	_
73-31	14536-14537	.	_

#Text=Connectivity seed regions were defined using the same combined region of interest mask employed in activation analyses, with each anatomical region representing a seed, whose BOLD signal time courses were correlated with all other seed regions of interest in the mask.
74-1	14538-14550	Connectivity	_
74-2	14551-14555	seed	_
74-3	14556-14563	regions	_
74-4	14564-14568	were	_
74-5	14569-14576	defined	_
74-6	14577-14582	using	_
74-7	14583-14586	the	_
74-8	14587-14591	same	_
74-9	14592-14600	combined	_
74-10	14601-14607	region	_
74-11	14608-14610	of	_
74-12	14611-14619	interest	_
74-13	14620-14624	mask	_
74-14	14625-14633	employed	_
74-15	14634-14636	in	_
74-16	14637-14647	activation	_
74-17	14648-14656	analyses	_
74-18	14656-14657	,	_
74-19	14658-14662	with	_
74-20	14663-14667	each	_
74-21	14668-14678	anatomical	_
74-22	14679-14685	region	_
74-23	14686-14698	representing	_
74-24	14699-14700	a	_
74-25	14701-14705	seed	_
74-26	14705-14706	,	_
74-27	14707-14712	whose	_
74-28	14713-14717	BOLD	_
74-29	14718-14724	signal	_
74-30	14725-14729	time	_
74-31	14730-14737	courses	_
74-32	14738-14742	were	_
74-33	14743-14753	correlated	_
74-34	14754-14758	with	_
74-35	14759-14762	all	_
74-36	14763-14768	other	_
74-37	14769-14773	seed	_
74-38	14774-14781	regions	_
74-39	14782-14784	of	_
74-40	14785-14793	interest	_
74-41	14794-14796	in	_
74-42	14797-14800	the	_
74-43	14801-14805	mask	_
74-44	14805-14806	.	_

#Text=Seeds were defined by averaging activation timeseries across each entire anatomical region, rather than defining seeds by arbitrarily selecting a single voxel within the region of interest.
75-1	14807-14812	Seeds	_
75-2	14813-14817	were	_
75-3	14818-14825	defined	_
75-4	14826-14828	by	_
75-5	14829-14838	averaging	_
75-6	14839-14849	activation	_
75-7	14850-14860	timeseries	_
75-8	14861-14867	across	_
75-9	14868-14872	each	_
75-10	14873-14879	entire	_
75-11	14880-14890	anatomical	_
75-12	14891-14897	region	_
75-13	14897-14898	,	_
75-14	14899-14905	rather	_
75-15	14906-14910	than	_
75-16	14911-14919	defining	_
75-17	14920-14925	seeds	_
75-18	14926-14928	by	_
75-19	14929-14940	arbitrarily	_
75-20	14941-14950	selecting	_
75-21	14951-14952	a	_
75-22	14953-14959	single	_
75-23	14960-14965	voxel	_
75-24	14966-14972	within	_
75-25	14973-14976	the	_
75-26	14977-14983	region	_
75-27	14984-14986	of	_
75-28	14987-14995	interest	_
75-29	14995-14996	.	_

#Text=Between-group functional activation and connectivity analyses adjusted for the potential confounding effects of gender and normalized in-scanner movement.
76-1	14997-15010	Between-group	_
76-2	15011-15021	functional	_
76-3	15022-15032	activation	_
76-4	15033-15036	and	_
76-5	15037-15049	connectivity	_
76-6	15050-15058	analyses	_
76-7	15059-15067	adjusted	_
76-8	15068-15071	for	_
76-9	15072-15075	the	_
76-10	15076-15085	potential	_
76-11	15086-15097	confounding	_
76-12	15098-15105	effects	_
76-13	15106-15108	of	_
76-14	15109-15115	gender	_
76-15	15116-15119	and	_
76-16	15120-15130	normalized	_
76-17	15131-15141	in-scanner	_
76-18	15142-15150	movement	_
76-19	15150-15151	.	_

#Text=Finally, correlation analyses examined the association between extracted BOLD signal activity/connectivity data showing significant between-group differences and chlorpromazine equivalent antipsychotic medication dose to assess the impact of medication on the study findings.
#Text=3.
77-1	15152-15159	Finally	_
77-2	15159-15160	,	_
77-3	15161-15172	correlation	_
77-4	15173-15181	analyses	_
77-5	15182-15190	examined	_
77-6	15191-15194	the	_
77-7	15195-15206	association	_
77-8	15207-15214	between	_
77-9	15215-15224	extracted	_
77-10	15225-15229	BOLD	_
77-11	15230-15236	signal	_
77-12	15237-15245	activity	_
77-13	15245-15246	/	_
77-14	15246-15258	connectivity	_
77-15	15259-15263	data	_
77-16	15264-15271	showing	_
77-17	15272-15283	significant	_
77-18	15284-15297	between-group	_
77-19	15298-15309	differences	_
77-20	15310-15313	and	_
77-21	15314-15328	chlorpromazine	_
77-22	15329-15339	equivalent	_
77-23	15340-15353	antipsychotic	_
77-24	15354-15364	medication	_
77-25	15365-15369	dose	_
77-26	15370-15372	to	_
77-27	15373-15379	assess	_
77-28	15380-15383	the	_
77-29	15384-15390	impact	_
77-30	15391-15393	of	_
77-31	15394-15404	medication	_
77-32	15405-15407	on	_
77-33	15408-15411	the	_
77-34	15412-15417	study	_
77-35	15418-15426	findings	_
77-36	15426-15427	.	_
77-37	15428-15429	3	_
77-38	15429-15430	.	_

#Text=Results
#Text=3.1.
78-1	15431-15438	Results	_
78-2	15439-15442	3.1	_
78-3	15442-15443	.	_

#Text=Visual Perspective-Taking Task Performance
#Text=Behavioral performance data during the visual perspective-taking task among participants with ASD, schizophrenia, and healthy volunteers are presented in Table 2.
79-1	15444-15450	Visual	_
79-2	15451-15469	Perspective-Taking	_
79-3	15470-15474	Task	_
79-4	15475-15486	Performance	_
79-5	15487-15497	Behavioral	_
79-6	15498-15509	performance	_
79-7	15510-15514	data	_
79-8	15515-15521	during	_
79-9	15522-15525	the	_
79-10	15526-15532	visual	_
79-11	15533-15551	perspective-taking	_
79-12	15552-15556	task	_
79-13	15557-15562	among	_
79-14	15563-15575	participants	_
79-15	15576-15580	with	_
79-16	15581-15584	ASD	_
79-17	15584-15585	,	_
79-18	15586-15599	schizophrenia	_
79-19	15599-15600	,	_
79-20	15601-15604	and	_
79-21	15605-15612	healthy	_
79-22	15613-15623	volunteers	_
79-23	15624-15627	are	_
79-24	15628-15637	presented	_
79-25	15638-15640	in	_
79-26	15641-15646	Table	_
79-27	15647-15648	2	_
79-28	15648-15649	.	_

#Text=As expected, accuracy was reduced during perspective-taking trials in both ASD and schizophrenia, compared to healthy individuals.
80-1	15650-15652	As	_
80-2	15653-15661	expected	_
80-3	15661-15662	,	_
80-4	15663-15671	accuracy	_
80-5	15672-15675	was	_
80-6	15676-15683	reduced	_
80-7	15684-15690	during	_
80-8	15691-15709	perspective-taking	_
80-9	15710-15716	trials	_
80-10	15717-15719	in	_
80-11	15720-15724	both	_
80-12	15725-15728	ASD	_
80-13	15729-15732	and	_
80-14	15733-15746	schizophrenia	_
80-15	15746-15747	,	_
80-16	15748-15756	compared	_
80-17	15757-15759	to	_
80-18	15760-15767	healthy	_
80-19	15768-15779	individuals	_
80-20	15779-15780	.	_

#Text=Latency of response was also decreased for control trials versus perspective-taking trials across all groups, although both participants with ASD and schizophrenia showed increased reaction times during control trials relative to healthy individuals.
81-1	15781-15788	Latency	_
81-2	15789-15791	of	_
81-3	15792-15800	response	_
81-4	15801-15804	was	_
81-5	15805-15809	also	_
81-6	15810-15819	decreased	_
81-7	15820-15823	for	_
81-8	15824-15831	control	_
81-9	15832-15838	trials	_
81-10	15839-15845	versus	_
81-11	15846-15864	perspective-taking	_
81-12	15865-15871	trials	_
81-13	15872-15878	across	_
81-14	15879-15882	all	_
81-15	15883-15889	groups	_
81-16	15889-15890	,	_
81-17	15891-15899	although	_
81-18	15900-15904	both	_
81-19	15905-15917	participants	_
81-20	15918-15922	with	_
81-21	15923-15926	ASD	_
81-22	15927-15930	and	_
81-23	15931-15944	schizophrenia	_
81-24	15945-15951	showed	_
81-25	15952-15961	increased	_
81-26	15962-15970	reaction	_
81-27	15971-15976	times	_
81-28	15977-15983	during	_
81-29	15984-15991	control	_
81-30	15992-15998	trials	_
81-31	15999-16007	relative	_
81-32	16008-16010	to	_
81-33	16011-16018	healthy	_
81-34	16019-16030	individuals	_
81-35	16030-16031	.	_

#Text=No significant differences were observed in latency of response between groups during perspective-taking trials.
#Text=3.2.
82-1	16032-16034	No	_
82-2	16035-16046	significant	_
82-3	16047-16058	differences	_
82-4	16059-16063	were	_
82-5	16064-16072	observed	_
82-6	16073-16075	in	_
82-7	16076-16083	latency	_
82-8	16084-16086	of	_
82-9	16087-16095	response	_
82-10	16096-16103	between	_
82-11	16104-16110	groups	_
82-12	16111-16117	during	_
82-13	16118-16136	perspective-taking	_
82-14	16137-16143	trials	_
82-15	16143-16144	.	_
82-16	16145-16148	3.2	_
82-17	16148-16149	.	_

#Text=Brain Activation During Visual Perspective-Taking in ASD and Schizophrenia
#Text=Figure 2 presents BOLD signal activation during perspective-taking versus control trials across the three study groups.
83-1	16150-16155	Brain	_
83-2	16156-16166	Activation	_
83-3	16167-16173	During	_
83-4	16174-16180	Visual	_
83-5	16181-16199	Perspective-Taking	_
83-6	16200-16202	in	_
83-7	16203-16206	ASD	_
83-8	16207-16210	and	_
83-9	16211-16224	Schizophrenia	_
83-10	16225-16231	Figure	_
83-11	16232-16233	2	_
83-12	16234-16242	presents	_
83-13	16243-16247	BOLD	_
83-14	16248-16254	signal	_
83-15	16255-16265	activation	_
83-16	16266-16272	during	_
83-17	16273-16291	perspective-taking	_
83-18	16292-16298	versus	_
83-19	16299-16306	control	_
83-20	16307-16313	trials	_
83-21	16314-16320	across	_
83-22	16321-16324	the	_
83-23	16325-16330	three	_
83-24	16331-16336	study	_
83-25	16337-16343	groups	_
83-26	16343-16344	.	_

#Text=Consistent with previous literature, regional patterns of activation during perspective-taking included broad areas of the medial and orbito prefrontal cortex, as well as the temporo-parietal junction and superior temporal gyrus.
84-1	16345-16355	Consistent	_
84-2	16356-16360	with	_
84-3	16361-16369	previous	_
84-4	16370-16380	literature	_
84-5	16380-16381	,	_
84-6	16382-16390	regional	_
84-7	16391-16399	patterns	_
84-8	16400-16402	of	_
84-9	16403-16413	activation	_
84-10	16414-16420	during	_
84-11	16421-16439	perspective-taking	_
84-12	16440-16448	included	_
84-13	16449-16454	broad	_
84-14	16455-16460	areas	_
84-15	16461-16463	of	_
84-16	16464-16467	the	_
84-17	16468-16474	medial	_
84-18	16475-16478	and	_
84-19	16479-16485	orbito	_
84-20	16486-16496	prefrontal	_
84-21	16497-16503	cortex	_
84-22	16503-16504	,	_
84-23	16505-16507	as	_
84-24	16508-16512	well	_
84-25	16513-16515	as	_
84-26	16516-16519	the	_
84-27	16520-16536	temporo-parietal	_
84-28	16537-16545	junction	_
84-29	16546-16549	and	_
84-30	16550-16558	superior	_
84-31	16559-16567	temporal	_
84-32	16568-16573	gyrus	_
84-33	16573-16574	.	_

#Text=Participants with ASD displayed less bilateral temporo-parietal junction activity than healthy individuals (see Table 3).
85-1	16575-16587	Participants	_
85-2	16588-16592	with	_
85-3	16593-16596	ASD	_
85-4	16597-16606	displayed	_
85-5	16607-16611	less	_
85-6	16612-16621	bilateral	_
85-7	16622-16638	temporo-parietal	_
85-8	16639-16647	junction	_
85-9	16648-16656	activity	_
85-10	16657-16661	than	_
85-11	16662-16669	healthy	_
85-12	16670-16681	individuals	_
85-13	16682-16683	(	_
85-14	16683-16686	see	_
85-15	16687-16692	Table	_
85-16	16693-16694	3	_
85-17	16694-16695	)	_
85-18	16695-16696	.	_

#Text=Conversely, individuals with schizophrenia demonstrated greater medial prefrontal and anterior cingulate activity during perspective-taking than healthy volunteers.
86-1	16697-16707	Conversely	_
86-2	16707-16708	,	_
86-3	16709-16720	individuals	_
86-4	16721-16725	with	_
86-5	16726-16739	schizophrenia	_
86-6	16740-16752	demonstrated	_
86-7	16753-16760	greater	_
86-8	16761-16767	medial	_
86-9	16768-16778	prefrontal	_
86-10	16779-16782	and	_
86-11	16783-16791	anterior	_
86-12	16792-16801	cingulate	_
86-13	16802-16810	activity	_
86-14	16811-16817	during	_
86-15	16818-16836	perspective-taking	_
86-16	16837-16841	than	_
86-17	16842-16849	healthy	_
86-18	16850-16860	volunteers	_
86-19	16860-16861	.	_

#Text=When comparing patient groups directly, participants with schizophrenia evidenced significantly greater ventromedial prefrontal and left temporo-parietal junction activity than participants with ASD.
#Text=3.3.
87-1	16862-16866	When	_
87-2	16867-16876	comparing	_
87-3	16877-16884	patient	_
87-4	16885-16891	groups	_
87-5	16892-16900	directly	_
87-6	16900-16901	,	_
87-7	16902-16914	participants	_
87-8	16915-16919	with	_
87-9	16920-16933	schizophrenia	_
87-10	16934-16943	evidenced	_
87-11	16944-16957	significantly	_
87-12	16958-16965	greater	_
87-13	16966-16978	ventromedial	_
87-14	16979-16989	prefrontal	_
87-15	16990-16993	and	_
87-16	16994-16998	left	_
87-17	16999-17015	temporo-parietal	_
87-18	17016-17024	junction	_
87-19	17025-17033	activity	_
87-20	17034-17038	than	_
87-21	17039-17051	participants	_
87-22	17052-17056	with	_
87-23	17057-17060	ASD	_
87-24	17060-17061	.	_
87-25	17062-17065	3.3	_
87-26	17065-17066	.	_

#Text=Brain Connectivity During Visual Perspective-Taking in ASD and Schizophrenia
#Text=As shown in Figure 3, seed-based connectivity analyses revealed significantly different patterns of brain connectivity between participants.
88-1	17067-17072	Brain	_
88-2	17073-17085	Connectivity	_
88-3	17086-17092	During	_
88-4	17093-17099	Visual	_
88-5	17100-17118	Perspective-Taking	_
88-6	17119-17121	in	_
88-7	17122-17125	ASD	_
88-8	17126-17129	and	_
88-9	17130-17143	Schizophrenia	_
88-10	17144-17146	As	_
88-11	17147-17152	shown	_
88-12	17153-17155	in	_
88-13	17156-17162	Figure	_
88-14	17163-17164	3	_
88-15	17164-17165	,	_
88-16	17166-17176	seed-based	_
88-17	17177-17189	connectivity	_
88-18	17190-17198	analyses	_
88-19	17199-17207	revealed	_
88-20	17208-17221	significantly	_
88-21	17222-17231	different	_
88-22	17232-17240	patterns	_
88-23	17241-17243	of	_
88-24	17244-17249	brain	_
88-25	17250-17262	connectivity	_
88-26	17263-17270	between	_
88-27	17271-17283	participants	_
88-28	17283-17284	.	_

#Text=Findings are organized around hubs of network connectivity, which represented seed regions with the highest number of connections to other region of interest seeds.
89-1	17285-17293	Findings	_
89-2	17294-17297	are	_
89-3	17298-17307	organized	_
89-4	17308-17314	around	_
89-5	17315-17319	hubs	_
89-6	17320-17322	of	_
89-7	17323-17330	network	_
89-8	17331-17343	connectivity	_
89-9	17343-17344	,	_
89-10	17345-17350	which	_
89-11	17351-17362	represented	_
89-12	17363-17367	seed	_
89-13	17368-17375	regions	_
89-14	17376-17380	with	_
89-15	17381-17384	the	_
89-16	17385-17392	highest	_
89-17	17393-17399	number	_
89-18	17400-17402	of	_
89-19	17403-17414	connections	_
89-20	17415-17417	to	_
89-21	17418-17423	other	_
89-22	17424-17430	region	_
89-23	17431-17433	of	_
89-24	17434-17442	interest	_
89-25	17443-17448	seeds	_
89-26	17448-17449	.	_

#Text=Healthy individuals displayed a single robust hub of coordination in the right temporo-parietal junction, which was consistently synchronized with medial prefrontal/orbitofrontal brain activity.
90-1	17450-17457	Healthy	_
90-2	17458-17469	individuals	_
90-3	17470-17479	displayed	_
90-4	17480-17481	a	_
90-5	17482-17488	single	_
90-6	17489-17495	robust	_
90-7	17496-17499	hub	_
90-8	17500-17502	of	_
90-9	17503-17515	coordination	_
90-10	17516-17518	in	_
90-11	17519-17522	the	_
90-12	17523-17528	right	_
90-13	17529-17545	temporo-parietal	_
90-14	17546-17554	junction	_
90-15	17554-17555	,	_
90-16	17556-17561	which	_
90-17	17562-17565	was	_
90-18	17566-17578	consistently	_
90-19	17579-17591	synchronized	_
90-20	17592-17596	with	_
90-21	17597-17603	medial	_
90-22	17604-17614	prefrontal	_
90-23	17614-17615	/	_
90-24	17615-17628	orbitofrontal	_
90-25	17629-17634	brain	_
90-26	17635-17643	activity	_
90-27	17643-17644	.	_

#Text=In contrast, individuals with ASD demonstrated a densely connected medial prefrontal circuit, as well as bilateral connections between the temporo-parietal junction and the medial prefrontal cortex.
91-1	17645-17647	In	_
91-2	17648-17656	contrast	_
91-3	17656-17657	,	_
91-4	17658-17669	individuals	_
91-5	17670-17674	with	_
91-6	17675-17678	ASD	_
91-7	17679-17691	demonstrated	_
91-8	17692-17693	a	_
91-9	17694-17701	densely	_
91-10	17702-17711	connected	_
91-11	17712-17718	medial	_
91-12	17719-17729	prefrontal	_
91-13	17730-17737	circuit	_
91-14	17737-17738	,	_
91-15	17739-17741	as	_
91-16	17742-17746	well	_
91-17	17747-17749	as	_
91-18	17750-17759	bilateral	_
91-19	17760-17771	connections	_
91-20	17772-17779	between	_
91-21	17780-17783	the	_
91-22	17784-17800	temporo-parietal	_
91-23	17801-17809	junction	_
91-24	17810-17813	and	_
91-25	17814-17817	the	_
91-26	17818-17824	medial	_
91-27	17825-17835	prefrontal	_
91-28	17836-17842	cortex	_
91-29	17842-17843	.	_

#Text=When examining the sample of participants with schizophrenia, only a single local positive connection between the left dorsolateral prefrontal and right ventromedial prefrontal cortices persisted after correction.
92-1	17844-17848	When	_
92-2	17849-17858	examining	_
92-3	17859-17862	the	_
92-4	17863-17869	sample	_
92-5	17870-17872	of	_
92-6	17873-17885	participants	_
92-7	17886-17890	with	_
92-8	17891-17904	schizophrenia	_
92-9	17904-17905	,	_
92-10	17906-17910	only	_
92-11	17911-17912	a	_
92-12	17913-17919	single	_
92-13	17920-17925	local	_
92-14	17926-17934	positive	_
92-15	17935-17945	connection	_
92-16	17946-17953	between	_
92-17	17954-17957	the	_
92-18	17958-17962	left	_
92-19	17963-17975	dorsolateral	_
92-20	17976-17986	prefrontal	_
92-21	17987-17990	and	_
92-22	17991-17996	right	_
92-23	17997-18009	ventromedial	_
92-24	18010-18020	prefrontal	_
92-25	18021-18029	cortices	_
92-26	18030-18039	persisted	_
92-27	18040-18045	after	_
92-28	18046-18056	correction	_
92-29	18056-18057	.	_

#Text=Direct comparisons of connectivity strength between study groups indicated that individuals with ASD had significantly greater connectivity between the left orbitofrontal cortex and bilateral medial prefrontal cortices, as well as the left temporo-parietal junction, compared to healthy participants (see Table 4).
93-1	18058-18064	Direct	_
93-2	18065-18076	comparisons	_
93-3	18077-18079	of	_
93-4	18080-18092	connectivity	_
93-5	18093-18101	strength	_
93-6	18102-18109	between	_
93-7	18110-18115	study	_
93-8	18116-18122	groups	_
93-9	18123-18132	indicated	_
93-10	18133-18137	that	_
93-11	18138-18149	individuals	_
93-12	18150-18154	with	_
93-13	18155-18158	ASD	_
93-14	18159-18162	had	_
93-15	18163-18176	significantly	_
93-16	18177-18184	greater	_
93-17	18185-18197	connectivity	_
93-18	18198-18205	between	_
93-19	18206-18209	the	_
93-20	18210-18214	left	_
93-21	18215-18228	orbitofrontal	_
93-22	18229-18235	cortex	_
93-23	18236-18239	and	_
93-24	18240-18249	bilateral	_
93-25	18250-18256	medial	_
93-26	18257-18267	prefrontal	_
93-27	18268-18276	cortices	_
93-28	18276-18277	,	_
93-29	18278-18280	as	_
93-30	18281-18285	well	_
93-31	18286-18288	as	_
93-32	18289-18292	the	_
93-33	18293-18297	left	_
93-34	18298-18314	temporo-parietal	_
93-35	18315-18323	junction	_
93-36	18323-18324	,	_
93-37	18325-18333	compared	_
93-38	18334-18336	to	_
93-39	18337-18344	healthy	_
93-40	18345-18357	participants	_
93-41	18358-18359	(	_
93-42	18359-18362	see	_
93-43	18363-18368	Table	_
93-44	18369-18370	4	_
93-45	18370-18371	)	_
93-46	18371-18372	.	_

#Text=In contrast, patients with schizophrenia demonstrated reduced connectivity between the right temporo-parietal junction and medial prefrontal cortex relative to controls.
94-1	18373-18375	In	_
94-2	18376-18384	contrast	_
94-3	18384-18385	,	_
94-4	18386-18394	patients	_
94-5	18395-18399	with	_
94-6	18400-18413	schizophrenia	_
94-7	18414-18426	demonstrated	_
94-8	18427-18434	reduced	_
94-9	18435-18447	connectivity	_
94-10	18448-18455	between	_
94-11	18456-18459	the	_
94-12	18460-18465	right	_
94-13	18466-18482	temporo-parietal	_
94-14	18483-18491	junction	_
94-15	18492-18495	and	_
94-16	18496-18502	medial	_
94-17	18503-18513	prefrontal	_
94-18	18514-18520	cortex	_
94-19	18521-18529	relative	_
94-20	18530-18532	to	_
94-21	18533-18541	controls	_
94-22	18541-18542	.	_

#Text=However, individuals with schizophrenia also displayed significantly greater orbitofrontal and anterior cingulate connectivity with the medial prefrontal cortex during perspective-taking compared to healthy individuals.
95-1	18543-18550	However	_
95-2	18550-18551	,	_
95-3	18552-18563	individuals	_
95-4	18564-18568	with	_
95-5	18569-18582	schizophrenia	_
95-6	18583-18587	also	_
95-7	18588-18597	displayed	_
95-8	18598-18611	significantly	_
95-9	18612-18619	greater	_
95-10	18620-18633	orbitofrontal	_
95-11	18634-18637	and	_
95-12	18638-18646	anterior	_
95-13	18647-18656	cingulate	_
95-14	18657-18669	connectivity	_
95-15	18670-18674	with	_
95-16	18675-18678	the	_
95-17	18679-18685	medial	_
95-18	18686-18696	prefrontal	_
95-19	18697-18703	cortex	_
95-20	18704-18710	during	_
95-21	18711-18729	perspective-taking	_
95-22	18730-18738	compared	_
95-23	18739-18741	to	_
95-24	18742-18749	healthy	_
95-25	18750-18761	individuals	_
95-26	18761-18762	.	_

#Text=Only two significant connectivity differences between individuals with ASD and schizophrenia were observed, indicating increased bilateral orbitofrontal connectivity in participants with ASD.
#Text=4.
96-1	18763-18767	Only	_
96-2	18768-18771	two	_
96-3	18772-18783	significant	_
96-4	18784-18796	connectivity	_
96-5	18797-18808	differences	_
96-6	18809-18816	between	_
96-7	18817-18828	individuals	_
96-8	18829-18833	with	_
96-9	18834-18837	ASD	_
96-10	18838-18841	and	_
96-11	18842-18855	schizophrenia	_
96-12	18856-18860	were	_
96-13	18861-18869	observed	_
96-14	18869-18870	,	_
96-15	18871-18881	indicating	_
96-16	18882-18891	increased	_
96-17	18892-18901	bilateral	_
96-18	18902-18915	orbitofrontal	_
96-19	18916-18928	connectivity	_
96-20	18929-18931	in	_
96-21	18932-18944	participants	_
96-22	18945-18949	with	_
96-23	18950-18953	ASD	_
96-24	18953-18954	.	_
96-25	18955-18956	4	_
96-26	18956-18957	.	_

#Text=Discussion
#Text=Autism and schizophrenia are neurodevelopmental conditions characterized by significant social disability that may reflect similar underlying neural dysfunction in social-cognitive brain networks.
97-1	18958-18968	Discussion	_
97-2	18969-18975	Autism	_
97-3	18976-18979	and	_
97-4	18980-18993	schizophrenia	_
97-5	18994-18997	are	_
97-6	18998-19016	neurodevelopmental	_
97-7	19017-19027	conditions	_
97-8	19028-19041	characterized	_
97-9	19042-19044	by	_
97-10	19045-19056	significant	_
97-11	19057-19063	social	_
97-12	19064-19074	disability	_
97-13	19075-19079	that	_
97-14	19080-19083	may	_
97-15	19084-19091	reflect	_
97-16	19092-19099	similar	_
97-17	19100-19110	underlying	_
97-18	19111-19117	neural	_
97-19	19118-19129	dysfunction	_
97-20	19130-19132	in	_
97-21	19133-19149	social-cognitive	_
97-22	19150-19155	brain	_
97-23	19156-19164	networks	_
97-24	19164-19165	.	_

#Text=This study examined fronto-temporal brain activity and connectivity during visual perspective-taking in a well-characterized sample of individuals with ASD, schizophrenia, and healthy volunteers to investigate the degree to which brain functions supporting social cognition are similarly altered across autism and schizophrenia spectra.
98-1	19166-19170	This	_
98-2	19171-19176	study	_
98-3	19177-19185	examined	_
98-4	19186-19201	fronto-temporal	_
98-5	19202-19207	brain	_
98-6	19208-19216	activity	_
98-7	19217-19220	and	_
98-8	19221-19233	connectivity	_
98-9	19234-19240	during	_
98-10	19241-19247	visual	_
98-11	19248-19266	perspective-taking	_
98-12	19267-19269	in	_
98-13	19270-19271	a	_
98-14	19272-19290	well-characterized	_
98-15	19291-19297	sample	_
98-16	19298-19300	of	_
98-17	19301-19312	individuals	_
98-18	19313-19317	with	_
98-19	19318-19321	ASD	_
98-20	19321-19322	,	_
98-21	19323-19336	schizophrenia	_
98-22	19336-19337	,	_
98-23	19338-19341	and	_
98-24	19342-19349	healthy	_
98-25	19350-19360	volunteers	_
98-26	19361-19363	to	_
98-27	19364-19375	investigate	_
98-28	19376-19379	the	_
98-29	19380-19386	degree	_
98-30	19387-19389	to	_
98-31	19390-19395	which	_
98-32	19396-19401	brain	_
98-33	19402-19411	functions	_
98-34	19412-19422	supporting	_
98-35	19423-19429	social	_
98-36	19430-19439	cognition	_
98-37	19440-19443	are	_
98-38	19444-19453	similarly	_
98-39	19454-19461	altered	_
98-40	19462-19468	across	_
98-41	19469-19475	autism	_
98-42	19476-19479	and	_
98-43	19480-19493	schizophrenia	_
98-44	19494-19501	spectra	_
98-45	19501-19502	.	_

#Text=Findings regarding brain activation indicated greater ventromedial prefrontal and temporo-parietal junction activity in schizophrenia relative to ASD.
99-1	19503-19511	Findings	_
99-2	19512-19521	regarding	_
99-3	19522-19527	brain	_
99-4	19528-19538	activation	_
99-5	19539-19548	indicated	_
99-6	19549-19556	greater	_
99-7	19557-19569	ventromedial	_
99-8	19570-19580	prefrontal	_
99-9	19581-19584	and	_
99-10	19585-19601	temporo-parietal	_
99-11	19602-19610	junction	_
99-12	19611-19619	activity	_
99-13	19620-19622	in	_
99-14	19623-19636	schizophrenia	_
99-15	19637-19645	relative	_
99-16	19646-19648	to	_
99-17	19649-19652	ASD	_
99-18	19652-19653	.	_

#Text=Differences in patterns of functional connectivity indicated that participants with ASD displayed significantly increased orbitofrontal connectivity compared to patients with schizophrenia.
100-1	19654-19665	Differences	_
100-2	19666-19668	in	_
100-3	19669-19677	patterns	_
100-4	19678-19680	of	_
100-5	19681-19691	functional	_
100-6	19692-19704	connectivity	_
100-7	19705-19714	indicated	_
100-8	19715-19719	that	_
100-9	19720-19732	participants	_
100-10	19733-19737	with	_
100-11	19738-19741	ASD	_
100-12	19742-19751	displayed	_
100-13	19752-19765	significantly	_
100-14	19766-19775	increased	_
100-15	19776-19789	orbitofrontal	_
100-16	19790-19802	connectivity	_
100-17	19803-19811	compared	_
100-18	19812-19814	to	_
100-19	19815-19823	patients	_
100-20	19824-19828	with	_
100-21	19829-19842	schizophrenia	_
100-22	19842-19843	.	_

#Text=These findings suggest that local social-cognitive networks may be significantly over-connected in ASD, as others have noted, which could contribute to inefficient and reduced activation of broader fronto-temporal systems involved in social cognition.
101-1	19844-19849	These	_
101-2	19850-19858	findings	_
101-3	19859-19866	suggest	_
101-4	19867-19871	that	_
101-5	19872-19877	local	_
101-6	19878-19894	social-cognitive	_
101-7	19895-19903	networks	_
101-8	19904-19907	may	_
101-9	19908-19910	be	_
101-10	19911-19924	significantly	_
101-11	19925-19939	over-connected	_
101-12	19940-19942	in	_
101-13	19943-19946	ASD	_
101-14	19946-19947	,	_
101-15	19948-19950	as	_
101-16	19951-19957	others	_
101-17	19958-19962	have	_
101-18	19963-19968	noted	_
101-19	19968-19969	,	_
101-20	19970-19975	which	_
101-21	19976-19981	could	_
101-22	19982-19992	contribute	_
101-23	19993-19995	to	_
101-24	19996-20007	inefficient	_
101-25	20008-20011	and	_
101-26	20012-20019	reduced	_
101-27	20020-20030	activation	_
101-28	20031-20033	of	_
101-29	20034-20041	broader	_
101-30	20042-20057	fronto-temporal	_
101-31	20058-20065	systems	_
101-32	20066-20074	involved	_
101-33	20075-20077	in	_
101-34	20078-20084	social	_
101-35	20085-20094	cognition	_
101-36	20094-20095	.	_

#Text=Although direct evidence for differentially reduced fronto-temporal connectivity in schizophrenia compared to ASD was not observed, it is interesting that comparisons with healthy individuals indicated less fronto-temporal connectivity in schizophrenia and greater connectivity in autism, lending some support to previous studies of fronto-temporal disconnection in schizophrenia.
102-1	20096-20104	Although	_
102-2	20105-20111	direct	_
102-3	20112-20120	evidence	_
102-4	20121-20124	for	_
102-5	20125-20139	differentially	_
102-6	20140-20147	reduced	_
102-7	20148-20163	fronto-temporal	_
102-8	20164-20176	connectivity	_
102-9	20177-20179	in	_
102-10	20180-20193	schizophrenia	_
102-11	20194-20202	compared	_
102-12	20203-20205	to	_
102-13	20206-20209	ASD	_
102-14	20210-20213	was	_
102-15	20214-20217	not	_
102-16	20218-20226	observed	_
102-17	20226-20227	,	_
102-18	20228-20230	it	_
102-19	20231-20233	is	_
102-20	20234-20245	interesting	_
102-21	20246-20250	that	_
102-22	20251-20262	comparisons	_
102-23	20263-20267	with	_
102-24	20268-20275	healthy	_
102-25	20276-20287	individuals	_
102-26	20288-20297	indicated	_
102-27	20298-20302	less	_
102-28	20303-20318	fronto-temporal	_
102-29	20319-20331	connectivity	_
102-30	20332-20334	in	_
102-31	20335-20348	schizophrenia	_
102-32	20349-20352	and	_
102-33	20353-20360	greater	_
102-34	20361-20373	connectivity	_
102-35	20374-20376	in	_
102-36	20377-20383	autism	_
102-37	20383-20384	,	_
102-38	20385-20392	lending	_
102-39	20393-20397	some	_
102-40	20398-20405	support	_
102-41	20406-20408	to	_
102-42	20409-20417	previous	_
102-43	20418-20425	studies	_
102-44	20426-20428	of	_
102-45	20429-20444	fronto-temporal	_
102-46	20445-20458	disconnection	_
102-47	20459-20461	in	_
102-48	20462-20475	schizophrenia	_
102-49	20475-20476	.	_

#Text=Overall, these findings suggest that unique neural mechanisms may underlie similar patterns of social impairment in autism and schizophrenia.
103-1	20477-20484	Overall	_
103-2	20484-20485	,	_
103-3	20486-20491	these	_
103-4	20492-20500	findings	_
103-5	20501-20508	suggest	_
103-6	20509-20513	that	_
103-7	20514-20520	unique	_
103-8	20521-20527	neural	_
103-9	20528-20538	mechanisms	_
103-10	20539-20542	may	_
103-11	20543-20551	underlie	_
103-12	20552-20559	similar	_
103-13	20560-20568	patterns	_
103-14	20569-20571	of	_
103-15	20572-20578	social	_
103-16	20579-20589	impairment	_
103-17	20590-20592	in	_
103-18	20593-20599	autism	_
103-19	20600-20603	and	_
103-20	20604-20617	schizophrenia	_
103-21	20617-20618	.	_

#Text=These findings contribute to a growing understanding of social brain processes in autism and schizophrenia, and diverge some from the small number of previously conducted studies. and both found reduced prefrontal and medial-temporal brain activity in schizophrenia and ASD during social-cognitive processing relative to healthy individuals, which we did not observe.
104-1	20619-20624	These	_
104-2	20625-20633	findings	_
104-3	20634-20644	contribute	_
104-4	20645-20647	to	_
104-5	20648-20649	a	_
104-6	20650-20657	growing	_
104-7	20658-20671	understanding	_
104-8	20672-20674	of	_
104-9	20675-20681	social	_
104-10	20682-20687	brain	_
104-11	20688-20697	processes	_
104-12	20698-20700	in	_
104-13	20701-20707	autism	_
104-14	20708-20711	and	_
104-15	20712-20725	schizophrenia	_
104-16	20725-20726	,	_
104-17	20727-20730	and	_
104-18	20731-20738	diverge	_
104-19	20739-20743	some	_
104-20	20744-20748	from	_
104-21	20749-20752	the	_
104-22	20753-20758	small	_
104-23	20759-20765	number	_
104-24	20766-20768	of	_
104-25	20769-20779	previously	_
104-26	20780-20789	conducted	_
104-27	20790-20797	studies	_
104-28	20797-20798	.	_
104-29	20799-20802	and	_
104-30	20803-20807	both	_
104-31	20808-20813	found	_
104-32	20814-20821	reduced	_
104-33	20822-20832	prefrontal	_
104-34	20833-20836	and	_
104-35	20837-20852	medial-temporal	_
104-36	20853-20858	brain	_
104-37	20859-20867	activity	_
104-38	20868-20870	in	_
104-39	20871-20884	schizophrenia	_
104-40	20885-20888	and	_
104-41	20889-20892	ASD	_
104-42	20893-20899	during	_
104-43	20900-20916	social-cognitive	_
104-44	20917-20927	processing	_
104-45	20928-20936	relative	_
104-46	20937-20939	to	_
104-47	20940-20947	healthy	_
104-48	20948-20959	individuals	_
104-49	20959-20960	,	_
104-50	20961-20966	which	_
104-51	20967-20969	we	_
104-52	20970-20973	did	_
104-53	20974-20977	not	_
104-54	20978-20985	observe	_
104-55	20985-20986	.	_

#Text=Patients with schizophrenia showed increased in medial prefrontal cortical activity, and participants with ASD displayed reduced temporal-parietal junction activity during perspective-taking.
105-1	20987-20995	Patients	_
105-2	20996-21000	with	_
105-3	21001-21014	schizophrenia	_
105-4	21015-21021	showed	_
105-5	21022-21031	increased	_
105-6	21032-21034	in	_
105-7	21035-21041	medial	_
105-8	21042-21052	prefrontal	_
105-9	21053-21061	cortical	_
105-10	21062-21070	activity	_
105-11	21070-21071	,	_
105-12	21072-21075	and	_
105-13	21076-21088	participants	_
105-14	21089-21093	with	_
105-15	21094-21097	ASD	_
105-16	21098-21107	displayed	_
105-17	21108-21115	reduced	_
105-18	21116-21133	temporal-parietal	_
105-19	21134-21142	junction	_
105-20	21143-21151	activity	_
105-21	21152-21158	during	_
105-22	21159-21177	perspective-taking	_
105-23	21177-21178	.	_

#Text=Variation in brain activation results may be due to methodological differences in the particular social-cognitive construct under study, as these investigations each assessed putatively different aspects of social cognition.
106-1	21179-21188	Variation	_
106-2	21189-21191	in	_
106-3	21192-21197	brain	_
106-4	21198-21208	activation	_
106-5	21209-21216	results	_
106-6	21217-21220	may	_
106-7	21221-21223	be	_
106-8	21224-21227	due	_
106-9	21228-21230	to	_
106-10	21231-21245	methodological	_
106-11	21246-21257	differences	_
106-12	21258-21260	in	_
106-13	21261-21264	the	_
106-14	21265-21275	particular	_
106-15	21276-21292	social-cognitive	_
106-16	21293-21302	construct	_
106-17	21303-21308	under	_
106-18	21309-21314	study	_
106-19	21314-21315	,	_
106-20	21316-21318	as	_
106-21	21319-21324	these	_
106-22	21325-21339	investigations	_
106-23	21340-21344	each	_
106-24	21345-21353	assessed	_
106-25	21354-21364	putatively	_
106-26	21365-21374	different	_
106-27	21375-21382	aspects	_
106-28	21383-21385	of	_
106-29	21386-21392	social	_
106-30	21393-21402	cognition	_
106-31	21402-21403	.	_

#Text=While participation of similar brain networks may be likely for various social-cognitive processes, far more research is needed to understand the neural basis of these constructs and their comparability across autism and schizophrenia spectra.
107-1	21404-21409	While	_
107-2	21410-21423	participation	_
107-3	21424-21426	of	_
107-4	21427-21434	similar	_
107-5	21435-21440	brain	_
107-6	21441-21449	networks	_
107-7	21450-21453	may	_
107-8	21454-21456	be	_
107-9	21457-21463	likely	_
107-10	21464-21467	for	_
107-11	21468-21475	various	_
107-12	21476-21492	social-cognitive	_
107-13	21493-21502	processes	_
107-14	21502-21503	,	_
107-15	21504-21507	far	_
107-16	21508-21512	more	_
107-17	21513-21521	research	_
107-18	21522-21524	is	_
107-19	21525-21531	needed	_
107-20	21532-21534	to	_
107-21	21535-21545	understand	_
107-22	21546-21549	the	_
107-23	21550-21556	neural	_
107-24	21557-21562	basis	_
107-25	21563-21565	of	_
107-26	21566-21571	these	_
107-27	21572-21582	constructs	_
107-28	21583-21586	and	_
107-29	21587-21592	their	_
107-30	21593-21606	comparability	_
107-31	21607-21613	across	_
107-32	21614-21620	autism	_
107-33	21621-21624	and	_
107-34	21625-21638	schizophrenia	_
107-35	21639-21646	spectra	_
107-36	21646-21647	.	_

#Text=Although this research holds implications for understanding the neural basis of social impairments in autism and schizophrenia, there are several limitations that temper our conclusions.
108-1	21648-21656	Although	_
108-2	21657-21661	this	_
108-3	21662-21670	research	_
108-4	21671-21676	holds	_
108-5	21677-21689	implications	_
108-6	21690-21693	for	_
108-7	21694-21707	understanding	_
108-8	21708-21711	the	_
108-9	21712-21718	neural	_
108-10	21719-21724	basis	_
108-11	21725-21727	of	_
108-12	21728-21734	social	_
108-13	21735-21746	impairments	_
108-14	21747-21749	in	_
108-15	21750-21756	autism	_
108-16	21757-21760	and	_
108-17	21761-21774	schizophrenia	_
108-18	21774-21775	,	_
108-19	21776-21781	there	_
108-20	21782-21785	are	_
108-21	21786-21793	several	_
108-22	21794-21805	limitations	_
108-23	21806-21810	that	_
108-24	21811-21817	temper	_
108-25	21818-21821	our	_
108-26	21822-21833	conclusions	_
108-27	21833-21834	.	_

#Text=First, participants were not matched on medication characteristics, although antipsychotic dose was unrelated to activation and connectivity values showing between-group differences (see Table S1).
109-1	21835-21840	First	_
109-2	21840-21841	,	_
109-3	21842-21854	participants	_
109-4	21855-21859	were	_
109-5	21860-21863	not	_
109-6	21864-21871	matched	_
109-7	21872-21874	on	_
109-8	21875-21885	medication	_
109-9	21886-21901	characteristics	_
109-10	21901-21902	,	_
109-11	21903-21911	although	_
109-12	21912-21925	antipsychotic	_
109-13	21926-21930	dose	_
109-14	21931-21934	was	_
109-15	21935-21944	unrelated	_
109-16	21945-21947	to	_
109-17	21948-21958	activation	_
109-18	21959-21962	and	_
109-19	21963-21975	connectivity	_
109-20	21976-21982	values	_
109-21	21983-21990	showing	_
109-22	21991-22004	between-group	_
109-23	22005-22016	differences	_
109-24	22017-22018	(	_
109-25	22018-22021	see	_
109-26	22022-22027	Table	_
109-27	22028-22030	S1	_
109-28	22030-22031	)	_
109-29	22031-22032	.	_

#Text=Second, our sample size was not large enough to permit meaningful subgroup analyses.
110-1	22033-22039	Second	_
110-2	22039-22040	,	_
110-3	22041-22044	our	_
110-4	22045-22051	sample	_
110-5	22052-22056	size	_
110-6	22057-22060	was	_
110-7	22061-22064	not	_
110-8	22065-22070	large	_
110-9	22071-22077	enough	_
110-10	22078-22080	to	_
110-11	22081-22087	permit	_
110-12	22088-22098	meaningful	_
110-13	22099-22107	subgroup	_
110-14	22108-22116	analyses	_
110-15	22116-22117	.	_

#Text=Both ASD and schizophrenia are highly heterogeneous conditions, and it will be important for future research to pool larger samples that can perform meaningful subgroup analyses to parse this heterogeneity.
111-1	22118-22122	Both	_
111-2	22123-22126	ASD	_
111-3	22127-22130	and	_
111-4	22131-22144	schizophrenia	_
111-5	22145-22148	are	_
111-6	22149-22155	highly	_
111-7	22156-22169	heterogeneous	_
111-8	22170-22180	conditions	_
111-9	22180-22181	,	_
111-10	22182-22185	and	_
111-11	22186-22188	it	_
111-12	22189-22193	will	_
111-13	22194-22196	be	_
111-14	22197-22206	important	_
111-15	22207-22210	for	_
111-16	22211-22217	future	_
111-17	22218-22226	research	_
111-18	22227-22229	to	_
111-19	22230-22234	pool	_
111-20	22235-22241	larger	_
111-21	22242-22249	samples	_
111-22	22250-22254	that	_
111-23	22255-22258	can	_
111-24	22259-22266	perform	_
111-25	22267-22277	meaningful	_
111-26	22278-22286	subgroup	_
111-27	22287-22295	analyses	_
111-28	22296-22298	to	_
111-29	22299-22304	parse	_
111-30	22305-22309	this	_
111-31	22310-22323	heterogeneity	_
111-32	22323-22324	.	_

#Text=In addition, our study is limited in that it did not conduct autism diagnostic assessments in patients with schizophrenia or vice versa, and such information will be important to collect in future studies seeking to understand heterogeneity and overlap between these conditions.
112-1	22325-22327	In	_
112-2	22328-22336	addition	_
112-3	22336-22337	,	_
112-4	22338-22341	our	_
112-5	22342-22347	study	_
112-6	22348-22350	is	_
112-7	22351-22358	limited	_
112-8	22359-22361	in	_
112-9	22362-22366	that	_
112-10	22367-22369	it	_
112-11	22370-22373	did	_
112-12	22374-22377	not	_
112-13	22378-22385	conduct	_
112-14	22386-22392	autism	_
112-15	22393-22403	diagnostic	_
112-16	22404-22415	assessments	_
112-17	22416-22418	in	_
112-18	22419-22427	patients	_
112-19	22428-22432	with	_
112-20	22433-22446	schizophrenia	_
112-21	22447-22449	or	_
112-22	22450-22454	vice	_
112-23	22455-22460	versa	_
112-24	22460-22461	,	_
112-25	22462-22465	and	_
112-26	22466-22470	such	_
112-27	22471-22482	information	_
112-28	22483-22487	will	_
112-29	22488-22490	be	_
112-30	22491-22500	important	_
112-31	22501-22503	to	_
112-32	22504-22511	collect	_
112-33	22512-22514	in	_
112-34	22515-22521	future	_
112-35	22522-22529	studies	_
112-36	22530-22537	seeking	_
112-37	22538-22540	to	_
112-38	22541-22551	understand	_
112-39	22552-22565	heterogeneity	_
112-40	22566-22569	and	_
112-41	22570-22577	overlap	_
112-42	22578-22585	between	_
112-43	22586-22591	these	_
112-44	22592-22602	conditions	_
112-45	22602-22603	.	_

#Text=Finally, while this research documents diverging abnormalities in brain function and connectivity in ASD and schizophrenia, it does not indicate what mechanisms may give rise to these changes.
113-1	22604-22611	Finally	_
113-2	22611-22612	,	_
113-3	22613-22618	while	_
113-4	22619-22623	this	_
113-5	22624-22632	research	_
113-6	22633-22642	documents	_
113-7	22643-22652	diverging	_
113-8	22653-22666	abnormalities	_
113-9	22667-22669	in	_
113-10	22670-22675	brain	_
113-11	22676-22684	function	_
113-12	22685-22688	and	_
113-13	22689-22701	connectivity	_
113-14	22702-22704	in	_
113-15	22705-22708	ASD	_
113-16	22709-22712	and	_
113-17	22713-22726	schizophrenia	_
113-18	22726-22727	,	_
113-19	22728-22730	it	_
113-20	22731-22735	does	_
113-21	22736-22739	not	_
113-22	22740-22748	indicate	_
113-23	22749-22753	what	_
113-24	22754-22764	mechanisms	_
113-25	22765-22768	may	_
113-26	22769-22773	give	_
113-27	22774-22778	rise	_
113-28	22779-22781	to	_
113-29	22782-22787	these	_
113-30	22788-22795	changes	_
113-31	22795-22796	.	_

#Text=Previous studies have found evidence for excessive synaptic pruning in schizophrenia, which may give rise to the generally under-connected nature of social-cognitive and other brain networks in that disorder.
114-1	22797-22805	Previous	_
114-2	22806-22813	studies	_
114-3	22814-22818	have	_
114-4	22819-22824	found	_
114-5	22825-22833	evidence	_
114-6	22834-22837	for	_
114-7	22838-22847	excessive	_
114-8	22848-22856	synaptic	_
114-9	22857-22864	pruning	_
114-10	22865-22867	in	_
114-11	22868-22881	schizophrenia	_
114-12	22881-22882	,	_
114-13	22883-22888	which	_
114-14	22889-22892	may	_
114-15	22893-22897	give	_
114-16	22898-22902	rise	_
114-17	22903-22905	to	_
114-18	22906-22909	the	_
114-19	22910-22919	generally	_
114-20	22920-22935	under-connected	_
114-21	22936-22942	nature	_
114-22	22943-22945	of	_
114-23	22946-22962	social-cognitive	_
114-24	22963-22966	and	_
114-25	22967-22972	other	_
114-26	22973-22978	brain	_
114-27	22979-22987	networks	_
114-28	22988-22990	in	_
114-29	22991-22995	that	_
114-30	22996-23004	disorder	_
114-31	23004-23005	.	_

#Text=Conversely, ASD appears to be characterized, in some cases, by reduced pruning of dendritic spines, possibly leading to hyper-connectivity.
115-1	23006-23016	Conversely	_
115-2	23016-23017	,	_
115-3	23018-23021	ASD	_
115-4	23022-23029	appears	_
115-5	23030-23032	to	_
115-6	23033-23035	be	_
115-7	23036-23049	characterized	_
115-8	23049-23050	,	_
115-9	23051-23053	in	_
115-10	23054-23058	some	_
115-11	23059-23064	cases	_
115-12	23064-23065	,	_
115-13	23066-23068	by	_
115-14	23069-23076	reduced	_
115-15	23077-23084	pruning	_
115-16	23085-23087	of	_
115-17	23088-23097	dendritic	_
115-18	23098-23104	spines	_
115-19	23104-23105	,	_
115-20	23106-23114	possibly	_
115-21	23115-23122	leading	_
115-22	23123-23125	to	_
115-23	23126-23144	hyper-connectivity	_
115-24	23144-23145	.	_

#Text=Future research might profitably investigate these differences in neurodevelopmental mechanisms and integrate functional and structural imaging data to arrive at a better understanding of the factors that contribute to altered functional connectivity during social-cognitive processing in autism and schizophrenia.
116-1	23146-23152	Future	_
116-2	23153-23161	research	_
116-3	23162-23167	might	_
116-4	23168-23178	profitably	_
116-5	23179-23190	investigate	_
116-6	23191-23196	these	_
116-7	23197-23208	differences	_
116-8	23209-23211	in	_
116-9	23212-23230	neurodevelopmental	_
116-10	23231-23241	mechanisms	_
116-11	23242-23245	and	_
116-12	23246-23255	integrate	_
116-13	23256-23266	functional	_
116-14	23267-23270	and	_
116-15	23271-23281	structural	_
116-16	23282-23289	imaging	_
116-17	23290-23294	data	_
116-18	23295-23297	to	_
116-19	23298-23304	arrive	_
116-20	23305-23307	at	_
116-21	23308-23309	a	_
116-22	23310-23316	better	_
116-23	23317-23330	understanding	_
116-24	23331-23333	of	_
116-25	23334-23337	the	_
116-26	23338-23345	factors	_
116-27	23346-23350	that	_
116-28	23351-23361	contribute	_
116-29	23362-23364	to	_
116-30	23365-23372	altered	_
116-31	23373-23383	functional	_
116-32	23384-23396	connectivity	_
116-33	23397-23403	during	_
116-34	23404-23420	social-cognitive	_
116-35	23421-23431	processing	_
116-36	23432-23434	in	_
116-37	23435-23441	autism	_
116-38	23442-23445	and	_
116-39	23446-23459	schizophrenia	_
116-40	23459-23460	.	_

#Text=Contributors
#Text=This study was designed by Drs.
117-1	23461-23473	Contributors	_
117-2	23474-23478	This	_
117-3	23479-23484	study	_
117-4	23485-23488	was	_
117-5	23489-23497	designed	_
117-6	23498-23500	by	_
117-7	23501-23504	Drs	_
117-8	23504-23505	.	_

#Text=Eack, Minshew, and Keshavan.
118-1	23506-23510	Eack	_
118-2	23510-23511	,	_
118-3	23512-23519	Minshew	_
118-4	23519-23520	,	_
118-5	23521-23524	and	_
118-6	23525-23533	Keshavan	_
118-7	23533-23534	.	_

#Text=Dr.
119-1	23535-23537	Dr	_
119-2	23537-23538	.	_

#Text=Eack wrote the initial draft of the manuscript, Drs.
120-1	23539-23543	Eack	_
120-2	23544-23549	wrote	_
120-3	23550-23553	the	_
120-4	23554-23561	initial	_
120-5	23562-23567	draft	_
120-6	23568-23570	of	_
120-7	23571-23574	the	_
120-8	23575-23585	manuscript	_
120-9	23585-23586	,	_
120-10	23587-23590	Drs	_
120-11	23590-23591	.	_

#Text=Minshew and Keshavan and Ms.
121-1	23592-23599	Minshew	_
121-2	23600-23603	and	_
121-3	23604-23612	Keshavan	_
121-4	23613-23616	and	_
121-5	23617-23619	Ms	_
121-6	23619-23620	.	_

#Text=Wojtalik provided critical revisions and feedback on both the manuscript and analyses.
122-1	23621-23629	Wojtalik	_
122-2	23630-23638	provided	_
122-3	23639-23647	critical	_
122-4	23648-23657	revisions	_
122-5	23658-23661	and	_
122-6	23662-23670	feedback	_
122-7	23671-23673	on	_
122-8	23674-23678	both	_
122-9	23679-23682	the	_
122-10	23683-23693	manuscript	_
122-11	23694-23697	and	_
122-12	23698-23706	analyses	_
122-13	23706-23707	.	_

#Text=Dr.
123-1	23708-23710	Dr	_
123-2	23710-23711	.	_

#Text=Minshew contributed to autism data collection and analysis, and Dr.
124-1	23712-23719	Minshew	_
124-2	23720-23731	contributed	_
124-3	23732-23734	to	_
124-4	23735-23741	autism	_
124-5	23742-23746	data	_
124-6	23747-23757	collection	_
124-7	23758-23761	and	_
124-8	23762-23770	analysis	_
124-9	23770-23771	,	_
124-10	23772-23775	and	_
124-11	23776-23778	Dr	_
124-12	23778-23779	.	_

#Text=Keshavan contributed to schizophrenia data collection and analysis.
125-1	23780-23788	Keshavan	_
125-2	23789-23800	contributed	_
125-3	23801-23803	to	_
125-4	23804-23817	schizophrenia	_
125-5	23818-23822	data	_
125-6	23823-23833	collection	_
125-7	23834-23837	and	_
125-8	23838-23846	analysis	_
125-9	23846-23847	.	_

#Text=Dr.
126-1	23848-23850	Dr	_
126-2	23850-23851	.	_

#Text=Eack oversaw all data collection and analysis aspects of the study.
127-1	23852-23856	Eack	_
127-2	23857-23864	oversaw	_
127-3	23865-23868	all	_
127-4	23869-23873	data	_
127-5	23874-23884	collection	_
127-6	23885-23888	and	_
127-7	23889-23897	analysis	_
127-8	23898-23905	aspects	_
127-9	23906-23908	of	_
127-10	23909-23912	the	_
127-11	23913-23918	study	_
127-12	23918-23919	.	_

#Text=All authors contributed to and have approved the final manuscript.
128-1	23920-23923	All	_
128-2	23924-23931	authors	_
128-3	23932-23943	contributed	_
128-4	23944-23946	to	_
128-5	23947-23950	and	_
128-6	23951-23955	have	_
128-7	23956-23964	approved	_
128-8	23965-23968	the	_
128-9	23969-23974	final	_
128-10	23975-23985	manuscript	_
128-11	23985-23986	.	_

#Text=Conflict of Interest
#Text=The authors report no conflicts of interest.
129-1	23987-23995	Conflict	_
129-2	23996-23998	of	_
129-3	23999-24007	Interest	_
129-4	24008-24011	The	_
129-5	24012-24019	authors	_
129-6	24020-24026	report	_
129-7	24027-24029	no	_
129-8	24030-24039	conflicts	_
129-9	24040-24042	of	_
129-10	24043-24051	interest	_
129-11	24051-24052	.	_

#Text=Dr.
130-1	24053-24055	Dr	_
130-2	24055-24056	.	_

#Text=Keshavan reports a grant from Sunovion within the past two years, and is a consultant for Forum Pharmaceuticals.
131-1	24057-24065	Keshavan	_
131-2	24066-24073	reports	_
131-3	24074-24075	a	_
131-4	24076-24081	grant	_
131-5	24082-24086	from	_
131-6	24087-24095	Sunovion	_
131-7	24096-24102	within	_
131-8	24103-24106	the	_
131-9	24107-24111	past	_
131-10	24112-24115	two	_
131-11	24116-24121	years	_
131-12	24121-24122	,	_
131-13	24123-24126	and	_
131-14	24127-24129	is	_
131-15	24130-24131	a	_
131-16	24132-24142	consultant	_
131-17	24143-24146	for	_
131-18	24147-24152	Forum	_
131-19	24153-24168	Pharmaceuticals	_
131-20	24168-24169	.	_

#Text=The remaining authors have no financial interests to disclose.
132-1	24170-24173	The	_
132-2	24174-24183	remaining	_
132-3	24184-24191	authors	_
132-4	24192-24196	have	_
132-5	24197-24199	no	_
132-6	24200-24209	financial	_
132-7	24210-24219	interests	_
132-8	24220-24222	to	_
132-9	24223-24231	disclose	_
132-10	24231-24232	.	_

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
133-1	24233-24237	This	_
133-2	24238-24240	is	_
133-3	24241-24242	a	_
133-4	24243-24246	PDF	_
133-5	24247-24251	file	_
133-6	24252-24254	of	_
133-7	24255-24257	an	_
133-8	24258-24266	unedited	_
133-9	24267-24277	manuscript	_
133-10	24278-24282	that	_
133-11	24283-24286	has	_
133-12	24287-24291	been	_
133-13	24292-24300	accepted	_
133-14	24301-24304	for	_
133-15	24305-24316	publication	_
133-16	24316-24317	.	_

#Text=As a service to our customers we are providing this early version of the manuscript.
134-1	24318-24320	As	_
134-2	24321-24322	a	_
134-3	24323-24330	service	_
134-4	24331-24333	to	_
134-5	24334-24337	our	_
134-6	24338-24347	customers	_
134-7	24348-24350	we	_
134-8	24351-24354	are	_
134-9	24355-24364	providing	_
134-10	24365-24369	this	_
134-11	24370-24375	early	_
134-12	24376-24383	version	_
134-13	24384-24386	of	_
134-14	24387-24390	the	_
134-15	24391-24401	manuscript	_
134-16	24401-24402	.	_

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
135-1	24403-24406	The	_
135-2	24407-24417	manuscript	_
135-3	24418-24422	will	_
135-4	24423-24430	undergo	_
135-5	24431-24442	copyediting	_
135-6	24442-24443	,	_
135-7	24444-24455	typesetting	_
135-8	24455-24456	,	_
135-9	24457-24460	and	_
135-10	24461-24467	review	_
135-11	24468-24470	of	_
135-12	24471-24474	the	_
135-13	24475-24484	resulting	_
135-14	24485-24490	proof	_
135-15	24491-24497	before	_
135-16	24498-24500	it	_
135-17	24501-24503	is	_
135-18	24504-24513	published	_
135-19	24514-24516	in	_
135-20	24517-24520	its	_
135-21	24521-24526	final	_
135-22	24527-24534	citable	_
135-23	24535-24539	form	_
135-24	24539-24540	.	_

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
136-1	24541-24547	Please	_
136-2	24548-24552	note	_
136-3	24553-24557	that	_
136-4	24558-24564	during	_
136-5	24565-24568	the	_
136-6	24569-24579	production	_
136-7	24580-24587	process	_
136-8	24588-24594	errors	_
136-9	24595-24598	may	_
136-10	24599-24601	be	_
136-11	24602-24612	discovered	_
136-12	24613-24618	which	_
136-13	24619-24624	could	_
136-14	24625-24631	affect	_
136-15	24632-24635	the	_
136-16	24636-24643	content	_
136-17	24643-24644	,	_
136-18	24645-24648	and	_
136-19	24649-24652	all	_
136-20	24653-24658	legal	_
136-21	24659-24670	disclaimers	_
136-22	24671-24675	that	_
136-23	24676-24681	apply	_
136-24	24682-24684	to	_
136-25	24685-24688	the	_
136-26	24689-24696	journal	_
136-27	24697-24704	pertain	_
136-28	24704-24705	.	_

#Text=A component based noise correction method (CompCor) for BOLD and perfusion based fMRI
#Text=Controlling the false discovery rate: a practical and powerful approach to multiple testing
#Text=Complex brain networks: Graph theoretical analysis of structural and functional systems
#Text=Are there theory of mind regions in the brain?
137-1	24707-24708	A	_
137-2	24709-24718	component	_
137-3	24719-24724	based	_
137-4	24725-24730	noise	_
137-5	24731-24741	correction	_
137-6	24742-24748	method	_
137-7	24749-24750	(	_
137-8	24750-24757	CompCor	_
137-9	24757-24758	)	_
137-10	24759-24762	for	_
137-11	24763-24767	BOLD	_
137-12	24768-24771	and	_
137-13	24772-24781	perfusion	_
137-14	24782-24787	based	_
137-15	24788-24792	fMRI	_
137-16	24793-24804	Controlling	_
137-17	24805-24808	the	_
137-18	24809-24814	false	_
137-19	24815-24824	discovery	_
137-20	24825-24829	rate	_
137-21	24829-24830	:	_
137-22	24831-24832	a	_
137-23	24833-24842	practical	_
137-24	24843-24846	and	_
137-25	24847-24855	powerful	_
137-26	24856-24864	approach	_
137-27	24865-24867	to	_
137-28	24868-24876	multiple	_
137-29	24877-24884	testing	_
137-30	24885-24892	Complex	_
137-31	24893-24898	brain	_
137-32	24899-24907	networks	_
137-33	24907-24908	:	_
137-34	24909-24914	Graph	_
137-35	24915-24926	theoretical	_
137-36	24927-24935	analysis	_
137-37	24936-24938	of	_
137-38	24939-24949	structural	_
137-39	24950-24953	and	_
137-40	24954-24964	functional	_
137-41	24965-24972	systems	_
137-42	24973-24976	Are	_
137-43	24977-24982	there	_
137-44	24983-24989	theory	_
137-45	24990-24992	of	_
137-46	24993-24997	mind	_
137-47	24998-25005	regions	_
137-48	25006-25008	in	_
137-49	25009-25012	the	_
137-50	25013-25018	brain	_
137-51	25018-25019	?	_

#Text=A review of the neuroimaging literature
#Text=Autistic disorders and schizophrenia: Related or remote?
138-1	25020-25021	A	_
138-2	25022-25028	review	_
138-3	25029-25031	of	_
138-4	25032-25035	the	_
138-5	25036-25048	neuroimaging	_
138-6	25049-25059	literature	_
138-7	25060-25068	Autistic	_
138-8	25069-25078	disorders	_
138-9	25079-25082	and	_
138-10	25083-25096	schizophrenia	_
138-11	25096-25097	:	_
138-12	25098-25105	Related	_
138-13	25106-25108	or	_
138-14	25109-25115	remote	_
138-15	25115-25116	?	_

#Text=An anatomical likelihood estimation
#Text=Schizophrenia and autism as contrasting minds: Neural evidence for the hypo-hyper-intentionality hypothesis
#Text=Comparison of social cognitive functioning in schizophrenia and high functioning autism: More convergence than divergence
#Text=Mentalizing in male schizophrenia patients is compromised by virtue of dysfunctional connectivity between task-positive and task-negative networks
#Text=Similar brain activation during false belief tasks in a large sample of adults with and without autism
#Text=Commonalities in social and non-social cognitive impairments in adults with autism spectrum disorder and schizophrenia
#Text=Quality of life for persons living with schizophrenia: More than just symptoms
#Text=Prefrontal cortical dysfunction during visual perspective-taking in schizophrenia
#Text=Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Perspective taking in children and adults: Equivalent egocentrism but differential correction
#Text=The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis
#Text=
#Text=Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation
#Text=Do patients with schizophrenia ever show periods of recovery?
139-1	25117-25119	An	_
139-2	25120-25130	anatomical	_
139-3	25131-25141	likelihood	_
139-4	25142-25152	estimation	_
139-5	25153-25166	Schizophrenia	_
139-6	25167-25170	and	_
139-7	25171-25177	autism	_
139-8	25178-25180	as	_
139-9	25181-25192	contrasting	_
139-10	25193-25198	minds	_
139-11	25198-25199	:	_
139-12	25200-25206	Neural	_
139-13	25207-25215	evidence	_
139-14	25216-25219	for	_
139-15	25220-25223	the	_
139-16	25224-25249	hypo-hyper-intentionality	_
139-17	25250-25260	hypothesis	_
139-18	25261-25271	Comparison	_
139-19	25272-25274	of	_
139-20	25275-25281	social	_
139-21	25282-25291	cognitive	_
139-22	25292-25303	functioning	_
139-23	25304-25306	in	_
139-24	25307-25320	schizophrenia	_
139-25	25321-25324	and	_
139-26	25325-25329	high	_
139-27	25330-25341	functioning	_
139-28	25342-25348	autism	_
139-29	25348-25349	:	_
139-30	25350-25354	More	_
139-31	25355-25366	convergence	_
139-32	25367-25371	than	_
139-33	25372-25382	divergence	_
139-34	25383-25394	Mentalizing	_
139-35	25395-25397	in	_
139-36	25398-25402	male	_
139-37	25403-25416	schizophrenia	_
139-38	25417-25425	patients	_
139-39	25426-25428	is	_
139-40	25429-25440	compromised	_
139-41	25441-25443	by	_
139-42	25444-25450	virtue	_
139-43	25451-25453	of	_
139-44	25454-25467	dysfunctional	_
139-45	25468-25480	connectivity	_
139-46	25481-25488	between	_
139-47	25489-25502	task-positive	_
139-48	25503-25506	and	_
139-49	25507-25520	task-negative	_
139-50	25521-25529	networks	_
139-51	25530-25537	Similar	_
139-52	25538-25543	brain	_
139-53	25544-25554	activation	_
139-54	25555-25561	during	_
139-55	25562-25567	false	_
139-56	25568-25574	belief	_
139-57	25575-25580	tasks	_
139-58	25581-25583	in	_
139-59	25584-25585	a	_
139-60	25586-25591	large	_
139-61	25592-25598	sample	_
139-62	25599-25601	of	_
139-63	25602-25608	adults	_
139-64	25609-25613	with	_
139-65	25614-25617	and	_
139-66	25618-25625	without	_
139-67	25626-25632	autism	_
139-68	25633-25646	Commonalities	_
139-69	25647-25649	in	_
139-70	25650-25656	social	_
139-71	25657-25660	and	_
139-72	25661-25671	non-social	_
139-73	25672-25681	cognitive	_
139-74	25682-25693	impairments	_
139-75	25694-25696	in	_
139-76	25697-25703	adults	_
139-77	25704-25708	with	_
139-78	25709-25715	autism	_
139-79	25716-25724	spectrum	_
139-80	25725-25733	disorder	_
139-81	25734-25737	and	_
139-82	25738-25751	schizophrenia	_
139-83	25752-25759	Quality	_
139-84	25760-25762	of	_
139-85	25763-25767	life	_
139-86	25768-25771	for	_
139-87	25772-25779	persons	_
139-88	25780-25786	living	_
139-89	25787-25791	with	_
139-90	25792-25805	schizophrenia	_
139-91	25805-25806	:	_
139-92	25807-25811	More	_
139-93	25812-25816	than	_
139-94	25817-25821	just	_
139-95	25822-25830	symptoms	_
139-96	25831-25841	Prefrontal	_
139-97	25842-25850	cortical	_
139-98	25851-25862	dysfunction	_
139-99	25863-25869	during	_
139-100	25870-25876	visual	_
139-101	25877-25895	perspective-taking	_
139-102	25896-25898	in	_
139-103	25899-25912	schizophrenia	_
139-104	25913-25920	Cluster	_
139-105	25921-25928	failure	_
139-106	25928-25929	:	_
139-107	25930-25933	Why	_
139-108	25934-25938	fMRI	_
139-109	25939-25949	inferences	_
139-110	25950-25953	for	_
139-111	25954-25961	spatial	_
139-112	25962-25968	extent	_
139-113	25969-25973	have	_
139-114	25974-25982	inflated	_
139-115	25983-25997	false-positive	_
139-116	25998-26003	rates	_
139-117	26004-26015	Perspective	_
139-118	26016-26022	taking	_
139-119	26023-26025	in	_
139-120	26026-26034	children	_
139-121	26035-26038	and	_
139-122	26039-26045	adults	_
139-123	26045-26046	:	_
139-124	26047-26057	Equivalent	_
139-125	26058-26069	egocentrism	_
139-126	26070-26073	but	_
139-127	26074-26086	differential	_
139-128	26087-26097	correction	_
139-129	26098-26101	The	_
139-130	26102-26114	relationship	_
139-131	26115-26122	between	_
139-132	26123-26137	neurocognition	_
139-133	26138-26141	and	_
139-134	26142-26148	social	_
139-135	26149-26158	cognition	_
139-136	26159-26163	with	_
139-137	26164-26174	functional	_
139-138	26175-26183	outcomes	_
139-139	26184-26186	in	_
139-140	26187-26200	schizophrenia	_
139-141	26200-26201	:	_
139-142	26202-26203	a	_
139-143	26204-26217	meta-analysis	_
139-144	26219-26228	Recurrent	_
139-145	26229-26243	rearrangements	_
139-146	26244-26246	in	_
139-147	26247-26255	synaptic	_
139-148	26256-26259	and	_
139-149	26260-26278	neurodevelopmental	_
139-150	26279-26284	genes	_
139-151	26285-26288	and	_
139-152	26289-26295	shared	_
139-153	26296-26304	biologic	_
139-154	26305-26313	pathways	_
139-155	26314-26316	in	_
139-156	26317-26330	schizophrenia	_
139-157	26330-26331	,	_
139-158	26332-26338	autism	_
139-159	26338-26339	,	_
139-160	26340-26343	and	_
139-161	26344-26350	mental	_
139-162	26351-26362	retardation	_
139-163	26363-26365	Do	_
139-164	26366-26374	patients	_
139-165	26375-26379	with	_
139-166	26380-26393	schizophrenia	_
139-167	26394-26398	ever	_
139-168	26399-26403	show	_
139-169	26404-26411	periods	_
139-170	26412-26414	of	_
139-171	26415-26423	recovery	_
139-172	26423-26424	?	_

#Text=A 15-year multi-follow-up study
#Text=Social outcomes in mid-to later adulthood among individuals diagnosed with autism and average nonverbal IQ as children
#Text=Infantile autism and the schizophrenias
#Text=Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex?
140-1	26425-26426	A	_
140-2	26427-26429	15	_
140-3	26429-26430	-	_
140-4	26430-26434	year	_
140-5	26435-26450	multi-follow-up	_
140-6	26451-26456	study	_
140-7	26457-26463	Social	_
140-8	26464-26472	outcomes	_
140-9	26473-26475	in	_
140-10	26476-26482	mid-to	_
140-11	26483-26488	later	_
140-12	26489-26498	adulthood	_
140-13	26499-26504	among	_
140-14	26505-26516	individuals	_
140-15	26517-26526	diagnosed	_
140-16	26527-26531	with	_
140-17	26532-26538	autism	_
140-18	26539-26542	and	_
140-19	26543-26550	average	_
140-20	26551-26560	nonverbal	_
140-21	26561-26563	IQ	_
140-22	26564-26566	as	_
140-23	26567-26575	children	_
140-24	26576-26585	Infantile	_
140-25	26586-26592	autism	_
140-26	26593-26596	and	_
140-27	26597-26600	the	_
140-28	26601-26615	schizophrenias	_
140-29	26616-26618	Is	_
140-30	26619-26632	schizophrenia	_
140-31	26633-26636	due	_
140-32	26637-26639	to	_
140-33	26640-26649	excessive	_
140-34	26650-26658	synaptic	_
140-35	26659-26666	pruning	_
140-36	26667-26669	in	_
140-37	26670-26673	the	_
140-38	26674-26684	prefrontal	_
140-39	26685-26691	cortex	_
140-40	26691-26692	?	_

#Text=The Feinberg hypothesis revisited
#Text=Abnormal superior temporal connectivity during fear perception in schizophrenia
#Text=Austism diagnostic observation schedule: A standardized observation of communicative and social behavior
#Text=The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls
#Text=Loneliness, friendship, and well-being in adults with autism spectrum disorders
#Text=Altered amygdala connectivity within the social brain in schizophrenia
#Text=What is social cognition?
141-1	26693-26696	The	_
141-2	26697-26705	Feinberg	_
141-3	26706-26716	hypothesis	_
141-4	26717-26726	revisited	_
141-5	26727-26735	Abnormal	_
141-6	26736-26744	superior	_
141-7	26745-26753	temporal	_
141-8	26754-26766	connectivity	_
141-9	26767-26773	during	_
141-10	26774-26778	fear	_
141-11	26779-26789	perception	_
141-12	26790-26792	in	_
141-13	26793-26806	schizophrenia	_
141-14	26807-26814	Austism	_
141-15	26815-26825	diagnostic	_
141-16	26826-26837	observation	_
141-17	26838-26846	schedule	_
141-18	26846-26847	:	_
141-19	26848-26849	A	_
141-20	26850-26862	standardized	_
141-21	26863-26874	observation	_
141-22	26875-26877	of	_
141-23	26878-26891	communicative	_
141-24	26892-26895	and	_
141-25	26896-26902	social	_
141-26	26903-26911	behavior	_
141-27	26912-26915	The	_
141-28	26916-26924	quantity	_
141-29	26925-26928	and	_
141-30	26929-26936	quality	_
141-31	26937-26939	of	_
141-32	26940-26943	the	_
141-33	26944-26950	social	_
141-34	26951-26959	networks	_
141-35	26960-26962	of	_
141-36	26963-26968	young	_
141-37	26969-26975	people	_
141-38	26976-26980	with	_
141-39	26981-26986	early	_
141-40	26987-26996	psychosis	_
141-41	26997-27005	compared	_
141-42	27006-27010	with	_
141-43	27011-27018	closely	_
141-44	27019-27026	matched	_
141-45	27027-27035	controls	_
141-46	27036-27046	Loneliness	_
141-47	27046-27047	,	_
141-48	27048-27058	friendship	_
141-49	27058-27059	,	_
141-50	27060-27063	and	_
141-51	27064-27074	well-being	_
141-52	27075-27077	in	_
141-53	27078-27084	adults	_
141-54	27085-27089	with	_
141-55	27090-27096	autism	_
141-56	27097-27105	spectrum	_
141-57	27106-27115	disorders	_
141-58	27116-27123	Altered	_
141-59	27124-27132	amygdala	_
141-60	27133-27145	connectivity	_
141-61	27146-27152	within	_
141-62	27153-27156	the	_
141-63	27157-27163	social	_
141-64	27164-27169	brain	_
141-65	27170-27172	in	_
141-66	27173-27186	schizophrenia	_
141-67	27187-27191	What	_
141-68	27192-27194	is	_
141-69	27195-27201	social	_
141-70	27202-27211	cognition	_
141-71	27211-27212	?	_

#Text=Four basic approaches and their implications for schizophrenia research
#Text=
#Text=Social participation among young adults with an autism spectrum disorder
#Text=The Brief Psychiatric Rating Scale
#Text=Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders
#Text=Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Recent progress and outstanding issues in motion correction in resting state fMRI
#Text=Structural alterations of the social brain: A comparison between schizophrenia and autism
#Text=Context effects on facial affect recognition in schizophrenia and autism: Behavioral and eye-tracking evidence
#Text=Orienting to social stimuli differentiates social cognitive impairment in autism and schizophrenia
#Text=Autism spectrum disorders and schizophrenia: Meta-analysis of the neural correlates of social cognition
#Text=Brain hyperconnectivity in children with autism and its links to social deficits
#Text=Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits
#Text=Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
#Text=Social cognition and the brain: A meta-analysis
#Text=Diminished sensitivity to sad facial expressions in high functioning autism spectrum disorders is associated with symptomatology and adaptive functioning
#Text=
#Text=
#Text=Visual Perspective-taking Task.
142-1	27213-27217	Four	_
142-2	27218-27223	basic	_
142-3	27224-27234	approaches	_
142-4	27235-27238	and	_
142-5	27239-27244	their	_
142-6	27245-27257	implications	_
142-7	27258-27261	for	_
142-8	27262-27275	schizophrenia	_
142-9	27276-27284	research	_
142-10	27286-27292	Social	_
142-11	27293-27306	participation	_
142-12	27307-27312	among	_
142-13	27313-27318	young	_
142-14	27319-27325	adults	_
142-15	27326-27330	with	_
142-16	27331-27333	an	_
142-17	27334-27340	autism	_
142-18	27341-27349	spectrum	_
142-19	27350-27358	disorder	_
142-20	27359-27362	The	_
142-21	27363-27368	Brief	_
142-22	27369-27380	Psychiatric	_
142-23	27381-27387	Rating	_
142-24	27388-27393	Scale	_
142-25	27394-27400	Neural	_
142-26	27401-27406	bases	_
142-27	27407-27410	for	_
142-28	27411-27419	impaired	_
142-29	27420-27426	social	_
142-30	27427-27436	cognition	_
142-31	27437-27439	in	_
142-32	27440-27453	schizophrenia	_
142-33	27454-27457	and	_
142-34	27458-27464	autism	_
142-35	27465-27473	spectrum	_
142-36	27474-27483	disorders	_
142-37	27484-27490	Neural	_
142-38	27491-27496	bases	_
142-39	27497-27500	for	_
142-40	27501-27509	impaired	_
142-41	27510-27516	social	_
142-42	27517-27526	cognition	_
142-43	27527-27529	in	_
142-44	27530-27543	schizophrenia	_
142-45	27544-27547	and	_
142-46	27548-27554	autism	_
142-47	27555-27563	spectrum	_
142-48	27564-27573	disorders	_
142-49	27574-27582	Spurious	_
142-50	27583-27586	but	_
142-51	27587-27597	systematic	_
142-52	27598-27610	correlations	_
142-53	27611-27613	in	_
142-54	27614-27624	functional	_
142-55	27625-27637	connectivity	_
142-56	27638-27641	MRI	_
142-57	27642-27650	networks	_
142-58	27651-27656	arise	_
142-59	27657-27661	from	_
142-60	27662-27669	subject	_
142-61	27670-27676	motion	_
142-62	27677-27683	Recent	_
142-63	27684-27692	progress	_
142-64	27693-27696	and	_
142-65	27697-27708	outstanding	_
142-66	27709-27715	issues	_
142-67	27716-27718	in	_
142-68	27719-27725	motion	_
142-69	27726-27736	correction	_
142-70	27737-27739	in	_
142-71	27740-27747	resting	_
142-72	27748-27753	state	_
142-73	27754-27758	fMRI	_
142-74	27759-27769	Structural	_
142-75	27770-27781	alterations	_
142-76	27782-27784	of	_
142-77	27785-27788	the	_
142-78	27789-27795	social	_
142-79	27796-27801	brain	_
142-80	27801-27802	:	_
142-81	27803-27804	A	_
142-82	27805-27815	comparison	_
142-83	27816-27823	between	_
142-84	27824-27837	schizophrenia	_
142-85	27838-27841	and	_
142-86	27842-27848	autism	_
142-87	27849-27856	Context	_
142-88	27857-27864	effects	_
142-89	27865-27867	on	_
142-90	27868-27874	facial	_
142-91	27875-27881	affect	_
142-92	27882-27893	recognition	_
142-93	27894-27896	in	_
142-94	27897-27910	schizophrenia	_
142-95	27911-27914	and	_
142-96	27915-27921	autism	_
142-97	27921-27922	:	_
142-98	27923-27933	Behavioral	_
142-99	27934-27937	and	_
142-100	27938-27950	eye-tracking	_
142-101	27951-27959	evidence	_
142-102	27960-27969	Orienting	_
142-103	27970-27972	to	_
142-104	27973-27979	social	_
142-105	27980-27987	stimuli	_
142-106	27988-28002	differentiates	_
142-107	28003-28009	social	_
142-108	28010-28019	cognitive	_
142-109	28020-28030	impairment	_
142-110	28031-28033	in	_
142-111	28034-28040	autism	_
142-112	28041-28044	and	_
142-113	28045-28058	schizophrenia	_
142-114	28059-28065	Autism	_
142-115	28066-28074	spectrum	_
142-116	28075-28084	disorders	_
142-117	28085-28088	and	_
142-118	28089-28102	schizophrenia	_
142-119	28102-28103	:	_
142-120	28104-28117	Meta-analysis	_
142-121	28118-28120	of	_
142-122	28121-28124	the	_
142-123	28125-28131	neural	_
142-124	28132-28142	correlates	_
142-125	28143-28145	of	_
142-126	28146-28152	social	_
142-127	28153-28162	cognition	_
142-128	28163-28168	Brain	_
142-129	28169-28186	hyperconnectivity	_
142-130	28187-28189	in	_
142-131	28190-28198	children	_
142-132	28199-28203	with	_
142-133	28204-28210	autism	_
142-134	28211-28214	and	_
142-135	28215-28218	its	_
142-136	28219-28224	links	_
142-137	28225-28227	to	_
142-138	28228-28234	social	_
142-139	28235-28243	deficits	_
142-140	28244-28248	Loss	_
142-141	28249-28251	of	_
142-142	28252-28266	mTOR-dependent	_
142-143	28267-28281	macroautophagy	_
142-144	28282-28288	causes	_
142-145	28289-28302	autistic-like	_
142-146	28303-28311	synaptic	_
142-147	28312-28319	pruning	_
142-148	28320-28328	deficits	_
142-149	28329-28338	Automated	_
142-150	28339-28349	anatomical	_
142-151	28350-28358	labeling	_
142-152	28359-28361	of	_
142-153	28362-28373	activations	_
142-154	28374-28376	in	_
142-155	28377-28380	SPM	_
142-156	28381-28386	using	_
142-157	28387-28388	a	_
142-158	28389-28400	macroscopic	_
142-159	28401-28411	anatomical	_
142-160	28412-28424	parcellation	_
142-161	28425-28427	of	_
142-162	28428-28431	the	_
142-163	28432-28435	MNI	_
142-164	28436-28439	MRI	_
142-165	28440-28454	single-subject	_
142-166	28455-28460	brain	_
142-167	28461-28467	Social	_
142-168	28468-28477	cognition	_
142-169	28478-28481	and	_
142-170	28482-28485	the	_
142-171	28486-28491	brain	_
142-172	28491-28492	:	_
142-173	28493-28494	A	_
142-174	28495-28508	meta-analysis	_
142-175	28509-28519	Diminished	_
142-176	28520-28531	sensitivity	_
142-177	28532-28534	to	_
142-178	28535-28538	sad	_
142-179	28539-28545	facial	_
142-180	28546-28557	expressions	_
142-181	28558-28560	in	_
142-182	28561-28565	high	_
142-183	28566-28577	functioning	_
142-184	28578-28584	autism	_
142-185	28585-28593	spectrum	_
142-186	28594-28603	disorders	_
142-187	28604-28606	is	_
142-188	28607-28617	associated	_
142-189	28618-28622	with	_
142-190	28623-28637	symptomatology	_
142-191	28638-28641	and	_
142-192	28642-28650	adaptive	_
142-193	28651-28662	functioning	_
142-194	28665-28671	Visual	_
142-195	28672-28690	Perspective-taking	_
142-196	28691-28695	Task	_
142-197	28695-28696	.	_

#Text=Regional Activation Maps During Visual Perspective-Taking in Autism Spectrum Disorder, Schizophrenia, and Healthy Volunteers.*
#Text=ASD = autism spectrum disorder; SZ = schizophrenia
#Text=*Images displayed in neurological convention and thresholded at uncorrected p < .005 and k > 5 voxels
#Text=Regional Connectivity Maps During Visual Perspective-Taking in Autism Spectrum Disorder, Schizophrenia, and Healthy Volunteers.*
#Text=ASD = autism spectrum disorder; SZ = schizophrenia
#Text=*Images displayed in neurological convention
#Text=Demographic and Clinical Characteristics of Individuals with Autism Spectrum Disorder, Schizophrenia, and Healthy Volunteers.
143-1	28697-28705	Regional	_
143-2	28706-28716	Activation	_
143-3	28717-28721	Maps	_
143-4	28722-28728	During	_
143-5	28729-28735	Visual	_
143-6	28736-28754	Perspective-Taking	_
143-7	28755-28757	in	_
143-8	28758-28764	Autism	_
143-9	28765-28773	Spectrum	_
143-10	28774-28782	Disorder	_
143-11	28782-28783	,	_
143-12	28784-28797	Schizophrenia	_
143-13	28797-28798	,	_
143-14	28799-28802	and	_
143-15	28803-28810	Healthy	_
143-16	28811-28821	Volunteers	_
143-17	28821-28822	.	_
143-18	28822-28823	*	_
143-19	28824-28827	ASD	_
143-20	28828-28829	=	_
143-21	28830-28836	autism	_
143-22	28837-28845	spectrum	_
143-23	28846-28854	disorder	_
143-24	28854-28855	;	_
143-25	28856-28858	SZ	_
143-26	28859-28860	=	_
143-27	28861-28874	schizophrenia	_
143-28	28875-28876	*	_
143-29	28876-28882	Images	_
143-30	28883-28892	displayed	_
143-31	28893-28895	in	_
143-32	28896-28908	neurological	_
143-33	28909-28919	convention	_
143-34	28920-28923	and	_
143-35	28924-28935	thresholded	_
143-36	28936-28938	at	_
143-37	28939-28950	uncorrected	_
143-38	28951-28952	p	_
143-39	28953-28954	<	_
143-40	28955-28959	.005	_
143-41	28960-28963	and	_
143-42	28964-28965	k	_
143-43	28966-28967	>	_
143-44	28968-28969	5	_
143-45	28970-28976	voxels	_
143-46	28977-28985	Regional	_
143-47	28986-28998	Connectivity	_
143-48	28999-29003	Maps	_
143-49	29004-29010	During	_
143-50	29011-29017	Visual	_
143-51	29018-29036	Perspective-Taking	_
143-52	29037-29039	in	_
143-53	29040-29046	Autism	_
143-54	29047-29055	Spectrum	_
143-55	29056-29064	Disorder	_
143-56	29064-29065	,	_
143-57	29066-29079	Schizophrenia	_
143-58	29079-29080	,	_
143-59	29081-29084	and	_
143-60	29085-29092	Healthy	_
143-61	29093-29103	Volunteers	_
143-62	29103-29104	.	_
143-63	29104-29105	*	_
143-64	29106-29109	ASD	_
143-65	29110-29111	=	_
143-66	29112-29118	autism	_
143-67	29119-29127	spectrum	_
143-68	29128-29136	disorder	_
143-69	29136-29137	;	_
143-70	29138-29140	SZ	_
143-71	29141-29142	=	_
143-72	29143-29156	schizophrenia	_
143-73	29157-29158	*	_
143-74	29158-29164	Images	_
143-75	29165-29174	displayed	_
143-76	29175-29177	in	_
143-77	29178-29190	neurological	_
143-78	29191-29201	convention	_
143-79	29202-29213	Demographic	_
143-80	29214-29217	and	_
143-81	29218-29226	Clinical	_
143-82	29227-29242	Characteristics	_
143-83	29243-29245	of	_
143-84	29246-29257	Individuals	_
143-85	29258-29262	with	_
143-86	29263-29269	Autism	_
143-87	29270-29278	Spectrum	_
143-88	29279-29287	Disorder	_
143-89	29287-29288	,	_
143-90	29289-29302	Schizophrenia	_
143-91	29302-29303	,	_
143-92	29304-29307	and	_
143-93	29308-29315	Healthy	_
143-94	29316-29326	Volunteers	_
143-95	29326-29327	.	_

#Text=Variable\tHC (N = 37)\tASD (N = 33)\tSZ (N = 36)\tpa\t \t\t \tM (SD)/N (%)\tM (SD)/N (%)\tM (SD)/N (%)\t \tAge\t25.41 (4.71)\t23.91 (6.05)\t26.25 (6.83)\t.257\t \tFemale\t8 (22%)\t3 (9%)\t14 (39%)\t.014\t \tNon-White\t7 (19%)\t4 (12%)\t10 (28%)\t.261\t \tYears of Education\t16.16 (2.70)\t14.06 (1.78)\t13.83 (2.18)\t< .001\t \tIQ\t106.70 (10.81)\t108.36 (14.13)\t107.25 (11.90)\t.849\t \tBPRS Total\t20.38 (2.45)\t32.82 (10.41)\t33.86 (8.80)\t< .001\t \t Anxiety/Depression\t1.30 (.39)\t2.45 (1.25)\t2.53 (.91)\t< .001\t \t Withdrawal/Motor Retardation\t1.11 (.24)\t2.09 (.70)\t1.63 (.88)\t< .001\t \t Thought Disorder\t1.17 (.23)\t1.71 (.64)\t2.05 (.75)\t< .001\t \t Hostility\t1.01 (.06)\t1.36 (.52)\t1.82 (.74)\t< .001\t \tADOS\t \t Communication\t-\t3.39 (1.17)\t-\t-\t \t Reciprocal Social Interaction\t-\t7.21 (2.38)\t-\t-\t \t Stereotyped Behavior\t-\t2.36 (1.34)\t-\t-\t \tReceiving antipsychotic medication\t-\t3 (9%)\t36 (100%)\t-\t \t Receiving second-generation\t-\t3 (100%)\t33 (92%)\t-\t \t Chlorpromazine equivalent dose\t-\t104.17 (83.23)\t416.92 (295.26)\t.079\t \t
#Text=Note.
144-1	29328-29336	Variable	_
144-2	29337-29339	HC	_
144-3	29340-29341	(	_
144-4	29341-29342	N	_
144-5	29343-29344	=	_
144-6	29345-29347	37	_
144-7	29347-29348	)	_
144-8	29349-29352	ASD	_
144-9	29353-29354	(	_
144-10	29354-29355	N	_
144-11	29356-29357	=	_
144-12	29358-29360	33	_
144-13	29360-29361	)	_
144-14	29362-29364	SZ	_
144-15	29365-29366	(	_
144-16	29366-29367	N	_
144-17	29368-29369	=	_
144-18	29370-29372	36	_
144-19	29372-29373	)	_
144-20	29374-29376	pa	_
144-21	29382-29383	M	_
144-22	29384-29385	(	_
144-23	29385-29387	SD	_
144-24	29387-29388	)	_
144-25	29388-29389	/	_
144-26	29389-29390	N	_
144-27	29391-29392	(	_
144-28	29392-29393	%	_
144-29	29393-29394	)	_
144-30	29395-29396	M	_
144-31	29397-29398	(	_
144-32	29398-29400	SD	_
144-33	29400-29401	)	_
144-34	29401-29402	/	_
144-35	29402-29403	N	_
144-36	29404-29405	(	_
144-37	29405-29406	%	_
144-38	29406-29407	)	_
144-39	29408-29409	M	_
144-40	29410-29411	(	_
144-41	29411-29413	SD	_
144-42	29413-29414	)	_
144-43	29414-29415	/	_
144-44	29415-29416	N	_
144-45	29417-29418	(	_
144-46	29418-29419	%	_
144-47	29419-29420	)	_
144-48	29423-29426	Age	_
144-49	29427-29432	25.41	_
144-50	29433-29434	(	_
144-51	29434-29438	4.71	_
144-52	29438-29439	)	_
144-53	29440-29445	23.91	_
144-54	29446-29447	(	_
144-55	29447-29451	6.05	_
144-56	29451-29452	)	_
144-57	29453-29458	26.25	_
144-58	29459-29460	(	_
144-59	29460-29464	6.83	_
144-60	29464-29465	)	_
144-61	29466-29470	.257	_
144-62	29473-29479	Female	_
144-63	29480-29481	8	_
144-64	29482-29483	(	_
144-65	29483-29486	22%	_
144-66	29486-29487	)	_
144-67	29488-29489	3	_
144-68	29490-29491	(	_
144-69	29491-29493	9%	_
144-70	29493-29494	)	_
144-71	29495-29497	14	_
144-72	29498-29499	(	_
144-73	29499-29502	39%	_
144-74	29502-29503	)	_
144-75	29504-29508	.014	_
144-76	29511-29520	Non-White	_
144-77	29521-29522	7	_
144-78	29523-29524	(	_
144-79	29524-29527	19%	_
144-80	29527-29528	)	_
144-81	29529-29530	4	_
144-82	29531-29532	(	_
144-83	29532-29535	12%	_
144-84	29535-29536	)	_
144-85	29537-29539	10	_
144-86	29540-29541	(	_
144-87	29541-29544	28%	_
144-88	29544-29545	)	_
144-89	29546-29550	.261	_
144-90	29553-29558	Years	_
144-91	29559-29561	of	_
144-92	29562-29571	Education	_
144-93	29572-29577	16.16	_
144-94	29578-29579	(	_
144-95	29579-29583	2.70	_
144-96	29583-29584	)	_
144-97	29585-29590	14.06	_
144-98	29591-29592	(	_
144-99	29592-29596	1.78	_
144-100	29596-29597	)	_
144-101	29598-29603	13.83	_
144-102	29604-29605	(	_
144-103	29605-29609	2.18	_
144-104	29609-29610	)	_
144-105	29611-29612	<	_
144-106	29613-29617	.001	_
144-107	29620-29622	IQ	_
144-108	29623-29629	106.70	_
144-109	29630-29631	(	_
144-110	29631-29636	10.81	_
144-111	29636-29637	)	_
144-112	29638-29644	108.36	_
144-113	29645-29646	(	_
144-114	29646-29651	14.13	_
144-115	29651-29652	)	_
144-116	29653-29659	107.25	_
144-117	29660-29661	(	_
144-118	29661-29666	11.90	_
144-119	29666-29667	)	_
144-120	29668-29672	.849	_
144-121	29675-29679	BPRS	_
144-122	29680-29685	Total	_
144-123	29686-29691	20.38	_
144-124	29692-29693	(	_
144-125	29693-29697	2.45	_
144-126	29697-29698	)	_
144-127	29699-29704	32.82	_
144-128	29705-29706	(	_
144-129	29706-29711	10.41	_
144-130	29711-29712	)	_
144-131	29713-29718	33.86	_
144-132	29719-29720	(	_
144-133	29720-29724	8.80	_
144-134	29724-29725	)	_
144-135	29726-29727	<	_
144-136	29728-29732	.001	_
144-137	29736-29743	Anxiety	_
144-138	29743-29744	/	_
144-139	29744-29754	Depression	_
144-140	29755-29759	1.30	_
144-141	29760-29761	(	_
144-142	29761-29764	.39	_
144-143	29764-29765	)	_
144-144	29766-29770	2.45	_
144-145	29771-29772	(	_
144-146	29772-29776	1.25	_
144-147	29776-29777	)	_
144-148	29778-29782	2.53	_
144-149	29783-29784	(	_
144-150	29784-29787	.91	_
144-151	29787-29788	)	_
144-152	29789-29790	<	_
144-153	29791-29795	.001	_
144-154	29799-29809	Withdrawal	_
144-155	29809-29810	/	_
144-156	29810-29815	Motor	_
144-157	29816-29827	Retardation	_
144-158	29828-29832	1.11	_
144-159	29833-29834	(	_
144-160	29834-29837	.24	_
144-161	29837-29838	)	_
144-162	29839-29843	2.09	_
144-163	29844-29845	(	_
144-164	29845-29848	.70	_
144-165	29848-29849	)	_
144-166	29850-29854	1.63	_
144-167	29855-29856	(	_
144-168	29856-29859	.88	_
144-169	29859-29860	)	_
144-170	29861-29862	<	_
144-171	29863-29867	.001	_
144-172	29871-29878	Thought	_
144-173	29879-29887	Disorder	_
144-174	29888-29892	1.17	_
144-175	29893-29894	(	_
144-176	29894-29897	.23	_
144-177	29897-29898	)	_
144-178	29899-29903	1.71	_
144-179	29904-29905	(	_
144-180	29905-29908	.64	_
144-181	29908-29909	)	_
144-182	29910-29914	2.05	_
144-183	29915-29916	(	_
144-184	29916-29919	.75	_
144-185	29919-29920	)	_
144-186	29921-29922	<	_
144-187	29923-29927	.001	_
144-188	29931-29940	Hostility	_
144-189	29941-29945	1.01	_
144-190	29946-29947	(	_
144-191	29947-29950	.06	_
144-192	29950-29951	)	_
144-193	29952-29956	1.36	_
144-194	29957-29958	(	_
144-195	29958-29961	.52	_
144-196	29961-29962	)	_
144-197	29963-29967	1.82	_
144-198	29968-29969	(	_
144-199	29969-29972	.74	_
144-200	29972-29973	)	_
144-201	29974-29975	<	_
144-202	29976-29980	.001	_
144-203	29983-29987	ADOS	_
144-204	29991-30004	Communication	_
144-205	30005-30006	-	_
144-206	30007-30011	3.39	_
144-207	30012-30013	(	_
144-208	30013-30017	1.17	_
144-209	30017-30018	)	_
144-210	30019-30020	-	_
144-211	30021-30022	-	_
144-212	30026-30036	Reciprocal	_
144-213	30037-30043	Social	_
144-214	30044-30055	Interaction	_
144-215	30056-30057	-	_
144-216	30058-30062	7.21	_
144-217	30063-30064	(	_
144-218	30064-30068	2.38	_
144-219	30068-30069	)	_
144-220	30070-30071	-	_
144-221	30072-30073	-	_
144-222	30077-30088	Stereotyped	_
144-223	30089-30097	Behavior	_
144-224	30098-30099	-	_
144-225	30100-30104	2.36	_
144-226	30105-30106	(	_
144-227	30106-30110	1.34	_
144-228	30110-30111	)	_
144-229	30112-30113	-	_
144-230	30114-30115	-	_
144-231	30118-30127	Receiving	_
144-232	30128-30141	antipsychotic	_
144-233	30142-30152	medication	_
144-234	30153-30154	-	_
144-235	30155-30156	3	_
144-236	30157-30158	(	_
144-237	30158-30160	9%	_
144-238	30160-30161	)	_
144-239	30162-30164	36	_
144-240	30165-30166	(	_
144-241	30166-30170	100%	_
144-242	30170-30171	)	_
144-243	30172-30173	-	_
144-244	30177-30186	Receiving	_
144-245	30187-30204	second-generation	_
144-246	30205-30206	-	_
144-247	30207-30208	3	_
144-248	30209-30210	(	_
144-249	30210-30214	100%	_
144-250	30214-30215	)	_
144-251	30216-30218	33	_
144-252	30219-30220	(	_
144-253	30220-30223	92%	_
144-254	30223-30224	)	_
144-255	30225-30226	-	_
144-256	30230-30244	Chlorpromazine	_
144-257	30245-30255	equivalent	_
144-258	30256-30260	dose	_
144-259	30261-30262	-	_
144-260	30263-30269	104.17	_
144-261	30270-30271	(	_
144-262	30271-30276	83.23	_
144-263	30276-30277	)	_
144-264	30278-30284	416.92	_
144-265	30285-30286	(	_
144-266	30286-30292	295.26	_
144-267	30292-30293	)	_
144-268	30294-30298	.079	_
144-269	30302-30306	Note	_
144-270	30306-30307	.	_

#Text=BPRS = Brief Psychiatric Rating Scale, HC = Healthy control, ASD = autism spectrum disorder, SZ = schizophrenia, ADOS = Autism Diagnostic Observation Schedule
#Text=χ2 test or analysis of variance, two-tailed, for significant differences between study groups
#Text=Behavioral Performance During Visual Perspective-Taking in Autism Spectrum Disorder, Schizophrenia, and Healthy Volunteers.
145-1	30308-30312	BPRS	_
145-2	30313-30314	=	_
145-3	30315-30320	Brief	_
145-4	30321-30332	Psychiatric	_
145-5	30333-30339	Rating	_
145-6	30340-30345	Scale	_
145-7	30345-30346	,	_
145-8	30347-30349	HC	_
145-9	30350-30351	=	_
145-10	30352-30359	Healthy	_
145-11	30360-30367	control	_
145-12	30367-30368	,	_
145-13	30369-30372	ASD	_
145-14	30373-30374	=	_
145-15	30375-30381	autism	_
145-16	30382-30390	spectrum	_
145-17	30391-30399	disorder	_
145-18	30399-30400	,	_
145-19	30401-30403	SZ	_
145-20	30404-30405	=	_
145-21	30406-30419	schizophrenia	_
145-22	30419-30420	,	_
145-23	30421-30425	ADOS	_
145-24	30426-30427	=	_
145-25	30428-30434	Autism	_
145-26	30435-30445	Diagnostic	_
145-27	30446-30457	Observation	_
145-28	30458-30466	Schedule	_
145-29	30467-30469	χ2	_
145-30	30470-30474	test	_
145-31	30475-30477	or	_
145-32	30478-30486	analysis	_
145-33	30487-30489	of	_
145-34	30490-30498	variance	_
145-35	30498-30499	,	_
145-36	30500-30510	two-tailed	_
145-37	30510-30511	,	_
145-38	30512-30515	for	_
145-39	30516-30527	significant	_
145-40	30528-30539	differences	_
145-41	30540-30547	between	_
145-42	30548-30553	study	_
145-43	30554-30560	groups	_
145-44	30561-30571	Behavioral	_
145-45	30572-30583	Performance	_
145-46	30584-30590	During	_
145-47	30591-30597	Visual	_
145-48	30598-30616	Perspective-Taking	_
145-49	30617-30619	in	_
145-50	30620-30626	Autism	_
145-51	30627-30635	Spectrum	_
145-52	30636-30644	Disorder	_
145-53	30644-30645	,	_
145-54	30646-30659	Schizophrenia	_
145-55	30659-30660	,	_
145-56	30661-30664	and	_
145-57	30665-30672	Healthy	_
145-58	30673-30683	Volunteers	_
145-59	30683-30684	.	_

#Text=Variable\tHC (N = 37)\tASD (N = 38)\tSZ (N = 41)\tDirectiona\t \t\t \tM (SE)\tM (SE)\tM (SE)\t \tAccuracy (% correct)\t \t Control\t95.44 (2.97)\t89.49 (2.96)\t92.95 (2.69)\t-\t \t Simple Perspective-Taking\t87.47 (2.97)\t72.39 (2.96)\t81.38 (2.69)\tHC, SZ > ASD\t \t Complex Perspective-Taking\t77.02 (2.97)\t59.86 (2.96)\t60.73 (2.69)\tHC > ASD, SZ\t \tReaction Time (ms)\t \t Control\t1555.30 (49.54)\t1697.96 (49.43)\t1732.96 (44.97)\tHC < ASD, SZ\t \t Simple Perspective-Taking\t2176.47 (49.54)\t2303.04 (49.43)\t2270.73 (44.97)\t-\t \t Complex Perspective-Taking\t2585.30 (49.54)\t2616.52 (49.43)\t2577.72 (44.97)\t-\t \t
#Text=Note.
146-1	30685-30693	Variable	_
146-2	30694-30696	HC	_
146-3	30697-30698	(	_
146-4	30698-30699	N	_
146-5	30700-30701	=	_
146-6	30702-30704	37	_
146-7	30704-30705	)	_
146-8	30706-30709	ASD	_
146-9	30710-30711	(	_
146-10	30711-30712	N	_
146-11	30713-30714	=	_
146-12	30715-30717	38	_
146-13	30717-30718	)	_
146-14	30719-30721	SZ	_
146-15	30722-30723	(	_
146-16	30723-30724	N	_
146-17	30725-30726	=	_
146-18	30727-30729	41	_
146-19	30729-30730	)	_
146-20	30731-30741	Directiona	_
146-21	30747-30748	M	_
146-22	30749-30750	(	_
146-23	30750-30752	SE	_
146-24	30752-30753	)	_
146-25	30754-30755	M	_
146-26	30756-30757	(	_
146-27	30757-30759	SE	_
146-28	30759-30760	)	_
146-29	30761-30762	M	_
146-30	30763-30764	(	_
146-31	30764-30766	SE	_
146-32	30766-30767	)	_
146-33	30770-30778	Accuracy	_
146-34	30779-30780	(	_
146-35	30780-30781	%	_
146-36	30782-30789	correct	_
146-37	30789-30790	)	_
146-38	30794-30801	Control	_
146-39	30802-30807	95.44	_
146-40	30808-30809	(	_
146-41	30809-30813	2.97	_
146-42	30813-30814	)	_
146-43	30815-30820	89.49	_
146-44	30821-30822	(	_
146-45	30822-30826	2.96	_
146-46	30826-30827	)	_
146-47	30828-30833	92.95	_
146-48	30834-30835	(	_
146-49	30835-30839	2.69	_
146-50	30839-30840	)	_
146-51	30841-30842	-	_
146-52	30846-30852	Simple	_
146-53	30853-30871	Perspective-Taking	_
146-54	30872-30877	87.47	_
146-55	30878-30879	(	_
146-56	30879-30883	2.97	_
146-57	30883-30884	)	_
146-58	30885-30890	72.39	_
146-59	30891-30892	(	_
146-60	30892-30896	2.96	_
146-61	30896-30897	)	_
146-62	30898-30903	81.38	_
146-63	30904-30905	(	_
146-64	30905-30909	2.69	_
146-65	30909-30910	)	_
146-66	30911-30913	HC	_
146-67	30913-30914	,	_
146-68	30915-30917	SZ	_
146-69	30918-30919	>	_
146-70	30920-30923	ASD	_
146-71	30927-30934	Complex	_
146-72	30935-30953	Perspective-Taking	_
146-73	30954-30959	77.02	_
146-74	30960-30961	(	_
146-75	30961-30965	2.97	_
146-76	30965-30966	)	_
146-77	30967-30972	59.86	_
146-78	30973-30974	(	_
146-79	30974-30978	2.96	_
146-80	30978-30979	)	_
146-81	30980-30985	60.73	_
146-82	30986-30987	(	_
146-83	30987-30991	2.69	_
146-84	30991-30992	)	_
146-85	30993-30995	HC	_
146-86	30996-30997	>	_
146-87	30998-31001	ASD	_
146-88	31001-31002	,	_
146-89	31003-31005	SZ	_
146-90	31008-31016	Reaction	_
146-91	31017-31021	Time	_
146-92	31022-31023	(	_
146-93	31023-31025	ms	_
146-94	31025-31026	)	_
146-95	31030-31037	Control	_
146-96	31038-31045	1555.30	_
146-97	31046-31047	(	_
146-98	31047-31052	49.54	_
146-99	31052-31053	)	_
146-100	31054-31061	1697.96	_
146-101	31062-31063	(	_
146-102	31063-31068	49.43	_
146-103	31068-31069	)	_
146-104	31070-31077	1732.96	_
146-105	31078-31079	(	_
146-106	31079-31084	44.97	_
146-107	31084-31085	)	_
146-108	31086-31088	HC	_
146-109	31089-31090	<	_
146-110	31091-31094	ASD	_
146-111	31094-31095	,	_
146-112	31096-31098	SZ	_
146-113	31102-31108	Simple	_
146-114	31109-31127	Perspective-Taking	_
146-115	31128-31135	2176.47	_
146-116	31136-31137	(	_
146-117	31137-31142	49.54	_
146-118	31142-31143	)	_
146-119	31144-31151	2303.04	_
146-120	31152-31153	(	_
146-121	31153-31158	49.43	_
146-122	31158-31159	)	_
146-123	31160-31167	2270.73	_
146-124	31168-31169	(	_
146-125	31169-31174	44.97	_
146-126	31174-31175	)	_
146-127	31176-31177	-	_
146-128	31181-31188	Complex	_
146-129	31189-31207	Perspective-Taking	_
146-130	31208-31215	2585.30	_
146-131	31216-31217	(	_
146-132	31217-31222	49.54	_
146-133	31222-31223	)	_
146-134	31224-31231	2616.52	_
146-135	31232-31233	(	_
146-136	31233-31238	49.43	_
146-137	31238-31239	)	_
146-138	31240-31247	2577.72	_
146-139	31248-31249	(	_
146-140	31249-31254	44.97	_
146-141	31254-31255	)	_
146-142	31256-31257	-	_
146-143	31261-31265	Note	_
146-144	31265-31266	.	_

#Text=HC = Healthy control, ASD = autism spectrum disorder, SZ = schizophrenia
#Text=Results of pairwise comparisons from mixed-effects models with multiplicity adjustment applied using the Benjamini and Hochberg approach.
147-1	31267-31269	HC	_
147-2	31270-31271	=	_
147-3	31272-31279	Healthy	_
147-4	31280-31287	control	_
147-5	31287-31288	,	_
147-6	31289-31292	ASD	_
147-7	31293-31294	=	_
147-8	31295-31301	autism	_
147-9	31302-31310	spectrum	_
147-10	31311-31319	disorder	_
147-11	31319-31320	,	_
147-12	31321-31323	SZ	_
147-13	31324-31325	=	_
147-14	31326-31339	schizophrenia	_
147-15	31340-31347	Results	_
147-16	31348-31350	of	_
147-17	31351-31359	pairwise	_
147-18	31360-31371	comparisons	_
147-19	31372-31376	from	_
147-20	31377-31390	mixed-effects	_
147-21	31391-31397	models	_
147-22	31398-31402	with	_
147-23	31403-31415	multiplicity	_
147-24	31416-31426	adjustment	_
147-25	31427-31434	applied	_
147-26	31435-31440	using	_
147-27	31441-31444	the	_
147-28	31445-31454	Benjamini	_
147-29	31455-31458	and	_
147-30	31459-31467	Hochberg	_
147-31	31468-31476	approach	_
147-32	31476-31477	.	_

#Text=Brain Activation During Visual Perspective-Taking in Autism Spectrum Disorder, Schizophrenia, and Healthy Volunteers.
148-1	31478-31483	Brain	_
148-2	31484-31494	Activation	_
148-3	31495-31501	During	_
148-4	31502-31508	Visual	_
148-5	31509-31527	Perspective-Taking	_
148-6	31528-31530	in	_
148-7	31531-31537	Autism	_
148-8	31538-31546	Spectrum	_
148-9	31547-31555	Disorder	_
148-10	31555-31556	,	_
148-11	31557-31570	Schizophrenia	_
148-12	31570-31571	,	_
148-13	31572-31575	and	_
148-14	31576-31583	Healthy	_
148-15	31584-31594	Volunteers	_
148-16	31594-31595	.	_

#Text=Coordinates\tk\tBA\tLabel\tz\tpa\tDirection\t \tHC\t \t6, 64, 14\t612\t9, 10\tMedial prefrontal cortex\t3.85\t< .001\tPT < Control\t \t46, 36, 26\t128\t10, 46\tVentromedial prefrontal cortex, dorsolateral prefrontal cortex\t3.72\t< .001\tPT > Control\t \t56, −36, 10\t113\t22\tSuperior temporal gyrus, temporo-parietal junction\t3.72\t< .001\tPT < Control\t \t26, 6, 50\t103\t6\tMiddle frontal gyrus\t3.28\t.001\tPT > Control\t \t−42, 36, 28\t101\t46\tVentromedial prefrontal cortex, dorsolateral prefrontal cortex\t3.50\t< .001\tPT > Control\t \t\t \tASD\t \t−44, −56, 18\t512\t39, 22\tSuperior temporal gyrus, temporo-parietal junction\t4.09\t< .001\tPT < Control\t \t8, 34, −8\t406\t32\tAnterior cingulate cortex\t3.98\t< .001\tPT < Control\t \t52, −56, 20\t301\t39\tSuperior temporal gyrus\t4.05\t< .001\tPT < Control\t \t8, 28, 34\t133\t9, 32\tMedial prefrontal cortex\t3.93\t< .001\tPT > Control\t \t\t \tSZ\t \t2, 28, 40\t396\t32\tMedial prefrontal cortex, anterior cingulate cortex\t3.90\t< .001\tPT > Control\t \t44, 38, 26\t386\t10, 46\tVentromedial prefrontal cortex, dorsolateral prefrontal cortex\t4.63\t< .001\tPT > Control\t \t−44, 42, 18\t328\t10\tVentromedial prefrontal cortex, dorsolateral prefrontal cortex\t4.71\t< .001\tPT > Control\t \t28, 8, 56\t129\t6\tMiddle frontal gyrus\t3.96\t< .001\tPT > Control\t \t\t \tHC vs.
149-1	31596-31607	Coordinates	_
149-2	31608-31609	k	_
149-3	31610-31612	BA	_
149-4	31613-31618	Label	_
149-5	31619-31620	z	_
149-6	31621-31623	pa	_
149-7	31624-31633	Direction	_
149-8	31636-31638	HC	_
149-9	31641-31642	6	_
149-10	31642-31643	,	_
149-11	31644-31646	64	_
149-12	31646-31647	,	_
149-13	31648-31650	14	_
149-14	31651-31654	612	_
149-15	31655-31656	9	_
149-16	31656-31657	,	_
149-17	31658-31660	10	_
149-18	31661-31667	Medial	_
149-19	31668-31678	prefrontal	_
149-20	31679-31685	cortex	_
149-21	31686-31690	3.85	_
149-22	31691-31692	<	_
149-23	31693-31697	.001	_
149-24	31698-31700	PT	_
149-25	31701-31702	<	_
149-26	31703-31710	Control	_
149-27	31713-31715	46	_
149-28	31715-31716	,	_
149-29	31717-31719	36	_
149-30	31719-31720	,	_
149-31	31721-31723	26	_
149-32	31724-31727	128	_
149-33	31728-31730	10	_
149-34	31730-31731	,	_
149-35	31732-31734	46	_
149-36	31735-31747	Ventromedial	_
149-37	31748-31758	prefrontal	_
149-38	31759-31765	cortex	_
149-39	31765-31766	,	_
149-40	31767-31779	dorsolateral	_
149-41	31780-31790	prefrontal	_
149-42	31791-31797	cortex	_
149-43	31798-31802	3.72	_
149-44	31803-31804	<	_
149-45	31805-31809	.001	_
149-46	31810-31812	PT	_
149-47	31813-31814	>	_
149-48	31815-31822	Control	_
149-49	31825-31827	56	_
149-50	31827-31828	,	_
149-51	31829-31830	−	_
149-52	31830-31832	36	_
149-53	31832-31833	,	_
149-54	31834-31836	10	_
149-55	31837-31840	113	_
149-56	31841-31843	22	_
149-57	31844-31852	Superior	_
149-58	31853-31861	temporal	_
149-59	31862-31867	gyrus	_
149-60	31867-31868	,	_
149-61	31869-31885	temporo-parietal	_
149-62	31886-31894	junction	_
149-63	31895-31899	3.72	_
149-64	31900-31901	<	_
149-65	31902-31906	.001	_
149-66	31907-31909	PT	_
149-67	31910-31911	<	_
149-68	31912-31919	Control	_
149-69	31922-31924	26	_
149-70	31924-31925	,	_
149-71	31926-31927	6	_
149-72	31927-31928	,	_
149-73	31929-31931	50	_
149-74	31932-31935	103	_
149-75	31936-31937	6	_
149-76	31938-31944	Middle	_
149-77	31945-31952	frontal	_
149-78	31953-31958	gyrus	_
149-79	31959-31963	3.28	_
149-80	31964-31968	.001	_
149-81	31969-31971	PT	_
149-82	31972-31973	>	_
149-83	31974-31981	Control	_
149-84	31984-31985	−	_
149-85	31985-31987	42	_
149-86	31987-31988	,	_
149-87	31989-31991	36	_
149-88	31991-31992	,	_
149-89	31993-31995	28	_
149-90	31996-31999	101	_
149-91	32000-32002	46	_
149-92	32003-32015	Ventromedial	_
149-93	32016-32026	prefrontal	_
149-94	32027-32033	cortex	_
149-95	32033-32034	,	_
149-96	32035-32047	dorsolateral	_
149-97	32048-32058	prefrontal	_
149-98	32059-32065	cortex	_
149-99	32066-32070	3.50	_
149-100	32071-32072	<	_
149-101	32073-32077	.001	_
149-102	32078-32080	PT	_
149-103	32081-32082	>	_
149-104	32083-32090	Control	_
149-105	32096-32099	ASD	_
149-106	32102-32103	−	_
149-107	32103-32105	44	_
149-108	32105-32106	,	_
149-109	32107-32108	−	_
149-110	32108-32110	56	_
149-111	32110-32111	,	_
149-112	32112-32114	18	_
149-113	32115-32118	512	_
149-114	32119-32121	39	_
149-115	32121-32122	,	_
149-116	32123-32125	22	_
149-117	32126-32134	Superior	_
149-118	32135-32143	temporal	_
149-119	32144-32149	gyrus	_
149-120	32149-32150	,	_
149-121	32151-32167	temporo-parietal	_
149-122	32168-32176	junction	_
149-123	32177-32181	4.09	_
149-124	32182-32183	<	_
149-125	32184-32188	.001	_
149-126	32189-32191	PT	_
149-127	32192-32193	<	_
149-128	32194-32201	Control	_
149-129	32204-32205	8	_
149-130	32205-32206	,	_
149-131	32207-32209	34	_
149-132	32209-32210	,	_
149-133	32211-32212	−	_
149-134	32212-32213	8	_
149-135	32214-32217	406	_
149-136	32218-32220	32	_
149-137	32221-32229	Anterior	_
149-138	32230-32239	cingulate	_
149-139	32240-32246	cortex	_
149-140	32247-32251	3.98	_
149-141	32252-32253	<	_
149-142	32254-32258	.001	_
149-143	32259-32261	PT	_
149-144	32262-32263	<	_
149-145	32264-32271	Control	_
149-146	32274-32276	52	_
149-147	32276-32277	,	_
149-148	32278-32279	−	_
149-149	32279-32281	56	_
149-150	32281-32282	,	_
149-151	32283-32285	20	_
149-152	32286-32289	301	_
149-153	32290-32292	39	_
149-154	32293-32301	Superior	_
149-155	32302-32310	temporal	_
149-156	32311-32316	gyrus	_
149-157	32317-32321	4.05	_
149-158	32322-32323	<	_
149-159	32324-32328	.001	_
149-160	32329-32331	PT	_
149-161	32332-32333	<	_
149-162	32334-32341	Control	_
149-163	32344-32345	8	_
149-164	32345-32346	,	_
149-165	32347-32349	28	_
149-166	32349-32350	,	_
149-167	32351-32353	34	_
149-168	32354-32357	133	_
149-169	32358-32359	9	_
149-170	32359-32360	,	_
149-171	32361-32363	32	_
149-172	32364-32370	Medial	_
149-173	32371-32381	prefrontal	_
149-174	32382-32388	cortex	_
149-175	32389-32393	3.93	_
149-176	32394-32395	<	_
149-177	32396-32400	.001	_
149-178	32401-32403	PT	_
149-179	32404-32405	>	_
149-180	32406-32413	Control	_
149-181	32419-32421	SZ	_
149-182	32424-32425	2	_
149-183	32425-32426	,	_
149-184	32427-32429	28	_
149-185	32429-32430	,	_
149-186	32431-32433	40	_
149-187	32434-32437	396	_
149-188	32438-32440	32	_
149-189	32441-32447	Medial	_
149-190	32448-32458	prefrontal	_
149-191	32459-32465	cortex	_
149-192	32465-32466	,	_
149-193	32467-32475	anterior	_
149-194	32476-32485	cingulate	_
149-195	32486-32492	cortex	_
149-196	32493-32497	3.90	_
149-197	32498-32499	<	_
149-198	32500-32504	.001	_
149-199	32505-32507	PT	_
149-200	32508-32509	>	_
149-201	32510-32517	Control	_
149-202	32520-32522	44	_
149-203	32522-32523	,	_
149-204	32524-32526	38	_
149-205	32526-32527	,	_
149-206	32528-32530	26	_
149-207	32531-32534	386	_
149-208	32535-32537	10	_
149-209	32537-32538	,	_
149-210	32539-32541	46	_
149-211	32542-32554	Ventromedial	_
149-212	32555-32565	prefrontal	_
149-213	32566-32572	cortex	_
149-214	32572-32573	,	_
149-215	32574-32586	dorsolateral	_
149-216	32587-32597	prefrontal	_
149-217	32598-32604	cortex	_
149-218	32605-32609	4.63	_
149-219	32610-32611	<	_
149-220	32612-32616	.001	_
149-221	32617-32619	PT	_
149-222	32620-32621	>	_
149-223	32622-32629	Control	_
149-224	32632-32633	−	_
149-225	32633-32635	44	_
149-226	32635-32636	,	_
149-227	32637-32639	42	_
149-228	32639-32640	,	_
149-229	32641-32643	18	_
149-230	32644-32647	328	_
149-231	32648-32650	10	_
149-232	32651-32663	Ventromedial	_
149-233	32664-32674	prefrontal	_
149-234	32675-32681	cortex	_
149-235	32681-32682	,	_
149-236	32683-32695	dorsolateral	_
149-237	32696-32706	prefrontal	_
149-238	32707-32713	cortex	_
149-239	32714-32718	4.71	_
149-240	32719-32720	<	_
149-241	32721-32725	.001	_
149-242	32726-32728	PT	_
149-243	32729-32730	>	_
149-244	32731-32738	Control	_
149-245	32741-32743	28	_
149-246	32743-32744	,	_
149-247	32745-32746	8	_
149-248	32746-32747	,	_
149-249	32748-32750	56	_
149-250	32751-32754	129	_
149-251	32755-32756	6	_
149-252	32757-32763	Middle	_
149-253	32764-32771	frontal	_
149-254	32772-32777	gyrus	_
149-255	32778-32782	3.96	_
149-256	32783-32784	<	_
149-257	32785-32789	.001	_
149-258	32790-32792	PT	_
149-259	32793-32794	>	_
149-260	32795-32802	Control	_
149-261	32808-32810	HC	_
149-262	32811-32813	vs	_
149-263	32813-32814	.	_

#Text=ASD\t \t−50, −50, 14\t226\t22\tTemporo-parietal junction\t3.49\t< .001\tHC > ASD\t \t52, −56, 20\t213\t39\tTemporo-parietal junction, angular gyrus\t3.66\t< .001\tHC > ASD\t \t\t \tHC vs.
150-1	32815-32818	ASD	_
150-2	32821-32822	−	_
150-3	32822-32824	50	_
150-4	32824-32825	,	_
150-5	32826-32827	−	_
150-6	32827-32829	50	_
150-7	32829-32830	,	_
150-8	32831-32833	14	_
150-9	32834-32837	226	_
150-10	32838-32840	22	_
150-11	32841-32857	Temporo-parietal	_
150-12	32858-32866	junction	_
150-13	32867-32871	3.49	_
150-14	32872-32873	<	_
150-15	32874-32878	.001	_
150-16	32879-32881	HC	_
150-17	32882-32883	>	_
150-18	32884-32887	ASD	_
150-19	32890-32892	52	_
150-20	32892-32893	,	_
150-21	32894-32895	−	_
150-22	32895-32897	56	_
150-23	32897-32898	,	_
150-24	32899-32901	20	_
150-25	32902-32905	213	_
150-26	32906-32908	39	_
150-27	32909-32925	Temporo-parietal	_
150-28	32926-32934	junction	_
150-29	32934-32935	,	_
150-30	32936-32943	angular	_
150-31	32944-32949	gyrus	_
150-32	32950-32954	3.66	_
150-33	32955-32956	<	_
150-34	32957-32961	.001	_
150-35	32962-32964	HC	_
150-36	32965-32966	>	_
150-37	32967-32970	ASD	_
150-38	32976-32978	HC	_
150-39	32979-32981	vs	_
150-40	32981-32982	.	_

#Text=SZ\t \t12, 66, 12\t145\t10\tMedial prefrontal cortex\t3.82\t< .001\tHC < SZ\t \t8, 40, 22\t82\t9, 32\tAnterior cingulate, medial prefrontal cortex\t3.33\t< .001\tHC < SZ\t \t\t \tASD vs.
151-1	32983-32985	SZ	_
151-2	32988-32990	12	_
151-3	32990-32991	,	_
151-4	32992-32994	66	_
151-5	32994-32995	,	_
151-6	32996-32998	12	_
151-7	32999-33002	145	_
151-8	33003-33005	10	_
151-9	33006-33012	Medial	_
151-10	33013-33023	prefrontal	_
151-11	33024-33030	cortex	_
151-12	33031-33035	3.82	_
151-13	33036-33037	<	_
151-14	33038-33042	.001	_
151-15	33043-33045	HC	_
151-16	33046-33047	<	_
151-17	33048-33050	SZ	_
151-18	33053-33054	8	_
151-19	33054-33055	,	_
151-20	33056-33058	40	_
151-21	33058-33059	,	_
151-22	33060-33062	22	_
151-23	33063-33065	82	_
151-24	33066-33067	9	_
151-25	33067-33068	,	_
151-26	33069-33071	32	_
151-27	33072-33080	Anterior	_
151-28	33081-33090	cingulate	_
151-29	33090-33091	,	_
151-30	33092-33098	medial	_
151-31	33099-33109	prefrontal	_
151-32	33110-33116	cortex	_
151-33	33117-33121	3.33	_
151-34	33122-33123	<	_
151-35	33124-33128	.001	_
151-36	33129-33131	HC	_
151-37	33132-33133	<	_
151-38	33134-33136	SZ	_
151-39	33142-33145	ASD	_
151-40	33146-33148	vs	_
151-41	33148-33149	.	_

#Text=SZ\t \t−40, 16, 24\t132\t9, 46\tVentromedial prefrontal cortex\t3.82\t< .001\tASD < SZ\t \t−52, 28, −2\t106\t47\tVentromedial prefrontal cortex, orbitofrontal cortex\t3.89\t< .001\tASD < SZ\t \t−60, −42, 8\t94\t22\tTemporo-parietal junction, superior temporal gyrus\t3.20\t.001\tASD < SZ\t \t
#Text=Note.
152-1	33150-33152	SZ	_
152-2	33155-33156	−	_
152-3	33156-33158	40	_
152-4	33158-33159	,	_
152-5	33160-33162	16	_
152-6	33162-33163	,	_
152-7	33164-33166	24	_
152-8	33167-33170	132	_
152-9	33171-33172	9	_
152-10	33172-33173	,	_
152-11	33174-33176	46	_
152-12	33177-33189	Ventromedial	_
152-13	33190-33200	prefrontal	_
152-14	33201-33207	cortex	_
152-15	33208-33212	3.82	_
152-16	33213-33214	<	_
152-17	33215-33219	.001	_
152-18	33220-33223	ASD	_
152-19	33224-33225	<	_
152-20	33226-33228	SZ	_
152-21	33231-33232	−	_
152-22	33232-33234	52	_
152-23	33234-33235	,	_
152-24	33236-33238	28	_
152-25	33238-33239	,	_
152-26	33240-33241	−	_
152-27	33241-33242	2	_
152-28	33243-33246	106	_
152-29	33247-33249	47	_
152-30	33250-33262	Ventromedial	_
152-31	33263-33273	prefrontal	_
152-32	33274-33280	cortex	_
152-33	33280-33281	,	_
152-34	33282-33295	orbitofrontal	_
152-35	33296-33302	cortex	_
152-36	33303-33307	3.89	_
152-37	33308-33309	<	_
152-38	33310-33314	.001	_
152-39	33315-33318	ASD	_
152-40	33319-33320	<	_
152-41	33321-33323	SZ	_
152-42	33326-33327	−	_
152-43	33327-33329	60	_
152-44	33329-33330	,	_
152-45	33331-33332	−	_
152-46	33332-33334	42	_
152-47	33334-33335	,	_
152-48	33336-33337	8	_
152-49	33338-33340	94	_
152-50	33341-33343	22	_
152-51	33344-33360	Temporo-parietal	_
152-52	33361-33369	junction	_
152-53	33369-33370	,	_
152-54	33371-33379	superior	_
152-55	33380-33388	temporal	_
152-56	33389-33394	gyrus	_
152-57	33395-33399	3.20	_
152-58	33400-33404	.001	_
152-59	33405-33408	ASD	_
152-60	33409-33410	<	_
152-61	33411-33413	SZ	_
152-62	33417-33421	Note	_
152-63	33421-33422	.	_

#Text=ASD = autism spectrum disorder, HC = healthy control, PT = perspective-taking, SZ = schizophrenia
#Text=Uncorrected p-values.
153-1	33423-33426	ASD	_
153-2	33427-33428	=	_
153-3	33429-33435	autism	_
153-4	33436-33444	spectrum	_
153-5	33445-33453	disorder	_
153-6	33453-33454	,	_
153-7	33455-33457	HC	_
153-8	33458-33459	=	_
153-9	33460-33467	healthy	_
153-10	33468-33475	control	_
153-11	33475-33476	,	_
153-12	33477-33479	PT	_
153-13	33480-33481	=	_
153-14	33482-33500	perspective-taking	_
153-15	33500-33501	,	_
153-16	33502-33504	SZ	_
153-17	33505-33506	=	_
153-18	33507-33520	schizophrenia	_
153-19	33521-33532	Uncorrected	_
153-20	33533-33541	p-values	_
153-21	33541-33542	.	_

#Text=Type I error was maintained at p < .05 using a combined uncorrected α threshold of .005 and voxel-extent threshold of 82 based on Monte Carlo simulations.
154-1	33543-33547	Type	_
154-2	33548-33549	I	_
154-3	33550-33555	error	_
154-4	33556-33559	was	_
154-5	33560-33570	maintained	_
154-6	33571-33573	at	_
154-7	33574-33575	p	_
154-8	33576-33577	<	_
154-9	33578-33581	.05	_
154-10	33582-33587	using	_
154-11	33588-33589	a	_
154-12	33590-33598	combined	_
154-13	33599-33610	uncorrected	_
154-14	33611-33612	α	_
154-15	33613-33622	threshold	_
154-16	33623-33625	of	_
154-17	33626-33630	.005	_
154-18	33631-33634	and	_
154-19	33635-33647	voxel-extent	_
154-20	33648-33657	threshold	_
154-21	33658-33660	of	_
154-22	33661-33663	82	_
154-23	33664-33669	based	_
154-24	33670-33672	on	_
154-25	33673-33678	Monte	_
154-26	33679-33684	Carlo	_
154-27	33685-33696	simulations	_
154-28	33696-33697	.	_

#Text=Fronto-Temporal Functional Connectivity Differences During Visual Perspective-Taking Between Adults with Autism Spectrum Disorder, Schizophrenia, and Healthy Volunteers.
155-1	33698-33713	Fronto-Temporal	_
155-2	33714-33724	Functional	_
155-3	33725-33737	Connectivity	_
155-4	33738-33749	Differences	_
155-5	33750-33756	During	_
155-6	33757-33763	Visual	_
155-7	33764-33782	Perspective-Taking	_
155-8	33783-33790	Between	_
155-9	33791-33797	Adults	_
155-10	33798-33802	with	_
155-11	33803-33809	Autism	_
155-12	33810-33818	Spectrum	_
155-13	33819-33827	Disorder	_
155-14	33827-33828	,	_
155-15	33829-33842	Schizophrenia	_
155-16	33842-33843	,	_
155-17	33844-33847	and	_
155-18	33848-33855	Healthy	_
155-19	33856-33866	Volunteers	_
155-20	33866-33867	.	_

#Text=Seed ROI\tTarget ROI\tβ\tpFDR\tDirection\t \tHC vs.
156-1	33868-33872	Seed	_
156-2	33873-33876	ROI	_
156-3	33877-33883	Target	_
156-4	33884-33887	ROI	_
156-5	33888-33889	β	_
156-6	33890-33894	pFDR	_
156-7	33895-33904	Direction	_
156-8	33907-33909	HC	_
156-9	33910-33912	vs	_
156-10	33912-33913	.	_

#Text=ASD\t \tHub #1: Middle orbitofrontal cortex (L)\tMedial prefrontal cortex (L)\t.14\t.013\tHC < ASD\t \t\tMedial prefrontal cortex (R)\t.10\t.047\tHC < ASD\t \t\tTemporo-parietal junction (L)\t.10\t.047\tHC < ASD\t \t\t \tHC vs.
157-1	33914-33917	ASD	_
157-2	33920-33923	Hub	_
157-3	33924-33926	#1	_
157-4	33926-33927	:	_
157-5	33928-33934	Middle	_
157-6	33935-33948	orbitofrontal	_
157-7	33949-33955	cortex	_
157-8	33956-33957	(	_
157-9	33957-33958	L	_
157-10	33958-33959	)	_
157-11	33960-33966	Medial	_
157-12	33967-33977	prefrontal	_
157-13	33978-33984	cortex	_
157-14	33985-33986	(	_
157-15	33986-33987	L	_
157-16	33987-33988	)	_
157-17	33989-33992	.14	_
157-18	33993-33997	.013	_
157-19	33998-34000	HC	_
157-20	34001-34002	<	_
157-21	34003-34006	ASD	_
157-22	34010-34016	Medial	_
157-23	34017-34027	prefrontal	_
157-24	34028-34034	cortex	_
157-25	34035-34036	(	_
157-26	34036-34037	R	_
157-27	34037-34038	)	_
157-28	34039-34042	.10	_
157-29	34043-34047	.047	_
157-30	34048-34050	HC	_
157-31	34051-34052	<	_
157-32	34053-34056	ASD	_
157-33	34060-34076	Temporo-parietal	_
157-34	34077-34085	junction	_
157-35	34086-34087	(	_
157-36	34087-34088	L	_
157-37	34088-34089	)	_
157-38	34090-34093	.10	_
157-39	34094-34098	.047	_
157-40	34099-34101	HC	_
157-41	34102-34103	<	_
157-42	34104-34107	ASD	_
157-43	34113-34115	HC	_
157-44	34116-34118	vs	_
157-45	34118-34119	.	_

#Text=SZ\t \tHub #1: Medial prefrontal cortex (R)\tMiddle obritofrontal cortex (R)\t.12\t.047\tHC < SZ\t \t\tAnterior cingulate (L)\t.10\t.047\tHC < SZ\t \tHub #2: Temporo-parietal junction (R)\tMedial orbitofrontal cortex (L)\t−.14\t.014\tHC > SZ\t \t\t \tASD vs.
158-1	34120-34122	SZ	_
158-2	34125-34128	Hub	_
158-3	34129-34131	#1	_
158-4	34131-34132	:	_
158-5	34133-34139	Medial	_
158-6	34140-34150	prefrontal	_
158-7	34151-34157	cortex	_
158-8	34158-34159	(	_
158-9	34159-34160	R	_
158-10	34160-34161	)	_
158-11	34162-34168	Middle	_
158-12	34169-34182	obritofrontal	_
158-13	34183-34189	cortex	_
158-14	34190-34191	(	_
158-15	34191-34192	R	_
158-16	34192-34193	)	_
158-17	34194-34197	.12	_
158-18	34198-34202	.047	_
158-19	34203-34205	HC	_
158-20	34206-34207	<	_
158-21	34208-34210	SZ	_
158-22	34214-34222	Anterior	_
158-23	34223-34232	cingulate	_
158-24	34233-34234	(	_
158-25	34234-34235	L	_
158-26	34235-34236	)	_
158-27	34237-34240	.10	_
158-28	34241-34245	.047	_
158-29	34246-34248	HC	_
158-30	34249-34250	<	_
158-31	34251-34253	SZ	_
158-32	34256-34259	Hub	_
158-33	34260-34262	#2	_
158-34	34262-34263	:	_
158-35	34264-34280	Temporo-parietal	_
158-36	34281-34289	junction	_
158-37	34290-34291	(	_
158-38	34291-34292	R	_
158-39	34292-34293	)	_
158-40	34294-34300	Medial	_
158-41	34301-34314	orbitofrontal	_
158-42	34315-34321	cortex	_
158-43	34322-34323	(	_
158-44	34323-34324	L	_
158-45	34324-34325	)	_
158-46	34326-34327	−	_
158-47	34327-34330	.14	_
158-48	34331-34335	.014	_
158-49	34336-34338	HC	_
158-50	34339-34340	>	_
158-51	34341-34343	SZ	_
158-52	34349-34352	ASD	_
158-53	34353-34355	vs	_
158-54	34355-34356	.	_

#Text=SZ\t \tHub #1: Middle orbitofrontal cortex (L)\tMedial orbitofrontal cortex (R)\t.14\t.004\tASD > SZ\t \t\tMedial orbitofrontal cortex (L)\t.13\t.027\tASD > SZ\t \t
#Text=Note.
159-1	34357-34359	SZ	_
159-2	34362-34365	Hub	_
159-3	34366-34368	#1	_
159-4	34368-34369	:	_
159-5	34370-34376	Middle	_
159-6	34377-34390	orbitofrontal	_
159-7	34391-34397	cortex	_
159-8	34398-34399	(	_
159-9	34399-34400	L	_
159-10	34400-34401	)	_
159-11	34402-34408	Medial	_
159-12	34409-34422	orbitofrontal	_
159-13	34423-34429	cortex	_
159-14	34430-34431	(	_
159-15	34431-34432	R	_
159-16	34432-34433	)	_
159-17	34434-34437	.14	_
159-18	34438-34442	.004	_
159-19	34443-34446	ASD	_
159-20	34447-34448	>	_
159-21	34449-34451	SZ	_
159-22	34455-34461	Medial	_
159-23	34462-34475	orbitofrontal	_
159-24	34476-34482	cortex	_
159-25	34483-34484	(	_
159-26	34484-34485	L	_
159-27	34485-34486	)	_
159-28	34487-34490	.13	_
159-29	34491-34495	.027	_
159-30	34496-34499	ASD	_
159-31	34500-34501	>	_
159-32	34502-34504	SZ	_
159-33	34508-34512	Note	_
159-34	34512-34513	.	_

#Text=ASD = autism spectrum disorder, HC = healthy control, SZ = schizophrenia
160-1	34514-34517	ASD	_
160-2	34518-34519	=	_
160-3	34520-34526	autism	_
160-4	34527-34535	spectrum	_
160-5	34536-34544	disorder	_
160-6	34544-34545	,	_
160-7	34546-34548	HC	_
160-8	34549-34550	=	_
160-9	34551-34558	healthy	_
160-10	34559-34566	control	_
160-11	34566-34567	,	_
160-12	34568-34570	SZ	_
160-13	34571-34572	=	_
160-14	34573-34586	schizophrenia	_
